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Abstract 
Within solid tumours, a microenvironment exists that causes resistance to 
chemotherapy. New drugs that target cells within this microenvironment are 
required, the first step in this process being the identification of new targets. The 
aim of this thesis was to characterise changes in the transcriptome and 
proteome within specific regions of multicell-tumour spheroids (MCTS), an 
experimental model that mimics many of the features of the tumour 
microenvironment. HT29 MCTS were separated by sequential trypsinisation into 
3 main regions; the outer surface layer (SL) the peri-necroric region (PN) and 
the necrotic core (NC). Using an iTRAQ quantitative proteomics approach, the 
proteome of the different MCTS regions was investigated. A 2 dimensional 
separation approach using Agilent‘s OffGel system and RP-nano HPLC was 
incorporated prior to MS analysis. MS analysis was done using both MALDI-
TOF-TOF (Bruker Ultraflex II) and ESI-Q-TOF (Agilent 6530 QTOF 
LC/MS) instruments. Gene expression profiles of the different MCTS 
were investigated and compared using Agilent‘s one -color 
oligonucleotide based microarrays. Transcriptomic and proteomic analysis 
identified several key differences in the proteins involved in cell metabolism 
between the SL and PN/NC regions. Similar metabolic changes were also noted 
between autophagic and normal monolayer cells. Many highlighted proteins 
represented established cancer associated proteins. Interestingly, a number of 
proteins were highlighted which have no previous association with cancer and 
may upon further validation, provide attractive leads for therapeutic intervention.  
Key words: Proteomics, transcritptomics, Multi-Cellular Tumour Spheroids, 
autophagy, metabolism, hypoxia. 
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I- General Introduction 
 
I-1 Cancer, incidence and mortality rates 
 
Cancer is a disease characterized by unregulated cell growth, the invasion and 
spread of cells from the site of origin to other sites in the body (Pecorino, 2005). 
It is predominantly a genetic disease, which has over 100 distinct types 
(Hanahan and Weinberg, 2000). In 2006 an estimated 3,191,600 cancer cases 
were diagnosed in Europe (Ferlay et al, 2007) and the most common cause of 
death occurred from lung cancer, with an estimated 334,800 deaths (Felay et al, 
2007). In the UK, the latest statistics to be released revealed that approximately 
149,500 males and 148,500 females were newly diagnosed with cancer each 
year from 2005-2007, with around 80,500 and 74,000 males and females dying 
from the disease each year, respectively. Despite continued and intensive 
efforts to tackle this disease, the mortality rate from cancer appears constant in 
the UK. What‘s more, the most common cancers still present the biggest 
burden, with breast and prostate being the most common cancers in men and 
women, respectively (www.statistics.gov.uk).  
 
I-2 The hallmarks of cancer 
 
Hanahan and Weinberg suggested that the large variations seen in cancer genome 
alterations can in fact be classified into just six alterations in cell physiology which 
collectively dictate malignant growth. These alterations are now regarded as the 
hallmarks of cancer (Hanahan and Weinberg, 2000), Recently Hanahan and 
Weinberg have gone on to review these hallmarks (Hanahan and Weinberg, 2011). 
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Taking into account conceptual progress in cancer research in the last decade, two 
enabling factors and two emerging hallmarks have been proposed. The current 
proposed hallmarks and enabling factors include the following;  
 
I-2.1 Self-sufficiency in growth signals  
Tumour cells lose their dependency on exogenous growth signals, which results in 
the disruption of important homeostatic mechanisms which ordinarily would ensure 
the correct behavior of the cell within its specific environment. Typical methods of 
achieving growth signal autonomy include alterations in extracellular growth signals 
and signal receptors, transcellular transducers and intracellular circuits which are 
linked to growth signals. Classic examples of these would include epidermal growth 
factor over expression (Libermann et al, 1985) and downstream cytoplasmic 
circuitry alterations such as those in the MAPK/ERK pathways (Reddy, Nabha and 
Atanaskova, 2003). Most recently excessive proliferative signaling has been shown 
to provoke cell senescence and/or apoptosis (Lowe et al, 2004. Collado and 
Serrano, 2010).  
 
I-2.2 Insensitivity to antigrowth signals 
Normal cells are subjected and subsequently respond to antigrowth signals which 
are important in maintaining cellular quiescence and tissue homeostasis. Many 
antigrowth signals exert their effect through halting progression of cells through the 
cells cycle. As the retinoblastoma protein (pRb) and its related pathways are 
involved in the majority of anti-proliferative signals (Weinberg, 1995), disruption of 
this pathway through for example the down-regulation of the TGFβ receptor, which 
governs the phosphorylation dependant activation of pRb (Moses, Yang and 
Pietenpol, 1990) is commonly seen in tumours (Fynan and Reiss, 1993).  
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I-2.3 Evading apoptosis 
The notion that apoptosis serves as a barrier to tumourigenesis is well established 
and was first indicated at the molecular level by the up-regulation of the bcl-2 anti-
apoptotic oncogene (Vaux, Cory and Adams, 1988). By down-regulating apoptosis 
abnormal cells are able to survive and pass on their abnormalities, such as 
damaged DNA, which will further promote tumourigenesis. 
Amendments to this hallmark in the reviewed work by Hanahan and Weinberg 
highlight the importance of other forms of cell death in facilitating tumourigensis. 
These include autophagy as a survival mechanism (Levine and Kroemer, 2008) 
and necrosis in stimulating pro-inflammatory signaling which can promote tumour 
development (Grivennikov et al, 2010).  
 
I-2.4 Limitless replicative potential 
The three previously mentioned hallmarks of cancer should in principle result in the 
generation of a large cell population or tumour mass, this however appears not to 
be the case. Further, alterations which allow for limitless replication are required 
(Hayflick, 1997). Limitless replication in normal cells is prevented due to the 
shortening of the telomere region of their chromosomes which ultimately results in 
crisis and cell death (Counter et al, 1998). Commonly, tumour cells circumvent this 
replication restriction by up-regulating the expression of the enzyme telomerase, 
which replenishes hexanucleotide repeats onto the ends of telomeric DNA (Bryan 
and Cech, 1999). Recent studies have shown that delayed acquisition of 
telomerase function aids the collection of tumour-promoting mutation, after which 
telomerase activity then stabilized the mutant genome (Raynaud et al, 2010).  
 
 
26 
 
I-2.5 Sustained angiogenesis 
In order to receive sufficient amounts of nutrients and oxygen, cells must reside 
within 100μm of a capillary blood vessel. Tumour cells must acquire the ability to 
form new blood vessels in order to support their growth. In most normal tissues this 
ability is lost following organogenesis but tumours reactivate the ability to develop 
new vessels from existing vasculature in a process termed angiogenesis. Tumour 
cells induce angiogenesis through a variety of mechanisms, which collectively 
activate the angiogenic switch, through increasing angiogenic inducers and 
decreasing inhibitors (Hanahan and Folkman, 1996).  
 
I-2.6 Tissue invasion and metastasis 
Metastasis is the term used to describe the ability of cancer to spread and colonise 
other tissues and it is responsible for 90% of human cancer deaths (Sporn, 1996). 
Tumour cells achieve the ability to migrate from the primary tumour site to other 
parts of the body through various mechanisms (reviewed by Chambers, Groom and 
MacDonald, 2002). The process involves several major steps including, migration, 
intravasation, transport, extravasation and metastatic colonization. Ultimately the 
process involves changes in the physical coupling of cells to their 
microenvironment, to each other and the activation of extracellular proteases 
required for intravasations and extravasation. Once at the secondary site, the 
tumour cells require the ability to adapt to its new microenvironment conditions in 
order to successfully colonize the new area. The mechanisms by which the cells 
achieve these adaptations are still largely undetermined and represent an 
important agenda for future research. 
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I-2.7 Enabling characteristics 
Two enabling characteristic have been proposed to allow for the acquisition of 
the original hallmarks. These include; 
I-2.7.1 Genome instability 
Attainment of the above mentioned hallmarks is achieved predominantly 
through genome alterations in tumour cells. Genome integrity is exceptionally 
well preserved in normal cells through a multitude of DNA monitoring and repair 
processes. As such the occurrence of mutations in the many genes required to 
bring about the alterations seen with the above mentioned hallmarks, is 
implausible under normal circumstances. Tumour cells therefore must increase 
their mutability through targeting key DNA ‗caretaking‘ processes. The most 
noteworthy example of this is mutations in the p53 tumour suppressor gene 
(Lane and Crawford, 1979. Linzer and Levine, 1979) which plays a number of 
roles in DNA damage monitoring and repair (Vogelstein, Levine and Lane, 
2000).   
I-2.7.2 Tumour promoting inflammation 
The presence of immune cells in tumours has been noted for some time 
(Dvorak, 1986). Previously, the presence of these immune cells was thought to 
reflect an attempt by the immune system to eradicate the tumour. New evidence 
has suggested a role for inflammation in enhancing tumourigensis, through the 
delivery of bioactive molecules to the tumour microenvironment. These 
molecules include; growth factors, survival factors, proangiogenic factors 
together with extracellular matrix-modifying enzymes which can further facilitate 
angiogenesis (Denardo et al, 2010. Grivennikov et al, 2010).  
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I-2.8 Emerging hallmarks 
Progress in cancer research in the last decade has lead to the proposal of two 
emerging hallmarks, which are; 
 
I-2.8.1 Reprogramming of energy metabolism 
Altered tumour metabolism was identified by Otto Warburg, who first 
demonstrated that cancer cells were performing lactic fermentation even in the 
presence of oxygen (Warburg, 1923). Warburg‘s in vitro observations were 
confirmed in vivo by Carl and Gerty Cori (Cori and Cori, 1925a, 1925b). The 
preferential reliance on aerobic glycolysis of cancer cells, even in the presence 
of oxygen has been extensively further studied and is now known as the 
‗Warburg effect‘ (Ferreira, 2010).   
 
Tumour cells facilitate increased rates of glycolysis via a number of 
mechanisms, most notably, though the up-regulation of glucose transporters 
such as GLUT1 (Hsu and Sabatini, 2008). Increased glucose uptake is an 
important characteristic of solid tumours and as such is used to diagnose 
tumours in vivo (FDG-PET). Once inside the cell glucose can participate in a 
number of metabolic pathways. These include glycogen synthesis, the pentose 
phosphate pathway or classically glycolysis. Evidence of a role for each of 
these pathways has previously been presented in the literature, with tumours 
long been known to exhibit a notable glycogen content (Cori and Cori, 1925a) 
and enzymes involved in the regulation of glycogen synthesis been proposed as 
therapeutic targets (Jope et al, 2007). The pentose phosphate pathway (PPP) is 
utilized by tumour cells to replenish NADPH and ribose 5-phoshate levels, 
which are in high demand for processes such as fatty acid and nuclei base 
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synthesis, both essential to the rapidly proliferating tumour cells. Indeed studies 
have shown that the proportion of glucose committed to the PPP increases 
progressively with increased carcinogenic transformation (Richardson et al, 
2008). 
Benefits to the tumour cell of increased levels of glycolysis could include the 
generation of glycolytic intermediates for multiple biosynthetic pathways, 
important in enabling the synthesis of nucleosides and amino acids, which in 
turn are required for biosynthesis of macromolecules and organelles required 
for the proliferating cells (Potter, 1958. Vander Heiden et al, 2009). Although not 
defined as emerging hallmark, alterations in a number of metabolic pathways 
are commonly seen in tumours cells. Such alterations include; 
 
I-2.8.1.1 Lipid metabolism 
Altered lipid metabolism, specifically, a higher rate of de novo fatty acid 
biosynthesis has been shown in many tumours (Medes, Thomas and 
Weinhouse, 1953). Key enzymes involved in supporting this increase in fatty 
acid synthesis, include, ATP citrate lyase and fatty acid synthase (FASN) 
(Bauer et al, 2005. Szutowicz, Kwiatkowski and Angielski, 1974). What‘s more, 
inhibition of either of these enzymes has shown suppression in tumour growth 
(Kuhajda et al, 2000. Hatzivassiliou et al, 2005). This would suggest a reliance 
of tumour cells on de novo fatty acid synthesis for their growth.  
 
I-2.8.1.2 Utilization of alternative metabolites 
Tumour cells have the ability to utilize a wide range of carbon sources 
(Rodrigues-Enriuez et al, 2000). These cells can harvest pyruvate via both 
glutamine-derived malate conversion and alanine transamination (reviewed 
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Frezza and Gottlieb, 2009). Cholesterologenesis would appear to be an 
important process utilized by tumour cells with the inhibition of one of its rate-
limited enzymes (3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase), giving rise to anti-proliferative effects in colon tumour cells 
(Wachtershauser et al, 2001).  
 
   I-2.8.2 Evading immune destruction 
Evading immune destruction has been proposed as the second emerging 
hallmark. The immune system plays a role in recognizing and eliminating 
cancer cells. This is supported by the increased occurrence of certain cancers 
seen in immunocompromised individuals (Vajdic and Van Leeuwen, 2009). 
Cancer cells may evade immune destruction through the secretion of 
immunosuppressive factors, such as cytotoxic T lymphocytes (CTL‘s) and 
natural killer cells (Yang et al, 2010. Sheilds et al, 2010). 
 
The established and emerging hallmarks of cancer provide an excellent 
conceptual framework for understanding the biology of cancer. Together with 
their enabling factors they represent significant differences between normal and 
tumour cells, which in turn drive forward therapeutic development. The 
importance of the tumour microenvironment and its influence of the various 
hallmarks of cancer is widely appreciated. As such any therapeutic target 
identification strategy should be considered in the context of the tumour 
microenvironment.  
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I-3 Tumour microenvironment  
The tumour microenvironment consists of a collection of different cell types all 
of which contribute to tumour growth and progression. Tumour cells 
themselves, although not entirely responsible for tumour progression provide 
the foundations via multiple oncogenic and tumour suppressor mutations which 
dictate their behavior. Typically human tumours are histopathologically diverse, 
containing cells which demonstrate varying degrees of vascularity, 
inflammation, invasiveness, proliferation and differentiation. The existence of 
cancer stem cells (CSCs) is now widely accepted (Reya et al, 2001) and their 
ability to self-renew is thought to contribute to treatment resistance. The tumour 
associated stroma includes endothelial cells, which provides the basis for 
tumour associated vasculature, both supporting and promoting this vasculature 
are pericytes (Berges and Song, 2005). Immune inflammatory cells are often 
seen to contribute to the tumour microenvironment and through the release of 
signaling molecules such as EGF and VEGF and enzyme including MMP-2, are 
thought to promote angiogenesis and enhance tumour cell migration and 
invasion (Qian and Pollard, 2010). The tumour stroma of many carcinomas 
predominantly contains fibroblasts, specifically, myofibroblasts, which are 
characterised by their expression of α-smooth muscle actin (SMA). The 
mechanisms by which tumour associated fibroblasts contribute to tumourigensis 
remains largely to be determined (Shimoda et al, 2010). The bone marrow has 
been implicated in supplying many of the different types of tumour associated 
stromal cells (Bergfeld and Declerck, 2010). The complexity of the tumour 
microenvironment and the many different cell types which it contains make it 
very difficult to obtain a comprehensive understanding of the molecular 
mechanisms underpinning its role in tumourigensis. 
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Figure 1: The cells of the tumour microenvironment. Taken from Hanahan and Weinberg, 2011. 
 
I-4 Tumour vasculature 
Tumour vasculature differs dramatically both morphologically and functionally 
from that seen in non-tumour tissue (Bergers and Benjamin, 2003). It is 
characterised by its irregular shape, tortuous architecture, dilated appearance 
and abrupt changes in diameter. Tumour vessels often include blunt ends, 
bulges and/or leaky sprouts. These differences are a consequence of the 
inefficient and disorganised nature of tumour vasculature formation which often 
includes the incorporation of existing normal blood vessels. Unlike normal blood 
vessel walls which consist only of endothelial and support cells, tumour vessel 
can include tumour cells (reviewed by Folkman, 1995). Tumours also possess 
the ability to recruit bone marrow derived endothelial precursor cells (Lydoen et 
al, 2001) and unlike normal tissue where vessel organization is determined by 
the metabolic and oxygen needs of that tissue, tumours often have excessive 
capillary growth.  
 
The abnormalities associated with tumour vasculature can themselves provide 
opportunities for novel therapeutic targeting approaches (reviewed by Neri and 
Bicknell, 2005), or perhaps more interestingly for the current project the unique 
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microenvironment which they create can proved a rich area to explore in the 
search for novel targets for therapeutic intervention. 
 
I-5 The physiological microenvironment  
The physiological microenvironment generated within solid tumours as a result 
of a poor and inefficient blood supply, includes gradients of oxygen tension, 
nutrients, catabolites, proliferation rates and extracellular pH, all of which vary 
as a function of distance from the supporting blood vessel (Brizel et al, 1995. 
Lartigau et al, 1997. Vaupel, Kallinowski, and Okunieff, 1989. Helmlinger, 
1997). The physiological microenvironment of solid tumours represents an 
attractive area in which to identify targets for therapeutic intervention. It exhibits 
important and exploitable differences to the physiological microenvironment of 
normal tissue and its study is not complicated by the presence of multiple cells 
types, which are seen with the entire tumour microenvironment.  
 
I-6 Experimental models of the tumour microenvironment: Multicell 
Spheroids (MCTS) 
Initial work in the area of MCTS was pioneered by Holtfreder (Holtfreder, 1944. 
Holtfreder, 1947) and Moscona (Moscona, 1952. Moscona, 1957a.b). These 
two groups made important observations using re-aggregated cultures of 
malignant and embryonic cells. Sutherland and colleagues went on to initiate 
the ongoing work using MCTS as an in vitro cancer model system (Sutherland, 
McCredie and Inch, 1971). The term multicell spheroid is used to describe 
tumour cells which are grown as 3-dimensional structures. By culturing tumour 
cells in this manner, the growth and microenvironmental conditions of solid 
tumours and micrometastases are simulated. The geometry of MCTS allows for 
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the reproducible concentric arrangement of cells to be to be established within 
the spheroid, different regions of the spheroid contain cells experiencing 
different microenvironmental conditions which affects their biochemistry and 
ultimately their behavior. This well defined geometry allows for direct 
relationships between structure and function, to be determined.  
MCTS more closely resemble in vivo tumours, in terms of morphology and intra 
cellular environment when compared to conventional monolayer cultures. As 
both cell shape and environmental conditions can determine the overall 
behavior of cells, through altered gene expression, this is an important 
consideration. 
MCTS have been said to be a particularly useful model for simulating 
chronically quiescent and hypoxic cells as they occur in a dynamic equilibrium 
between necrotic and proliferating compartments in vivo (Sutherland, 1988). 
These similarities between MCTS and tumours in vivo, together with others, 
suggest that MCTS are a model that reflects several pathophysiological 
properties of tumours in vivo, many of which are important determinants of 
response to therapy. 
 
I-6.1 Regions of the spheroid 
MCTS (>250μm) consist of a peripheral layer of proliferating cells which here in 
will be termed the surface layer. Within the spheroid lies an intermediate area 
which consists of viable yet quiescent cells, surrounding the necrotic core, this 
is often referred to as the hypoxic region, in the current study this will be termed 
the peri-necrotic core. The centre of MCTS often consists of necrotic cells and 
is referred to as the necrotic core. These spheroid regions were first described 
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by Sutherland and colleagues (Sutherland, McCredie and Inch, 1971). Figure 2 
illustrates these regions.   
 
Figure 2: Glut-1 staining of a section taken from a mature DLD1 MCTS, highlighting the three 
distinct regions. 
 
I-6.1.1 Surface layer   
The surface layer of MCTS contains cells which are actively proliferating. These 
cells have been shown to be very similar to exponentially growing monolayer 
cultures (Freyer and Sutherland, 1980). Cells within the surface layer 
demonstrate a high degree of DNA-synthesis activity and they exhibit complete 
viability and have maximal clonogenic capacity (Freyer and Sutherland, 1980). 
Cells in this peripheral region are often significantly larger than those found 
closer to the spheroid centre (Freyer and Sutherland, 1980). This maybe due to 
a decrease in the amount of mitochondria per cell as distance into the spheroid 
increases, thus one would expect to see a decrease in mitochondrial protein 
levels in the peri-necrotic and necrotic core regions of the spheroid. This would 
be expected to be true as mitochondrial activity has been shown to be highest 
Peri - 
necrotic  
core 
Necrotic core 
Surface layer 
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in the cells of the spheroid periphery (Kunz-Schughart, Habbersett and Freyer, 
1997). 
Following the emergence of necrosis it is often observed that the thickness of 
the surface layer remains relatively constant throughout the continued growth of 
the spheroid. The thickness being dependant on diffusion limits. This 
phenomenon is not, however, universally true and will ultimately depend on the 
characteristics of the spheroid necrotic core region. A decrease in surface layer 
thickness has previously been noted to occur at a later stage of spheroid 
growth, with the mechanism responsible for this being attributed to the presence 
of so called ‗viability inhibitors‘ which include toxic factors released in the 
process of necrosis occurring within the core of the spheroid (Freyer and 
Sutherland, 1986. Freyer,1988). 
 
I-6.1.2 Peri-necrotic region 
The fraction of cells which are present within this region has been shown to 
increase with increasing spheroid size (Sutherland, McCredie and Inch, 1971). 
Due to diffusion limits, the cells present within this region generally suffer from 
hypoxia, the extent or ‗depth‘ of which varies depending on cell type and 
distance from the surface. Hypoxia has been previously used as a target for 
therapeutic intervention, for instance with the use of bioreductive drugs (Lin et 
al, 1973). Despite efforts to target hypoxia in this manner, its presence in 
human solid tumours still presents a significant challenge for anticancer 
treatments such as chemotherapy. Furthermore, the presence of hypoxia in 
solid tumours is associated with poor prognosis, with poor responses seen and 
greater risks for metastasis (Brizel et al, 1999. Brizel et al, 1997. Brown and 
Giaccia, 1998. Vaupel and Hockel, 2002). 
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This region consists of a high proportion of quiescent cells with an accumulation 
of cells arrested at the Go phase of the cell cycle. Quiescent cell populations 
present numerous challenges to the treatment of cancer using anticancer 
therapies. These include, re-growth resistance (Brown and Giaccia, 1998), 
which requires the need for multiple treatments which in turn increases the 
likelihood of further resistance occurring.  
 
I-6.1.3 Necrotic core    
When MCTS grow beyond a certain diameter (typically >400 μm), a necrotic 
core develops. This core is clearly visible in cross section (figure 2) but it is also 
visible down the light microscope where it appears as a dark area at the centre 
of the spheroid (see Section II, figure 12 for a representative image). The origin 
of this necrotic core is likely to be oxygen and nutrient starvation in conjunction 
with a build up of catabolic waste products that accumulate around cells in this 
region.  The exact mechanisms responsible for the formation of the necrotic 
core are not fully understood however and several possible mechanisms exist. 
It has been proposed that MCTS can be classified into three groups according 
to their oxygen status at the time in which necrosis first occurs (Mueller-Klieser, 
2000). The groups are as follows; 
Group 1: MCTS which belong to this group conform to models generated which 
use diffusion modeling (Groebe and Mueller-Klieser, 1996). With these 
spheroids hypoxia is preceded by necrosis.  
Group 2: Spheroids which fit into this category have been shown using 
bioluminescence imaging to contain cells which have relatively high ATP levels 
despite having PO2 values close to 0mmHg (Walenta et al, 2000). This would 
suggest that cells remain viable despite the presence of hypoxia. 
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Group 3: These spheroids show the emergence of necrosis which precedes that 
of hypoxia. The cause of necrosis in these spheroids is unclear. Some evidence 
would suggest that the metabolic environment within such spheroids is 
unfavorable which may lead to the induction of apoptosis in some cells. It is 
thought that this may in turn lead to secondary necrosis, which is triggered by 
structural disintegration. Specifically it has previously been shown that 
glutathione (GSH) levels were increased in association with an accumulation of 
apoptosis within the centre of MCTS (Romero, Zukowski and Mueller-Klieser, 
1997). This increase in GSH level is not apparent once secondary necrosis 
occurs. Whether this increase in GSH levels is related to its role in defense 
against oxidative stress remains to be seen.   
 
It would be reasonable to assume that no single factor alone is responsible for 
the development of the necrotic core (Acher et al, 1987. Carlsson and Acker, 
1988). These authors have gone on to speculate that it may be a combination of 
factors include, hypoxia, low nutrient availability, accumulation of waste and low 
pH which may contribute to an unfavorable environment or ‗toxic environment‘ 
within the centre of the spheroid. Faced with this environment, cells are unable 
to maintain there intercellular homeostasis and as a result large scale necrosis 
is seen. A comprehensive knowledge of cell death in MCTS has thus far not 
been achieved and therefore remains an important challenge to this area of 
research.  
 
I-6.2 Solid tumours and Spheroids 
As mentioned previously, by culturing cells as MCTS, physiological conditions 
are created that more faithfully represent those found in solid tumours in vivo.  
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Some of the main similarities between MCTS and in vivo solid tumours are 
highlighted below; 
 
I-6.2.1 Histological structure 
The histological structure of MCTS has been shown to be more representative 
of tumours in vivo, with spheroids generated using HT29 (human, colon, 
adenocarcinoma) cells shown to retain the distinctive thick filament network 
which covers the surface of in vivo tumours (Rosai, 1996). The ability to 
represent aspects of the histological structure of in vivo solid tumours is an 
important consideration for any in vitro tumour model system, as the 
relationship between the cell shape, cellular environment and cell phenotype is 
gaining increasing importance. Previously, the incidence of K-ras mutations, 
which is characteristically seen with specific colorectal tumours, was shown to 
coincide with the point in which the tumours acquire 3D growth patterns (Rak et 
al, 1995).  
 
I-6.2.2 Oxygen gradients and respiratory activity 
As a result of the architecture of MCTS, gradients in the partial pressure of 
oxygen (PO2) are present throughout the spheroid, with a lowering of PO2 
values seen with increasing distance from the spheroid‘s surface. The results 
seen with direct measures of O2 tension within spheroids are difficult to 
interpret, as different research groups have produced contradicting results, with 
both low and high PO2 values having previously been reported (Kaufman et al, 
1981. Carlsson et al, 1979). At least some of these discrepancies have been 
shown to be a result of methodological differences in both the performance of 
the microelectrode measurements and spheroid culturing techniques, used in 
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each case (Mueller-Klieser and Sutherland, 1982a,b). The lower PO2 values 
seen within the inner regions of spheroids provide a microenvironmental factor 
which is similar to that faced by cells within solid tumours (Vaupel, Frinak and 
Bicher, 1981).  
 
The oxygen status of the cells within the spheroid can impact upon the 
respiratory activity of the cells, with a decrease in O2 supply possibly leading to 
a decrease in respiratory activity (Mueller-Klieser, 1984). Also, it has been 
proposed that the chronic restrictions in glucose supply seen within tumor 
spheroids, may enhance cellular respiration rates (Mueller-Klieser, 1984). 
These adaptations in respiratory activity in response to O2 and glucose supply 
occur during spheroid growth (Freyer et al, 1984), where the levels of both 
would be expected to become increasingly lower. Unlike monolayer cells, large 
MCTS exhibit cellular respiration rates which are typical of small solid tumors 
(Freyer et al, 1984. Muller-Klieser and Sutherland, 1985. Mueller-Klieser et al, 
1985). 
 
I-6.2.3 The establishment of various pathophysiological gradients 
The concentric arrangement of cells seen with MCTS leads to the establishment 
of various pathophysiological gradients. These gradients are comparable to 
those seen within avascular tumour microregions, inter-capillary tumour regions 
and micrometastasis, as detailed in figure 3.  The main pathophysiological 
gradients include those in proliferation rates, metabolite, catabolites, oxygen 
and other nutrients concentrations.  
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Figure 3:  A comparison of spheroid, tumour microregions and micrometastasis (Adapted from 
Kunz-Schughart, 1999). 
 
Cells located some distance from a capillary supply and also avascular 
micrometastasis, become deficient in required nutrients, including, oxygen and 
glucose (Thews and Vaupel, 1978. Vaupel and Thews.1974). These effects can 
also occur through acute restrictions in the delivery of nutrient to cells as a 
result of capillary shunting or decreases in local blood flow (Boaq, 1977. 
Reinhold, Blachiewicz and Berg-Blok, 1979). As MCTS are also avascular they 
too become deficient in required nutrients. Cells which face nutrient deficiencies 
for prolonged periods of time develop altered cellular properties. These include 
a decreased rate of metabolite consumption (Gullino, 1978) and an altered cell 
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cycle distribution (Tannock, 1968). These changes in cellular properties in many 
cases will result in altered response to therapy. This is especially true for 
instance where an altered cell cycle distribution occurs, as many conventional 
anticancer treatments are targeted towards specific events within the cell cycle. 
Altered cell cycle distributions are seen in cells within MCTS (Durand, 1976), 
and may represent an important benefit of the model in determining drug 
responses. Increased lactate levels have also been shown to be present within 
the central regions of MCTS, this was shown to occur shortly before cell death 
(Walenta et al, 2000). 
 
I-6.2.4 Spatial variations in cellular proliferation 
Within solid tumours those cells which are located in areas with an adequate 
supply of oxygen and nutrients will show a high level of proliferation (Rajewsky, 
1965. Tannock, 1968. Burns and Tannock, 1970. Denekamp and Kallman, 
1973. Brammer et al, 1979). In comparison, those cells in regions of the tumour 
which are not in close proximity to blood vessels, show proliferation rates which 
are greatly reduced. This occurs as cell cycle times are increased as a 
consequence of diffusion-limited nutritive supply and also the restricted removal 
of waste products (Koch et al, 1973a. Koch et al, 1973b. Born et al, 1976). The 
presence of similar proliferation gradients are seen within MCTS (Sutherland, 
Mccredie and Inch, 1971). The proliferative population of cells in large MCTS 
are localized to the spheroids superficial layers, which are within 50-100µm of 
the spheroid surface (Sutherland, McCredie and Inch, 1971). It has previously 
been suggested that the quiescent cells found within MCTS, show more 
similarity with GO- phase cells in vivo, than do plateau-phase cells cultured as a 
monolayer (Bauer et al, 1982). 
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I-6.2.5 Matrix component expression 
MCTS have previously been shown to express matrix components which are 
similar to their respective original tumours. These components include 
glycosaminoglycans (Angello and Hosick, 1982) and collagen (Grover et al, 
1983). The capacity of equivalent monolayer cells to synthesis extracellular 
matrix materials would appear to be reduced or perhaps absent altogether. 
MCTS also appear to be able to retain a similar degree of structural and 
functional differentiation as the primary tumours from which they are derived 
(Ricci-Vitiani et al, 2007). This may in part be due to the expression of matrix 
components. Recently, using primary colon carcinoma cells, Ricci-Vitiani and 
colleagues demonstrated that the so called ‗cancer stem cell‘ population of the 
colon carcinoma primary cells was maintained when grown as MCTS but was 
lost when the same cells were grown as a monolayer (Ricci-Vitiani et al, 2007). 
Furthermore, the presence of this cancer stem cell population was shown to 
determine the tumorigenic potential of the cell line (Ricci-Vitiani et al, 2007).   
 
MCTS are a promising model in which to study tumour- stroma interactions. For 
this type of investigation ‗heterospheroids‘ are required, which are established 
by co-culturing tumour cells, fibroblasts and supportive skeleton fibrous tissue. 
Heterospheroids have been generated which maintained the individual 
characteristics of the original colon carcinoma specimen, from which it was 
derived (Kammerer and Von Kleist, 1995).  
 
I-6.2.6 Cell adhesion molecules 
Specific molecules are expressed on the cell surface which are involved in cell-
matrix and cell-cell binding. These receptor/ligands are responsible for the 
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transduction of extracellular signals to molecules and specific targets within the 
cell (Joseph-Silverstein and Silverstein, 1998). Integrins, which are a major cell 
adhesion molecule family, have previously been shown to exhibit a similar 
receptor expression pattern in spheroids as is expressed in vivo (Waleh et al, 
1994). This has not been shown to be the case with monolayer cells, which 
exhibit increased expression levels of integrins (Hauptmann et al, 1995). 
 
I-6.2.7 Cell signalling 
Altered signal transduction has been noted between 2D and 3D systems with 
some suggestions of entirely separate regulatory pathways involved in each 
case (Cukierman et al, 2001). Differences in pathways such as ERK1/2 have 
been shown between 2D and 3D systems (Daniel et al, 2010).  
 
I-6.2.8 Response to therapy  
MCTS cells have been shown to be more resistant to ionizing radiation than 
monolayer cells; furthermore, this increase in resistance was shown to be 
independent of supply conditions (Durand and Sutherland, 1971).  This 
differential response to radiation was proposed to be a result of a contact effect 
between the cells of the spheroid (Durand and Sutherland, 1972). This so called 
‗contact resistance‘ appears to correlate with the occurrence of gap junctions 
and to a lesser extent with the electrical coupling between cells (Dertinger and 
Hϋlser, 1981).  Alternative resistance mechanisms have been proposed. These 
include, the ability of spheroids to possibly exhibit more efficient DNA repair. 
This was proposed to be due to the specific nuclear shape and DNA packing in 
spheroids (Olive and Durand, 1994), however conclusive mechanisms remain 
to be determined.  Radiation responsiveness in vivo has been previously shown 
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to correlate with that of the corresponding spheroids in vitro (Rofstad, Wahl and 
Brustad, 1986). As MCTS exhibit oxygen concentration gradients, they have 
been used extensively in radiation response studies.  Detailed reviews on this 
topic have been published by Olive and Durand (1994) and Santini and 
Colleagues (Santini, Rainaldi and Indovina, 1999).  
 
A multicellular-mediated resistance to alkylating drugs has been previously 
observed in MCTS (Graham et al, 1994). Numerous mechanisms for this 
resistance have been proposed, these include those previously suggested for 
ionizing radiation resistance as outlined above. Also, some researchers have 
proposed that the higher chemoresistance, seen with MCTS maybe associated 
with poor penetration of drugs into the deeper layers of the MCTS (Kohno, 
Ohnuma and Truog, 1994). Work using verapamil, cyclosporin A, 
orthovanadate, and quinidine to reverse P-glycoprotein (Pgp)-mediated 
multidrug resistance, suggested that quiescent cells within the inner region of 
the spheroid maintain low drug concentration through active efflux of the 
cytotoxic agents (Wartenberg et al, 1998). Despite this active efflux effect, 
concentrations of the cytotoxic agent did exceed that of clinically relevant 
conditions (Chen, Au and Wientjes, 1998), therefore active efflux alone cannot 
be responsible for the resistance seen in MCTS.  The decreased proliferation 
rates seen with cells located inside the spheroids deeper layers may confer an 
increased resistance to cytotoxic agents (St. Croix et al, 1996).  
 
MCTS have been shown to exhibit altered gene and protein expression levels 
when compared to their 2D monolayer counterparts (Ohmori et al, 1998). 
Furthermore, these altered expression levels were shown to be responsible for 
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altered drug responses which were highly predictive of those patterns of drug 
response seen in vivo, with the corresponding tumor type (Ohmori et al, 1998).   
 
The effect of anticancer agents on multiple cell population can be assessed 
using MCTS. Due to the encouraging results seen with spheroids and their 
response to therapy, interest has increased in the prospect of incorporating 
MCTS into drug screening protocols. Many hurdles remain in using MCTS in 
this manner; these hurdles include a general lack of simple automated 
analytical tools and a need for more standardized and defined endpoints. 
Progress is being made in this area of MCTS research and a recent review by 
Friedrich and colleges (2007) details these efforts. 
 
I.6.3 Limitations of Spheroids 
Whilst MCTS mimic many features of solid tumours, it is important to 
acknowledge that the model has several important limitations. This includes the 
fact that not all cell lines form tightly packed spheroids but instead form loose 
aggregates. These aggregates are quite different in morphology from the tightly 
packed MCTS and their use in studying the effect of the physiological 
microenvironment on tumour biology and response to therapy is restricted. 
Furthermore, the properties of MCTS can be highly variable and are dependant 
on a number of factors including the origin of the cell and methodology used in 
the formation of the spheroids together with media and growth conditions. The 
most important limitation of the MCTS system is that it cannot mimic the full 
complexity seen with tumours in vivo. Tumours consist of numerous cell types 
and extracellular matrices that contribute to the malignant phenotype and these 
cannot be completely recaptured using MCTS. By using MCTS co-cultures, 
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however, simpler heterogeneous cell relationships and tumour cell interaction 
can be studied. There is a wealth of co-culture systems in use today and it is in 
this area which the general field is heading towards. A recent review details the 
achievements in this area (Friedrich, Ebner and Kunz-Schughart, 2007). 
 
I-6.4 Drug discovery using MCTS as a model 
There is a need to develop new therapies to treat cells within the physiological 
microenvironment of tumours and this requires the identification of new targets. 
The following sections will describe some of the techniques that can be applied 
towards the identification of new targets based upon analysis of mRNA and 
protein in cells isolated from different regions of the MCTS. Compared to 
conventional 2D systems 3D MCTS provide a physiological microenvironment 
that more closely mimics that of in vivo solid tumours. This feature is critical for 
therapeutic target identification, since biochemical adaptations which occur as a 
result of different physiological microenvironmetal conditions, may facilitate cell 
survival and thus represent an attracted target for therapeutic intervention.  
I-7 Genomics 
Genomics is a term used to describe the study of all of the nucleotide 
sequences, including structural genes, regulatory sequences, and non-coding 
DNA segments, in the chromosomes of an organism. The field of genomics was 
pioneered by Fredrick Sanger who together with his colleagues developed the 
chain termination method of DNA sequencing (Sanger, Nicklen and Coulson, 
1977). Using this method Dr Sanger and colleagues successfully sequenced 
the very first DNA-based genome (Fiddes et al, 1977). Many genomes were 
subsequently sequenced with perhaps the most noteworthy being the human 
genome, which was completed in 2001 (Venter et al, 2001).  
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I-8 Why study proteins? 
Despite the enormous contribution genomics has provided to medical research, 
the study of genes alone provides only a limited source of information. The 
behaviour of all cells is dependant upon the proteins that they express.  As 
proteins are responsible for the phenotype of cells, the study of proteins will 
provide an improved understanding of the mechanisms of disease. 
 
I-8.1 mRNA and Protein comparisons 
Previously mRNA expression levels have been used to investigate gene 
expression, and these types of studies have dominated the field of functional 
genomics. However, although there is value in determining mRNA levels, these 
levels do not show good correlation with their respective protein levels 
(Anderson and Seilhamer, 1997). What is more, some experimental samples, 
such as serum and urine contain no mRNA. 
 
I-8.2 Cellular control mechanism controlled solely in the protein domain  
Many cellular control mechanisms rely on the post translational modification of 
proteins. These modifications include, phosphorylation, as is the case with the 
activation of p53 (Levine, 1997). Since these modification events would not be 
evident from RNA or mRNA studies, protein studies are required to investigate 
them.   
 
Proteins are amongst the most important functional molecules in all cells and 
within all organisms. As would be expected from their diverse roles in cellular 
processes and the complexity of their actions, the study of proteins poses novel 
challenges.  It has been suggested that the sum of all our genes may generate 
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approximately 1 million distinguishing functional entities at the protein level; 
when taking into account the possible differential splicing and translation of 
each human gene and protein post translational modifications (Kolch, Mischak 
and Pitt, 2005).  Figure 4 outlines the opportunities which can give rise to 
multiple gene products at the protein level.  
 
Figure 4: Opportunities to create differences between DNA and its encoded protein.  Adapted 
from Graves and Haystead, 2002) 
   
Despite the many challenges facing the study of proteins and the proteome, it is 
of great importance as they represent an immense opportunity for therapeutic 
intervention. The HUPO (the Human Proteome Organisation) which promotes 
―a broader understanding of the importance of proteomics and the opportunities 
it offers in the diagnosis, prognosis and therapy of disease‖ was set up in 2001 
(Vidal, 2001. Abbott, 2001) and aims to unite the field of human proteome 
research. In appreciation for the importance of studying the proteome and its 
potential to reveal novel targets for chemotherapeutic drug development the 
current project will primarily incorporate a proteomics strategy for target 
identification.  
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I-9 Proteomics 
The term proteomics refers to the large scale study of proteins. The term was 
coined as an analogy to genomics, with a proteome representing the entire set 
of proteins produced by an organism at a defined time point (Wasinger et al, 
1995). Despite the term proteomics being coined in 1995, protein studies were 
being carried out long before this time. These studies were first possible, 
through the introduction of Edman degradation sequencing (Edman, 1949) and 
two-dimensional (2D) gel electrophoresis (O‘Farrell, 1975).  Despite the 
enormous benefits which the introduction of 2D electrophoresis brought, it did 
suffer a major limitation, in that those proteins which were separated could not 
be easily identified. Increases in Edman sequencing sensitivity, achieved in the 
late 1980‘s allowed the first 2D gel separated proteins to be identified 
(Aebersold et al, 1987). 
 
A major breakthrough in protein identification came with the development of 
mass spectrometry (MS) technologies. This breakthrough has together with the 
large-scale nucleotide sequencing of genomic DNA, been responsible for the 
growth of proteomics as a research field, over the last couple of decades. The 
availability of public protein sequence databases together with search engines 
which allow a comparison of mass spectrometry data with protein sequences, 
has been instrumental in the development of proteomics. Improvements in the 
accuracy and sensitivity of mass spectrometry technologies together with 
increases in DNA sequence databases, continues to drive the field of 
proteomics forward to this day.  
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I-9.1 Proteomics work flow  
Investigations carried out looking at the entire proteome require 
multidimensional separation approaches prior to protein identification, due to 
the large dynamic range of protein expression levels, which has previously been 
shown to vary by as much as 7-12 orders of magnitude (Anderson and 
Anderson, 1998). Multi-Dimensional Protein Identification Technology (MudPIT) 
is a termed used to describe a typical workflow for the analysis of an entire 
proteome and is illustrated in Figure 5.  
 Figure 5: Proteomics Mudpit workflow. 
 
I-9.1.1 Protein isolation 
Prior to proteomic investigations, proteins must be isolated from the vast 
mixture of other molecules, which are present within biological samples, such 
as cells or tissue extracts. Proteomics can be applied to a diverse range of 
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biological samples, the nature of which will determine the method of protein 
isolation and subsequent sample preparation.  
 
I-9.1.2 Protein fractionation 
Separation at the protein level is possible and may be beneficial should you 
wish to analyse proteins from specific sub-cellular locations or of a specific 
molecular weight for instance. Within proteomics, 1D and 2D PAGE (O‘Farrell, 
1975) can be considered as preparative separation methods, rather than as the 
traditional analytical tools. 2D gels are most often utilized in comparative 
studies, whereas one dimensional gels are usually used in combination with 
other separation methods to provide 2D separation prior to mass spectrometry 
analysis.  
 
Using 2D PAGE (O‘Farrell, 1975), proteins are separated firstly by isoelectric 
focusing (IEF) which separates them according to their isolelectric point (pI). 
This is then followed sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE), which separates the proteins according to their 
molecular weight.  
 
A variety of alternative protein fractionation methods are available, the details of 
which, are beyond the scope of this introduction. These include, numerous 
types of chromatography techniques, such as; ion exchange chromatography, 
hydrophobic interaction chromatography (HIC), size exclusion chromatography 
(SEC) and gel permeation chromatography, which can be used to separate 
proteins depending on their charge, hydrophobicity, and on their size, 
respectively. Affinity chromatography utilizing the non-covalent interaction 
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between a specific analyte which binds to the protein or protein family of interest 
provides an additional chromatographic preparative separation method 
(Simpson, 2003).  
 
Non-chromatographic methods such as immunoprecipitation, sequential 
solubilisation and subcellular fractionation can also be used to separate proteins 
either on their own or as part of a multi-dimensional separation approach.  The 
separation methods incorporated into any protocol will be dependant on the 
specifics of the experiment including sample type as well as the overall 
objectives of the project.      
 
I-9.1.3 Digestion 
The sensitivity and mass accuracy of mass spectrometers is directly related to 
the size of the peptide or protein, with the optimum analyte mass typically being 
between 1-5kDa. Furthermore, peptides are more readily ionized than are intact 
proteins.  It is, therefore, desirable to digest proteins into peptides prior to mass 
spectrometry using specific proteases. Trypsin is the most common enzyme 
used for this purpose. Trypsin hydrolyzes proteins on the C-terminal side of 
lysine and arginine (unless these residues are on the N-terminal side of proline). 
Other approaches are available for degrading proteins, including chemical 
(CNBr and formic acid) and proteases (arg-C endoproteinase) based methods. 
 
I-9.1.4 Peptide Separation and/or enrichment  
Multiple sequential separation methods are frequently required to provide 
samples which are of reduced complexity for mass spectrometry analysis. In 
these instances, methods which separate the peptides based on different 
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physical properties are often used. Multidimensional separation is often 
achieved using sequential liquid chromatographic methods (Link et al, 1999), 
such as isoelectric focusing (IEF) followed by nano reverse phase liquid 
chromatograph (RP HPLC) (Kennedy and Jorgenson, 1989). RP HPLC 
approaches, as well as providing separation of peptide, can also concentrate 
the peptides prior to their analysis by MS. Sample concentration in this case 
can be achieved through depositing samples onto a MALDI target plate.  
 
I-9.1.5 Mass Spectrometry 
There is a number of different mass spectrometry techniques used for 
proteomics. These can differ in terms of their ionisation method, the method of 
analysis used, the number of analysers that are used in tandem and the method 
of fragmenting the precursor ion in tandem MS. 
 
The components of a mass spectrometer are shown in figure 6. 
Figure 6: Generic components of a mass spectrometer. 
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I-9.1.5.1 Ion Sources 
The primary step in any mass spectrometric analysis is the production of gas-
phase ions of the compound to be analysed, this process is referred to as 
ionization and is achieved by the incorporation of an ion source within a mass 
spectrometer.  
 
There are a wide variety of ion sources which can be used to achieve ionization 
of a sample within a mass spectrometer. These include, electron (Dempster, 
1936), chemical ionization (Harrison, 1983), fast atom bombardment (FAB) 
(Barber et al, 1981), plasma desorption (Macfarlane and Torgerson, 1976), 
matrix assisted laser desorption (Karas and Hillenkamp, 1987), thermospray 
(Blakney and Vestal, 1983) and electrospray (Fenn et al, 1989).  
 
Mass spectrometers most commonly used for proteomics include either ESI or 
MALDI technology: Electrospray Ionization (ESI) (Fenn, 1989) was developed 
following the observation that proteins can produce multiple charged ions. With 
electrospray, the analyte is introduced into the ion source in combination with a 
solvent into which it has been dissolved.  The solvent/analyte solution is passed 
through a small charged capillary (Fenn et al, 1990).  As the solvent/analyte 
solution leaves the capillary, an aerosol or spray is generated. This is created 
as a result of the positively charged analyte ions being repelled by the 
negatively charged capillary from which they emerged. Nitrogen gas or heat is 
then used to evaporate the neutrally charged solvent particles. Once the solvent 
particles are evaporated, the analyte ions are forced into closer proximity, as 
this occurs their like charges repel and the analytes, through the process of 
Coulombic fission, produce gas phase ions. After the analyte ions are separated 
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from the solvent completely, they then enter the mass analysers. In mass 
spectrometry, nanospray is based on the same principles, but with ions 
produced from the charged capillary at a flow rate of 0.01-0.5μl/min. Below is a 
diagrammatic representation of electrospray ionization; 
 
Figure 7: Electrospray ionization. Adapted from http://www.ich.ucl.ac.uk 
 
ESI technology can be interfaced with online liquid chromatography (LC) such 
as reverse phase, which allows for complete automation of the process from 
separation to analysis. By using nano LC at low flow rates, the volume in which 
the eluate is eluted can be reduced. As ESI mass spectrometry is concentration 
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dependent this can be used to improve the instruments overall sensitivity, 
allowing for very small peptide quantities to be analysed.  ESI technology has 
however, a very low tolerance to detergent and buffers.  
 
The ability to form highly charged ions without causing fragmentation, is a 
characteristic of ESI, this serves to lower the mass/charge range of the ions, 
therefore, allowing ESI technology to be applied to a wide range of mass 
analysers. These include, ESI coupled to TOF analysers (Boyles and 
Whitehouse, 1992), ESI coupled to Fourier transform ion cyclotron mass 
analysers (Henry et al, 1989) and ESI coupled to ion trap mass analysers 
(McLuckey et al, 1994).  
 
Matrix assisted laser desorption ionisation (Karas et al, 1987) involves the 
mixing of the analyte with a matrix solution, which exhibits a strong absorption 
at the same wavelength as that of the mass spectrometers laser. Upon mixing 
the analyte and matrix solution a crystalline layer is formed on the sample target 
plate (Gobom et al, 2001). A common matrix solution is α-cyano-4-
hydroxycinnamic acid (CHCA), however the choice of matrix is dependant on 
the laser wavelength used and the type of analyte. Following excitation from the 
laser beam, it is proposed that laser desorption of the analyte/matrix mixture 
occurs, which results in the formation of a molecular plume of charged 
matrix/analyte molecules. Alternative ionisation pathways and mechanisms 
have been suggested, however, the above is currently the most widely 
accepted (Zenobi and Knochenmuss, 1998).  MALDI typically generates singly 
charged molecular species.  Figure 8. illustrates the process by which MALDI 
achieves analyte ionization. 
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Figure 8: MALDI ionization process. Adapted from www.magnet.fsu.edu. 
 
The combination of MALDI technology together with a TOF analyser produces 
an accurate mass spectrometer, with a measuring accuracy of above +/- 10ppm 
(Clauser, Baker and Burlingame, 1999). 
 
As well as being amenable to a high throughput automated workflow, a primary 
benefit of using MALDI mass spectrometry is its ability to provide multiple 
opportunities for repeat analysis on the same sample until it is exhausted, as 
the analyte is immobilised on the MALDI target. Compared with other ionization 
techniques, MALDI demonstrates relatively lower sensitivity to contamination.  
 
With MALDI ionization technology, discrete pulsed ion packets are generated 
rather than a continuous beam of ions, which makes interfacing with many 
types of analyers, more difficult. Despite this, MALDI technology is available in 
combination with quadrupole ion traps (Jonscher et al, 1993), TOF analysers 
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(Spengler et al, 1992), and Fourier-transform mass analysers (Castoro and 
Wilkins, 1993).  
 
Different mass spectrometers often produce non-redundant information, 
therefore providing complementary approaches as each has a preference for 
the ionization of peptides with different efficiency.  
 
I-9.1.5.2 Mass Analysers 
Following the generation of the molecular ions, they are separated according to 
their mass-to-charge ratio in the mass analyser.   
 
There are a range of mass analysers currently used in commercial instruments, 
which include, time of flight (TOF), Q-TOF, QQQ, ion trap, Orbitrap and FTMS 
mass analysers. TOF analysers use a field-free region, within which, the time 
the ions take to pass from the ionisation point (laser pulse trigger in the case of 
MALDI) until they reach the detector is measured. This type of analyser relies 
on the principle of Newton‘s second law of motion.  
 
Fourier transform mass analysers, such as ion cyclotron resonance (ICR) apply 
the Lorentz force law, which uses the frequency of the cycling ions to determine 
their mass to charge ratio. A variation of Fourier transform mass analyser is the 
Orbitrap which uses the frequency of oscillating ions to determine their mass-to-
charge ratio.   
Some mass analysers also contain quadrupoles (Q), which use a combination 
of constant DC and radio frequencies to generate oscillating AC electric fields 
and focus specific ions (Paul and Steinwedel, 1953). 
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Ion Traps, such as linear ion traps, confine particular ions both radially and 
axially using a two-dimensional radio frequency field and by applying potentials 
to the end cap electrodes, respectively.    
 
I-9.1.5.3 Tandem Mass spectrometry MS/MS 
It is common for mass spectrometers used in proteomics to incorporate two 
stages of mass analysis,  referred to as tandem mass spectrometers, which are 
used to acquire MS/MS data. Examples of tandem mass spectrometers include 
Q-TOF, TOF-TOF and LTQ-Orbitrap. 
 
I-9.1.5.3.1 MS and MS/MS analysis 
Originally protein identification through mass spectrometry analysis was 
achieved using the peptide mass finger (PMF) approach (Henzel et al, 1993. 
Pappin, Højrup and Bleasby, 1993, Mann, Højrup and Roepstorff, 1993) in MS 
mode using a MALDI mass spectrometer. With increasing database sizes, PMF 
data is often insufficient for confident protein identification.  To overcome this 
issue tandem mass spectrometry (MS/MS) analysis of peptides to generate 
sequence-specific fragments is used (Mann and Wilm, 1994). MS/MS involves 
two stages of mass analysis, between which a selected parent ion is 
fragmented to produce fragments which are measured in an MS/MS spectra. 
There are two main types, those which achieve MS/MS in space and those 
which achieve MS/MS in time. With the former, parents ions are selected which 
achieve an appropriate level of intensity in the first MS spectra, which is then 
allowed to pass into a collision cell where upon collision with a neutral atom or 
molecule in the gas phase it is fragmented. The fragment ions are analyzed 
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using a second mass analyzer. In the latter, parent ions are stored prior to 
fragmentation and further MS and MS/MS analyses. Parent ion fragmentation is 
often achieved using collision-activated (CAD) or collision-induced 
decomposition (CID). Parent ions which are fragmented using CID or CAD, 
fragment along their peptide backbone, therefore producing signature fragment 
ions, the masses of which corresponds to the amino acid sequence (Roepstorff 
and Fohlman, 1984). Other MS/MS fragmentation methods have recently been 
developed, including, electron transfer dissociation (ETD) and electron capture 
dissociation (ECD) which both induce fragmentation of cations through the 
transfer of electrons, with ECD this is specifically low energy electrons. 
 
I-9.1.5.4 Detectors 
 Detectors represent the final element of a mass spectrometer and function 
predominantly by recording either the current or charge produced when an ion 
reaches or passes by its surface. To increase signal intensity amplification is 
often necessary.  
 
I-9.1.5.5 MS analysis  
Upon ionization the mass-to-charge ratio of the charged peptides within the 
sample is determined. With peptide mass fingerprinting (PMF), protein 
identification is achieved with this data alone, by searching the data against a 
database containing the predicted theoretical masses which would be 
generated following the proteolysis of the known proteins within the database. A 
requirement of PMF algorithms is that they assume that the peptides identified 
come from a single protein. For this reason samples containing a mixture of 
digested proteins require MS/MS analysis for their identification.  
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I-9.1.5.6 MS/MS analysis 
By using tandem TOF analyzers, extremely accurate protein identification can 
be achieved. This is done through matching both parent ion and fragment ion 
data to in silico sequences, within publicly accessible databases (Clauser, 
Baker and Burlingame, 1999).  
 
Using automated analysis tools peptides which achieve a pre-determined 
intensity threshold value upon MS analysis, are selected for MS/MS analysis, 
using one of the methods previously outlined in this report. Following 
fragmentation characteristic peptide fragment ions are produced. These are 
ultimately dependent on the method of fragmentation used, however, those ions 
which are commonly seen include b- and y- series ions, and are outlined in 
Figure 9 
 
 
 
Figure 9: Common ions seen during MS/MS. Adapted from www.matrixscience.com. 
 
In order to be detected, fragments must carry at least one charge. Should this 
charge be retained on the N terminal fragment then the ion is assigned as either 
a, b or c, alternatively, if the charge is retained on the fragments C terminus, the 
ion is classed as either x, y or z. This method of ion nomenclature was originally 
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proposed by Roepstorff and Fohlman (1984) and later modified by Johnson et 
al (1987). 
 
Within this fragment information amino acids can be identified. The mass 
difference between 2 consecutive b- or y- series ions will correspond to an 
amino acid. Thus, using the identified ion series, it is possible to obtain the 
sequence of the peptide. 
 
I-9.1.6 Protein Identification  
Once the mass spectrometer has acquired MS or MS/MS data for the analyzed 
peptides, this information is then compared with sequences within relevant 
databases, such as UniProt. Specific search algorithms have been developed 
for this purpose including MASCOT (Perkins et al, 1999) which uses a 
probability-based approach to score the degree of agreement between in silico 
sequence data with that of the experimentally derived data. Mascot uses an 
advancement of the Mowse algorithm (Pappin, 1993). A mascot score is 
defined as, ‘Mascot the absolute probability that the observed match is a 
random event‘ (Matrixscience.com) and can be applied to both PMF (MS) and 
PFF (MS/MS) data.  
 
Taking into consideration numerous search parameters the MASCOT search 
algorithm generates a threshold cut off score, which represents a 95% 
confidence level (p Value = 0.05). It is not unusual for only two unique peptides 
to be sufficient to identify a particular protein within a sample. Failure to detect a 
particular protein using MS, does not confirm the absence of that protein within 
the analysed sample. It maybe the case, that for a number of reasons, the 
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peptides associated with that protein are below the threshold level of detection, 
using MS. These reasons could include peptide signal suppression.  
 
I-9.2 Qualitative Proteomics 
Initially the primary objective of proteomics as a research field was to identify all 
the components of a proteome, with the aim of generating complete protein 
databases or biological maps. This qualitative approach to proteomics is still 
ongoing with impressive efforts, for example, demonstrated with the generation 
of the non-MS based human protein atlas (Persson, Hober and Uhlen, 2006). 
 
I-9.3 Quantitative Proteomics 
At present there is considerable interest in using proteomics in a biological 
and/or clinical assay. The use of proteomics in this manner, involves the 
investigation of dynamic changes in a proteome following external or internal 
perturbations. For proteomics to be a valuable research tool in this manner, 
proteins must be studied quantitatively. Comparisons can then be drawn 
between different experimental states.  
 
Relative quantitation of proteins has been achieved in the past with, for 
example, Western blotting (Renart, Reiser and Stark, 1979) or the use of 
protein stains (Merril 1990). These methods are low throughput and somewhat 
inaccurate, compared with mass spectrometry.   
 
I-9.3.1 Approaches to quantitative proteomics 
Classically protein separation and comparison was achieved through 2D-PAGE 
followed by mass spectrometry. Using this approach, following SDS-PAGE 
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separation the proteins are visualised within the gel by the addition of an 
appropriate stain. Relative quantitation is then achieved using densitometry. 
Here, staining intensity is correlated to protein abundance.  
The development of fluorescence difference gel electrophoresis (2D-DIGE) has 
greatly improved the accuracy and reproducibility of protein quantitation using 
2D gels (Unlu, 1997). The technique involves fluorescently tagging of proteins in 
different samples using different fluorescent dyes such as Cy3, Cy5, Cy2, which 
then allows samples to be resolved together on the same gel, eliminating 
potential gel-to-gel variability.  
 
A major limitation associated with the use of 2D gels, is that they do not allow 
for the quantitation of all proteins. Specific types of proteins which are 
particularly difficult to discriminate include; hydrophobic membrane associated 
protein, proteins of low abundance (dynamic range of the stain is low), proteins 
of very low (less than 10kDa) and very high molecular weight (greater than 
250kDa) and  proteins which exhibit extreme high/low pI‘s. 
 
An additional concern with using 2D gels for quantitative proteomics comes 
from the fact that multiple post-translational forms of a particular protein will be 
located in multiple spots within the gel, and therefore, will distort any 
quantitation of that protein which would be based on a single spot for instance. 
Furthermore, multiple proteins may reside in a single gel band causing further 
inaccuracies in quantitation. The above mentioned factors which contribute to 
inaccuracies with 2D gels, also mean that 2D gels suffer from low 
reproducibility. This problem maybe further exaggerated by the inability to fully 
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automate the running of 2D gels and the recovery and subsequent analysis of 
the proteins separated within the gel.  
 
Previously, protein identification scores from mass spectrometry database 
searching were thought to correlate well with the abundance of that particular 
protein within a sample (Allet et al, 2004) however, others have shown poor 
correlation with protein abundance (Rappsilber et al, 2003). Spectral counting is 
an alternative non labeling approach for quantitation. This method uses the 
number of mass spectra which are identified for a particular protein to determine 
its overall abundance (Gao et al, 2003). This methods does however, require 
many replicates for each sample, in order to provide robust statistically sound 
results.  
 
Protein abundance indices (PAI) have been developed which use the 
relationship between number of identified peptides with protein amount, this is 
normalized by the number of observable peptides for the protein under 
investigation (Rappsilber et al, 2002. Sanders et al, 2002). PAI are used as a 
more accurate method of quantification than just using protein identification 
scores alone.  PAIs have more recently been modified to take into account the 
logarithmic relationship between the two parameters (Ishihama, 2005).  
 
The extracted ion current (XIC), which is the area under the curve of the 
chromatographic peak signal for a particular peptide, can be used in 
combination with XICs of additional peptides, from the same protein, to give a 
quantitative measure of that particular protein (Andersen et al, 2003). The 
accuracy of this quantitative method is low, however, due to the ability to use 
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raw data without the requirement of additional data acquisition, this method 
remains of interest.  
 
In general quantitation methods which are based on signal peptides and/or 
comparing individual MS datasets can be hazardous. This is due to not all 
peptides being analyzable by MS, and also the effects of sample processing 
variability between MS analysis. In general, multiple replicate analyses are 
required to gain a statistically significant understanding of the variation in 
protein expression, requiring increased sample amount, which maybe an issue 
where limited sample availability is encountered. 
 
Unlike other quantitative proteomics approaches, which provide only relative 
protein amounts, multiple reaction monitoring (MRM) can be used to determine 
absolute values for protein amounts. Using the MRM method a proteotypic 
peptide is selected based on experimental data and software applications such 
as MRM Atlas. A peptide which is selected is ideally a unique peptide from the 
protein of interest, which would be generated following protease digestion, 
using for instance trypsin. Peptides to avoid would include; those with chemical 
reactive residues such as arginine or lysine, residues with post translational 
modification, peptides which are adjacent to multiple cleavage sites or large 
peptides. Once selected, a synthetic version of the peptide, containing a stable 
isotope labeled amino acid is created. This is mixed with the experimental 
sample and MS analysis carried out. The intensity of the synthetic peptide 
verses that of the natural peptide is compared, to reveal the quantity of the 
protein from which it originates. Following ionization of the experimental sample, 
the mass of the analyte of interest is selected for fragmentation. A specific 
68 
 
fragment is selected and used to compare the relative abundance between the 
synthetic peptide and that of the experimental peptide of interest. As the 
absolute amount of the synthetic peptides is known one can determine the 
absolute amount of the naturally occurring peptide within the experimental 
sample, and thus determine the protein amount. Limitations with this 
quantitation method include it only being amenable to testing using a triple 
quadrupole mass spectrometer. 
 
Metabolic stable isotope labeling is regarded as the gold standard method for 
quantification. With metabolic stable isotope labeling, stable isotope-containing 
amino acids, such as heavy and light arginine or lysine, are incorporated into 
the host proteome during cellular metabolism and protein synthesis. Most 
commonly, stable isotope-incorporated amino acids are used. To incorporate 
these modified amino acids, cells are grown in vitro in the presence of media 
containing stable isotope labeled amino acids. As labeling is carried out at the 
earliest possible moment in the experiment this minimises quantitative 
inaccuracies arising from the experimental procedure. A limitation with this 
method is that not all samples can be manipulated to accurately incorporate the 
isotopic labels, this is especially true for patients specimens and 3D culture 
systems. 
     
During proteolysis two oxygen atoms from the solvent are incorporated into the 
C-terminus of the cleaved peptide. By carrying out proteolysis in the presence 
water containing different isotopic forms of oxygen, comparative quantitation 
can be achieved for two different samples. With one sample proteolysis should 
take place in the presence of water containing 18O oxygen isotope, the second 
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sample should be digested in the presence of water containing the light oxygen 
isotope 16O. Quantitation is achieved during mass spectrometry analysis, by 
comparing the peak intensities of the two differentially O2 labeled variations of 
each peptide, which will differ in mass by 4 Daltons (Da) (Yao et al, 2001). 
 
A major limitation with this quantitation approach comes as a result of different 
proteolytic enzymes incorporating different levels of water during digestion 
(Reynolds, Yao and Fenselau, 2002). These differences can generate data 
which is ambiguous, as mass shifts may be less than 4Da. Furthermore the 
natural variation of isotopes in the sample can increase the chance of 
inaccurate data being generated.  Efforts have been made to overcome the 
above mentioned limitation. These include inverse 18O-labelling (Wang et al, 
2001).  
 
For all instances where the experimental sample is not amenable to metabolic 
labeling, chemical labeling offers an attractive alternative. As the pooling of the 
samples to be compared occurs later in the workflow, chemical labeling 
compared to metabolic labeling, it is more prone to experimental variation.  
There are currently a wide range of chemical tags available for quantitative 
proteomics. These tags are often specific for specific peptide residues. For 
example, ICAT isotope coded affinity tags (Gygi et al, 1999) which are thought 
of as the prototypical isotope coded affinity tag, modify cysteine residues. Those 
peptides which contain no cysteine residues are therefore excluded from the 
quantitative analysis, resulting in a limited number of peptides available for 
MS/MS, thus, reducing the chance of achieving a definitive ID or statistical 
significance. In some instances this discrimination of non-cysteine-containing 
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peptides is an advantage, in that it reduces the complexity of the sample to be 
analysed. However, in instances where a global analysis of protein abundance 
is required ICAT is not ideally suited.  
 
iTRAQ isobaric tags for relative and absolute quantitation (Ross, 2004), were 
developed to provide a non-discriminative protein quantification method. This is 
achieved through the tagging of peptides on lysine residues and at the N-
termini, thus all peptides are iTRAQ reagent tagged.  iTRAQ reagents can also 
be used at the protein level prior to proteolytic digestion.  
 
iTRAQ reagents provide an excellent tool for protein expression analysis. The 
structure of the iTRAQ reagent is outlined in figure 10. Four different tags were 
originally created to allow for 4plex analysis. Each reagent consists of an NHS-
ester peptide reactive group, N-methylpiperazine reporter group and a carbonyl 
balancer group. The overall mass of the each of the four iTRAQ reagent tags 
remains constant at 145Da, however, each reagent contains a different reporter 
group and balancer group mass, ranging from 114-117 Da and 28-31 Da, 
respectively.  
Figure 10: Outline of the structure of iTRAQ  
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More recently iTRAQ 8plex reagents became available; with these 8 separate 
experimental samples can be compared (Choe et al, 2007).  
 
Using iTRAQ, peptides are quantified in the MS/MS mode. During the initial MS 
scan the same peptide labeled with different iTRAQ reporter reagents (from 
different samples) appears as a single peak, for MS/MS analysis this allows 
those peptides to be analysed in combination. Quantitation is achieved following 
liberation of the iTRAQ reporter groups during fragmentation of the parent ions 
prior to MS/MS analysis. The peak area of each reporter group for that peptide 
is used to quantify the levels of that peptide in multiple samples. Ratios can be 
generated to compare different peptides. The sum of all reporter group peak 
areas for peptides associated with a particular protein is used to quantify its 
levels, within a particular sample.  
 
By allowing quantitation at the peptide level iTRAQ generates multiple 
quantitation measures for any one protein, providing increased confidence in 
the measures. The opportunity to multiplex represents a huge benefit of iTRAQ. 
Draw backs to using iTRAQ include issues relating to variability. This is true for 
labeling efficiency which can vary and protein digestion which is required prior 
to labeling at the peptide level. iTRAQ appears to suffer from inherent dynamic 
range limitations resulting in ratio compression (Desouza et al, 2007 and 2009).  
 
Considerable advances in the field of proteomics have provided a wealth of 
tools with complimentary approaches to explore a given proteome. Each tool 
will suffer from some drawbacks but will also have its own merits. The difficulty 
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lies in selecting the appropriate tools and related strategies for a particular 
investigation.  Proteomics applied to the MCTS as a model system presents its 
own challenges, many of which relate to its 3D structure. For instance, 
metabolic labeling despite being the gold standard for quantitation, can not be 
applied as equal distribution within the MCTS can not be achieved. Taking 
everything into consideration including available and appropriate tools, 
resources, current expertise within the laboratory and the aims of investigation, 
a MudPit approach using iTRAQ for peptide quantitation was used to explore 
the MCTS.  
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II-Aims and Objectives 
 
The limited number of effective novel therapies reaching the clinic together with 
poor response and/or acquired resistance seen to established therapies 
highlights the need for novel cancer drug treatments. Cancer research efforts 
have revealed and continue to reveal the extremely complex molecular basis of 
the disease. Despite this groundbreaking discoveries have pinpointed key areas 
that facilitate tumourigenesis and provide encouragement that cancer can be 
treated through appropriate targeted therapy.  
 
Initial stages of target identification are traditionally carried out using in vitro 
model systems, however the most reliable models should mimic the in vivo 
scenario as closely as possible. To reduce toxicity differences between normal 
and tumour tissue should be exploited. The physiological microenvironment of 
solid tumours differs significantly from that of normal tissues. MCTS mimic 
many of the key features within the physiological microenvironment of solid 
tumours. As such the exploration of this in vitro model system may reveal 
potential targets for therapeutic intervention.  
 
Proteins are amongst the most important functional molecules and ultimately 
their expression influences the behavior of normal and cancerous cells. Major 
advances in the field of proteomics have generated a selection of tools which 
can be used to explore the human proteome. The incorporation of some of 
these tools within an appropriate experimental approach enables them to be 
successfully applied to the study of MCTS.  
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This study using an iTRAQ proteomics strategy, supplemented by enzymology, 
immunohistochemistry, Western blotting and gene microarray analysis, aims to 
explore and compare protein expression within and between different regions of 
the MCTS. The regions to be compared include the surface layer (SL), peri-
necrotic region (PN) and the necrotic core (NC). These regions differ 
significantly from each other in terms of the physiological microenvironment 
conditions within them. It is hoped that the comparison of these regions will 
highlight key proteins which may facilitate cell survival and as such may provide 
viable targets for therapeutic intervention.  
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III-Multi-cellular tumour spheroid culture and sub-regional separation 
 
Successful comparison of the different MCTS regions relies on the ability to 
isolate each region. To achieve this attention must be paid initially to the 
culturing of the spheroids, ensuring good quality asymmetrical universal sized 
spheroids prior to their separation. By ensuring spheroids are both 
asymmetrical and approximately equal in size to each other, the proportion of 
each region within any one spheroid will remain relatively constant, thus 
allowing spheroids to be separated as a group.  
This chapter will outline results for the growth and sub-regional separation of 
MCTS. Various methods will be applied to help confirm that isolation of each 
region was achieved. 
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III-1 Materials and methods 
 
III-1.1 Materials  
All tissue culture plastics were obtained from Costar (Germany) unless otherwise 
stated. Reagents for iTRAQ labeling were obtained from Applied Biosystems (UK). 
All other reagents were obtained from Sigma-Aldrich (UK) unless specified 
otherwise. 
 
III-1.2 Cell lines and Culture conditions 
The human colon adenocarcinoma cell lines DLD1 and HT-29 were obtained 
from the European collection of cell cultures (ECACC). . Both cell lines were 
maintained in Roswell Park Memorial Institute (RPMI) 1640 medium 
supplemented with 10% foetal bovine serum, 2mM L-glutamine, penicillin 
(50IU/ml)/streptomycin (50 µg/ml) and 1mM sodium pyruvate.  This will be 
referred to as complete growth medium henceforth. Cells lines were maintained 
at 37˚C in a 5% CO2 humidified atmosphere. 
  
III-1.3 Routine cell maintenance  
Cells were kept in exponential growth by regular subculturing into a 75cm2 flask. 
As cells reached approximately  80% confluence,  the adhered cells were 
washed twice using Hanks balanced salt solution (HBSS) prior to trypsinisation 
using a 0.25% Trypsin-EDTA solution. Once the cells were detached from the 
flask, the trypsin solution was diluted and inactivated by the addition of 10ml of 
complete growth medium. The cell suspension was subsequently centrifuged 
for 5min at 2000 g. The cell pellet was then re-suspended in 10 ml fresh culture 
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medium and 1ml of cell suspension was transferred into a new culture flask 
containing 10ml of complete growth medium.  
 
III-1.4 Spheroid cell culture 
To initiate spheroid formation, cells in the exponential phase of the growth curve 
were collected from T75 flasks and transferred to T75 flasks that had been 
base-coated with 1% agar. This served to prevent the adhesion of the cells to 
the plastic. Cells were counted using a hemocytometer. Cells were seeded at 
5x105 cells per flask. These cells were then incubated at 37°C for 3 days, at 
which time small multi-cellular aggregates were visible to the naked eye. These 
aggregates were collected into a 20ml universal tube. Large asymmetrical 
aggregates were first removed by allowing them to sediment under gravity. The 
remaining supernatant containing the immature spheroids were transferred to a 
500ml spinner flask (Bibby Scientific Limited, Staffordshire) containing 250ml of 
complete growth medium and these were maintained in suspension by stirring 
at 50 rpm (at 37°C).  
 
III-1.4.1 Spheroid growth curves 
Every second day, samples were removed from the spinner flask and the 
diameter of 20 spheroids was measured by light microscope using an eyepiece 
graticule (calibrated using a stage micrometer at the same magnification).  
 
III-1.5 Spheroid separation 
Once spheroids had reached a diameter of approximately 600μm they were 
separated layer by layer using serial trypsin treatment, adapted from a 
previously described method (Knowles and Phillips, 2001) 
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III-1.5.1 Separation of the surface layer 
Firstly, the outer most layer of the spheroid was removed. This was achieved by 
incubating the mature spheroids with 0.25% Trypsin-EDTA solution. Once the 
supernatant became cloudy the trypsin solution was diluted and inactivated with 
complete medium. The supernatant was collected and centrifuged in order to 
pellet the cells which were successfully removed.  The spheroids were washed 
twice using hanks balanced salt solution (HBSS) and the whole procedure was 
repeated twice. The cell pellet from the second trypsinisation step was 
combined with the first cell pellet and this was defined as the surface layer.   
 
III-1.5.2 Separation of the peri-necrotic region 
Following the removal of the surface layer, further sequential trypsin treatments 
were carried out, in order to remove the outer layers of the spheroid which 
contain the aerobic cells (the cells removed in this process were collected and 
assigned as the intermediate region). Following the removal of approximately 9-
11 layers of cells (the number of which is dependant on original spheroid size) 
the remaining spheroids, containing only the peri and inner necrotic core 
regions, were gently homogenized, using a pestle (Sigma) with spheroids 
residing in a 1.5ml eppendorf. This homogenization results in the bursting of the 
spheroids, and the fragmentation of the peri-necrotic region of the spheroid. 
These fragments were separated from the necrotic core (which contains non-
adherent cells) by sedimentation.  Once separated, these fragments were 
washed using HBSS, this was repeated twice. This fraction of cells was defined 
as the peri-necrotic layer  
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III-1.5.3 Separation of the necrotic core cells 
Once the spheroids were homogenized, the necrotic core cells were liberated 
and were part of the supernatant. The supernatant was collected and 
centrifuged at 14.1 x10 rcf, with the resulting pellet being used as the necrotic 
core sample for analysis.  
 
In order to obtain a measure of distance from the surface of the spheroid, the 
diameter of spheroids was measured (as described for Spheroid growth curves 
III-1.4.1) at each stage of the sequential trypsinisation procedure as described 
above.  
 
III-1.6 Paraffin embedding of spheroids and spheroid sub-regions 
Samples which were to be paraffin embedded were first allowed to sediment in 
a universal tube. Spheroids were fixed using 10% phosphate buffered formalin 
(pH 7.5). Fixation was carried out for 2 hours at room temperature (RT). 
Following this, spheroids were dehydrated through incubation in 70% ethanol at 
RT overnight, 90% ethanol for 1hour and 100% ethanol for 3 times 30 minutes. 
The spheroids were subsequently placed in 100% xylene for 3 times 30 minute 
incubation  at RT. Once fixed and fully dehydrated, spheroids were transferred 
into a suitably sized wax mould. Spheroids were incubated in paraffin wax for 
30 minutes at 60°C in the warming oven. This process was repeated twice 
before  allowing the wax block containing the spheroid sample, to set at RT.  
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Following processing of the spheroids into wax blocks, sections were cut (5 μm 
thick) using a microtome (Leica RM2155). Sections were collected onto 3-
aminopropyltriethoxysilane (APES) coated slides.  
 
III-1.7 Haematoxylin and eosin staining of spheroid sections 
Spheroid sections were de-waxed and rehydrated prior to staining. This was 
achieved through successive incubation in 100% xylene for 10 minutes, 50% 
xylene/ethanol for 5 minutes, 100% ethanol for 10 minutes, 90% ethanol for 5 
minutes and 70% ethanol for 5 minutes. All incubations were carried out at RT.  
 
Spheroid sections were stained in Harris‘s haematoxylin for 10 minutes and 
then  washed in running water. The haematoxylin staining was differentiated by 
briefly incubating the sections in acid alcohol for 5 seconds. The sections were 
then washed briefly in tap water, before being stained blue by incubating in 
Scott‘s tap water for 2 minutes. Sections were then counterstained using 1% 
aqueous eosin (w/v) for 1 minute.  
 
Once stained, the sections were again dehydrated. This time through incubation 
in absolute ethanol for 4 minutes, 50% xylene/ethanol for 3 minutes and 100% 
xylene for 6 minutes. All incubations were carried out at RT. Section coverslip‘s 
were mounted using DPX.   
 
III-1.8 Glut-1 and CAIX staining 
Spheroid sections were de-waxed and rehydrated prior to immunodetection. 
This was achieved through successive incubations in 100% xylene for 10 
minutes, 50% xylene/ethanol for 5 minutes, 100% ethanol for 10 minutes, 90% 
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ethanol for 5 minutes and 70% ethanol for 5 minutes. All incubations were 
carried out at RT.  
 
 
III-1.8.1 Glut-1 antibodies 
GLUT1 is a specific marker of increased glucose uptake and can be used to 
indicate the presence of hypoxia and anaerobic metabolism. GLUT1 was used 
to investigate the localization of hypoxia within intact DLD1 spheroids. Anti-
human Glut-1 rabbit polyclonal (Chemicon International) primary antibody was 
used for this analysis.  
 
III-1.8.2 CAIX antibodies 
CA IX  is a transmembrane carbonic anhydrase isoenzyme predominantly 
expressed in human tumours in a HIF-1 regulated response to hypoxia (Wykoff 
et al, 2000) CAIX staining was used to investigate the efficacy of the spheroid 
separation approach.  Anti-human CAIX goat polyclonal (Santa Cruz) primary 
antibody was used for this analysis.  
 
III-1.8.3 Immunohistochemistry procedures 
De-waxed and rehydrated sections were incubated with an appropriate primary 
antibody (Glut-1 and CAIX, 1:800 and 1:40, respectively,) made up in 0.01M 
PBS. Incubation was carried out for 60 and 45 minutes at RT, for Glut-1 and 
CAIX respectively. Prior to primary antibody incubation, microwave mediated 
antigen retrieval (Cattoretti et al, 1993) in the presence of citrate buffer (100mM, 
pH 6.0), was required to reveal the epitopes to which both primary antibodies 
bind. Sections were microwave heated on medium power for 3x8 minutes and 
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3x10 minutes for Glut-1 and CA1X, respectively. Slides were then allowed to 
cool completely before treatment with primary antibody.  
 
Biotinylated secondary antibodies (Vector) were used at a 1:200 dilution in PBS. 
Positive staining was visualized using DAB reagent (Vector) counterstained with 
Scotts tap water. Images were captured using a QiCam attached to a Leica DM 
RB light microscope using Qcapture software (Spectra Services, Ontario, 
Canada). IHC negative controls were prepared by omitting the primary antibody. 
III-1.9 FAC analysis 
MCTS were grown in spinner flasks for 12 days. During the exponential growth 
phase, 10 ml of culture was harvested and transferred into a universal tube. 
MCTS were pelleted by gravity, washed in PBS and transferred into a clean 1.5 
ml eppendorf. The necrotic core and surface layer of MCTS were separated by 
applying gentle pressure using a sterile pestle (Sigma). The necrotic core was 
released into the supernatant and transferred into a clean 1.5 ml eppendorf. 
The surface layer of MCTS was treated with trypsin to obtain a homogenous 
cell suspension and washed in PBS. Cell morphology analysis of the surface 
layer (SL) and necrotic core (NC) was performed on a FACSCalibur (Becton 
Dickinson, Oxford, UK), using scatter plot analysis to assess cell size (FSC) and 
granularity (SSC), using the CellQuest software. 
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III-2 Results 
III-2.1 Growth and fractionation of MCTS  
III-2.1.1 DLD1 and HT29 growth curves 
  
Figure 11: DLD1 (A) and HT29 (B) spheroid growth curves. Error bars are used to indicate standard deviation.
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Both DLD1 and HT29 MCTS showed a gradual increase in size over culture 
period, as demonstrated in figures 11A and B. In general, the different spheroid 
batches showed a consistent growth pattern. However, the time at which the 
spheroids reached a desired size for analysis, was variable between the 
different batches. This was true for both cell lines. Despite the overall 
consistency in growth patterns, large variations in spheroid diameter between 
spheroids within the same batch, were seen as indicated by large standard 
deviations. HT29 MCTS generally demonstrated more consistent growth 
kinetics across their growth period. Both cell lines ultimately gave rise to very 
similar sized spheroids, within the same period of time (approximately 12 days).   
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Figure 12: Growth of MCTS and the emergence of the necrotic core.  (A) A series of images of HT29 spheroids under light microscopy (x20 objective). (B) H&E 
staining of HT29 spheroids. The black line equates to 200μm. 
 
The emergence of the necrotic core (NC) can be seen with increasing spheroid growth. The NC can initially be seen in HT29 spheroids 
with a diameter of approximately 150μm and continues to expand in size as the spheroid grows, whilst the diameters of the other regions 
of the MCTS remain relative constant.  
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III-2.1.2 Glut-1 staining highlighting regions of hypoxia within DLD1 
MCTS  
 
 
Figure 13: DLD1 spheroid stained with anti-GLUT-1.  
 
GLUT-1, a marker for hypoxia (Stein et al, 1995) was used to highlight the 
hypoxic cells residing predominantly in the perinecrotic region (PN) of intact 
spheroids. The dark brown membrane localised staining highlights those cells of 
the MCTS which are expressing high levels of Glut-1. Positive staining mainly 
penetrates throughout the perinecrotic core, with only small pockets of positive 
staining residing outside this region.  
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III-2.1.3 Separation of the MCTS regions 
 
 
Figure 14: Separation of the spheroid regions. 1. HT29 spheroid prior to any treatment, 2. following 3 serial trypsin treatments to remove the surface layer, 3. 
following 13 serial trypsin treatments, revealing the perinecrotic region and 4. following homogenization to separate the peri-necrotic and necrotic core regions.  
 
 
 
1. 2. 3. 4. 
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In order to establish the ability of sequential trypsinisation to generate the 
region-specific cell pellets for proteomics analysis, histological analysis of 
MCTS cross-sections was performed, during the fractionation process. The 
sequential removal of outer surface cell layers is illustrated in Figure 14.2, with 
the removal and collection of the SL region requiring 3 trypsin treatments 
(Figure 14.1-2). A further 13 trypsin treatments were required to reveal the 
perinecrotic core (Figure 14.3) At this point homogenisation was used to 
fracture the remaining spheroid structure, which caused the non-adherent cells 
of the necrotic core to disperse into the supernatant and enabled their 
separation from the larger adherent peri-necrotic fragments (Figure 14.4), 
through sedimentation. Cells harvested in the process of 13 serial trypsin 
treatments between the SL and PN were also collected and analysed as the 
intermediate region to provide a comprehensive analysis of the MCTS.  
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III-2.1.4 CAIX staining to confirm the isolation of the perinecrotic region and its hypoxic status 
 
 
Figure 15: 1. CAIX staining highlighting the hypoxic nature of the perinecrotic region of HT29 spheroids. 2. Staining of the spheroid following the removal of the 
surface layer and intermediate regions, confirming the isolation of the perinecrotic region of the spheroid. 3. Positive CAIX staining penetrating the entire perinecrotic 
region of the HT29 spheroid. The black line equates to 100μm. 
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Positive CAIX staining penetrating the entire PN region of the HT29 MCTS 
highlights the presence of hypoxic cells, which would be expected in this 
population of cells (Loncaster et al, 2001) (Figure 15.1). Successful isolation of 
these cells is demonstrated with the CAIX positive staining spanning the entire 
PN region following it‘s isolation (Figure 15.2&3).     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
91 
 
III-2.1. 5 FAC analysis of separated surface layer and necrotic core cells 
 
 
 
 
Figure 16:. FAC analysis demonstrating the size distribution of the surface layer and necrotic core cells, 1 and 2, respectively. The unique distribution of the two cell 
populations, highlighted by combining the two (3).  
 
 1. 
4. 
2. 3. 
5. 6. 
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Cells isolated from the surface layer (SL) and the necrotic core (NC) were 
analysed by FACS and shown to be distinct populations, with characteristically 
larger cells in the surface layer and smaller cells in the necrotic core. 
 
Taken together the results thus far would suggest that the three main regions of 
the spheroid, surface layer (SL), perinecrotic region (PN) and necrotic core (NC) 
were successfully isolated, with an intermediate region (IR) between SL and PN 
to ensure complete separation of these populations.  
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III-3 Discussion 
The techniques employed in this chapter were chosen to produce good quality 
MCTS which upon reaching approximately 700μm in diameter could be 
separated to yield 3 distinct sub-regions (with a forth being the IR). Separation 
of the MCTS regions required optimization. Issues concerning separation 
included; establishing the correct number of sequential trypsin treatment in 
order to reveal the PN, NC contamination of the separated PN, either due to 
incomplete fracturing of the PN structures following homogenization or NC cells 
remaining in the PN fragments following their homogenization. These 
challenges were evaluated/assessed by employing technical check points. 
Histological and immunohistochemistry analysis was used to determine that 3 
serial trypsin treatment resulted in the removal of the SL and 10-13 further 
treatments were successful in revealing the PN. More intense homogenization 
corrected for NC contamination of the PN due to incomplete fracturing of the PN 
structure and washing the PN fragments following homogenization removed 
trapped contaminating NC cells.  
 
DLD1 and HT29 cell lines ultimately gave rise to very similar size MCTS. The 
NC region was seen to emerge at approximately 5 days of culture. Prolonged 
culturing (>15days) resulting in the NC becoming extremely large and 
compromising the integrity of the MCTS structure.  
 
The results thus far demonstrate the feasibility of segregating the MCTS into the 
4 defined regions. The histology images would support  this conclusion. Positive 
CAIX staining penetrating the entire peri-necrotic highlights the hypoxic nature 
of these cells as expected and would support the analysis of this region as an 
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independently defined region. FAC analysis showing the SL and NC cells as 
distinct populations supports the successful isolation of these regions. 
 
Alternative approaches to MCTS separation could result in improvements to the 
current technique.  Separating MCTS using flow cytometry following Hoechst 
33342 staining (Durand, 1982) could be an option. Hoechst 33342 staining of 
MCTS results in unequal distribution of the stain throughout the spheroid, with 
lesser staining present with increasing depth into the MCTS centre. Following 
the disaggregation of the Hoechst 33342 treated spheroids the cells can then 
be separated by fluorescent activated cell sorting, according to their degree of 
staining, which will reflect their depth within the spheroid (Durand, 1982).     
 
In conclusion, the results demonstrated that MCTS can be stripped to isolate 
cells that reside at different depths within the viable rim of MCTS. The use of 
very gentle homogenisation liberated cells from within the NC of MCTS and 
FACS analysis demonstrates that cells with different size profiles can be 
isolated. Whilst contamination of the NC by cells from the PN region cannot be 
entirely ruled out, FACS analysis suggests that contamination is minimal. 
Contamination of the PN region with cells of the NC represents the main area 
for concern, methods to limit this were discovered.  
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IV- Proteomics analysis of HT29 MCTS by MALDI- TOF-TOF and ESI-Q-
TOF MS 
 
Following confirmation of the successful isolation of the four distinct MCTS 
regions, these samples were taken through for quantitative proteomics analysis 
using both LC-MALDI-MS/MS and LC-ESI-MS/MS. 
 
IV- 1 Methods 
 
IV- 1.1 Proteomics sample preparation 
The separated surface layer, intermediate, perinecrotic and necrotic core 
regions of HT29 spheroids were taken through proteomics analysis.  
Samples were homogenised in 150µl of lysis solution (5M Urea, 2M Thiourea, 
4% CHAPS and 1% C7BzO) by sonication, 3 times 15 sec at 50% intensity, 
using a SH70A sonicator.   
 
IV- 1.1.1 Protein isolation and purification  
To isolate the protein content of the spheroid cells, whilst purifying the sample 
of any contaminants which may interfere with downstream sample processing, 
acetone precipitation of the samples was carried out. 
 
IV- 1.1.1 Precipitation 
To each cell pellet, 10x the volume chilled acetone (-20°C) was added. The 
sample was mixed and then allowed to precipitate overnight at -20°C.  
Following overnight precipitation, the samples were spun at 12,000 g for 5 
minutes. The supernatant was discarded and the pellet re-suspended in 150μl 
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of 1M tetraethylammonium borohydride (TEAB) with 2% sodium dodecyl 
sulphate (SDS). Samples were sonicated for 20 seconds at 50% intensity using 
a SH70A sonicator to completely resolubilise the acetone precipitated sample. 
Upon resolubilisation the protein concentration of the sample was determined 
using the Bradford assay. 
 
IV- 1.1.2 Bradford Assay 
The total protein concentration in each sample was measured using the 
Bradford assay (Bradford, 1976), which relies on the linear relationship between 
absorption and the amount of Coomassie dye bound to the proteins present in 
the lysate.  
 
The standard curve was established by preparing serial dilutions of bovine 
serum albumin (BSA) ranging from 0.03125 mg/ml to1 mg/ml in final volume of 
100 µl of distilled water (dH2O). The blank consisted of distilled water (100 µl). 
The cell lysate samples were diluted 20 times in distilled water in a final volume 
of 100 µl. Bradford reagent (3ml) was then added to all samples. The reactions 
were mixed by vortexing and incubated for 15 min at room temperature (RT). 
The sample absorbance at 595nm was measured using a Cary 50 Bio UV- 
Visible spectrophotometer (Varian Ltd, UK). The absorbance was read thrice 
with the resulting absorbance expressed as a mean of the three readings. The 
standard curve was automatically plotted and each sample protein 
concentration determined from the linear regression equation of the standard 
curve. 
Once the protein concentration of the samples was determined, each sample 
was divided into 50μg aliquots.  
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IV- 1.1.3 Reduction, alkylation and trypsin digestion 
Protein aliquots were reduced (cysteine residues) by adding 1μl of 50mM 
dithiothreitol (DTT) and incubating for 20 minutes at 60°C. Once reduced the 
aliquots were alkylated using 1μl of 100mM iodoacetamide (IAA) and incubated 
for 20 minutes at room temperature, in the dark. Trypsin digestion was carried 
out using a 1:10 trypsin to protein ratio (1:10 w/w). Trypsin (Sigma, proteomics 
grade) was re-suspended using 2mM hydrogen chloride and digestion was 
carried out overnight at 37°C.   
 
IV-1.2 iTRAQ reagent labeling 
Samples were taken to dryness and re-suspended using 0.5M 
tetraethylammonium borohydride (TEAB) to a final volume of 30μl. The contents 
of each iTRAQ reagent tube were re-suspended in 70μl of ethanol. This was 
transferred to the sample-containing tube.  Samples were incubated with iTRAQ 
reagent for 90 minutes at RT. iTRAQ 4-plex reagents were purchased as a kit 
from Applied Biosystems (Carlsbad, California) 
 
IV-1.3 OFFGEL peptide separation 
The 3100 OFFGEL IEF system (Agilent Technology) was used to perform 
peptide fractionation based on their pIs. Fractionation was carried out according 
to the manufacturers‘ protocol. Peptides were separated into 24 fractions using 
the 24-cm-long IPG gel strips, with a linear pH gradient ranging at 3–10. A two-
phase method focuses the peptides initially for 50kVh, (8000V, 2000 mW and a 
current of 50μA) and then, once focusing is completed the instrument used at 
500V, 50mW of power and a current of 20μA to hold the peptides in their 
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focused position.  Separated peptides were recovered in liquid phase from each 
of the 24 wells. 
 
IV-1.4 Manual MS analysis of OFFGEL separated peptides 
MS spectra for each OFFGEL peptide fraction was generated using a MALDI-
TOF/TOF UltraFlex II instrument (Bruker Daltonics, Bremen, Germany). Each 
fraction (10μl) was desalted using C18 ZipTip‘s (Millipore). Desalted peptides 
were eluted in 2μl of 80% acetonitrile (CH3CN) onto an MTP 384 massive target 
T plate (Bruker Daltonics, Bremen, Germany), together with 0.5μl of -cyano-4-
hydroxycinnamic acid at 10mg/ml (Fluka). MS spectra were generated with the 
instrument in reflector positive mode in the mass range of 700-4000Da. From a 
total of 500 cumulative shots.  
 
Fractions were desalted using Isolute C18 1ml (Sorbent mass 100mg) cartridges 
(International Sorbent Technology, Hengoed, UK). Peptides were eluted using 
1ml of 80% CH3CN and lyophilized before storing at -20
oC until further analysis. 
 
IV-1.5 Reverse Phase NanoHPLC coupled to MALDI – MS/MS analysis 
 
IV-1.5.1 Reverse Phase Nano-LC 
Once desalted the peptides where separated by nanoscale reverse phase liquid 
chromatography using an LC Packings UltiMate 3000 capillary high-
performance liquid chromatography system (Dionex, Camberley, Surrey, UK). 
 
The sample was re-suspended in 10% CH3CN and was injected into the LC 
system via a sample loop (carrier solvent, 0.05% trifluoroacetic acid (TFA)) onto 
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a C18, 300μm x 5mm, 5μm, 100Ǻ PepMap pre-column (LC Packings, 
Sunnyvale, CA). Once on the pre-column the sample was washed for 3.5 
minutes at a flow rate of 300nl/min, with the carrier solvent. The sample was 
then transferred onto a C18, 75μm x 15cm, 3μm, 100 Ǻ PepMap column (LC 
Packings) which was equilibrated with 2% CH3CN with 0.05% TFA (Mobile 
phase A). 
 
IV-1.5.1.1 Reverse Phase Nano-LC peptide separation conditions 
The mobile phase was modified at 6 minutes post-injection to incorporate 10% 
mobile phase B (80% CH3CN with 0.05% TFA), the contribution of mobile 
phase B was then increased linearly to 40% until 81 minutes post-injection, 
followed by 100% mobile phase B from 81.1 minutes to 86 minutes post-
injection. The column was then re-equilibrated with mobile phase A until the end 
of the run at 100 minutes post-injection 
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Figure 17: Outline of the nano-LC mobile phase B gradient during peptide separation (LC-
MALDI). 
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IV-1.5.2 Fraction Collection 
IV-1.5.2.2 MALDI Matrix 
α-Cyano-4-hydroxycinnamic acid (CHCA) was used as the matrix of choice. A 
stock solution was prepared by solubilizing CHCA in 1ml of 30% (v/v) CH3CN 
with 0.1% (v/v) TFA. CHCA was solubilized by vortexing for 2 minutes and 
sonicating for 30 minutes to generate a saturated solution.   
 
From the stock solution a working solution is prepared, comprising 1.056ml of 
ethanol:acetone (2:1 ratio), 120μl of the CHCA stock solution. 12μl of 100mM 
ammonium phosphate and 12μl 10% TFA.  
Using the outlined LC gradient a total of 384, 15 seconds (75nl) fractions were 
collected, for each OFFGEL pooled fraction, onto a MTP AnchorChip 800/384 
target plate (Bruker Daltonics, Bremen, Germany) using a Proteineer FC 
Fraction Collector (Bruker Daltonics, Bremen, Germany). Each fraction was co-
eluted with 1.2μl of saturated α-cyano-4-hydroxy cinnamic acid (CHCA) matrix 
solution. 
IV-1.5.2.3 MS External Calibration 
Peptide Calibration Standard II (Bruker Daltonics, Bremen, Germany), 
comprising Angiotensin I, Angiotensin II, Substrate P, Bombesin, ACTH clip 1-
17, ACTH clip 18-39, Somatostatin 28, Bradykinin fragment 1-7 and Renin 
Substrate Tetradecapeptide porcine; covering the mass range 700-3200 Da, 
was applied between every group of 4 fractions. 
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IV-1.5.3 MALDI-MS  
A MALDI-TOF/TOF UltraFlex II mass spectrometer was used for analysis using 
reflector positive ion mode. For MS analysis, a sum of 400 shots in 50 shot 
steps were accumulated within the mass range set at 700-4000 Da. Within 
WarpLC, the stable isotopic labeling experiment (SILE) parameters were 
selected. Within these parameters iTRAQ isobaric labeling strategy was chosen 
as the SILE type, with the mono-isotopic mass of the included labels entered 
together with the ratio in which the labels are to be compared. Purity correction 
values, which are provided by the supplier for each individual iTRAQ kit, were 
also entered. Following MS analysis, a maximum of 20 precursors per spot with 
a minimum signal-to-noise ratio of 7 were selected for MS/MS analysis.   
 
Collision energy was used for collision induced dissociation, and 300 shots for 
the parent ion and 1500 shots for the fragment ions were accumulated, for each 
MS/MS spectrum.  
 
IV-1.5.4 Protein Identification 
Proteins were identified using Mascot software (Perkins et al, 1999) which 
compared MS/MS generated data against the SwissProt protein database using 
the Bruker Biotools (version 3.2) interface. Search parameters included in the 
Mascot search, were variable modification of carbamidomethylated cysteines, 
methionine oxidation, iTRAQ labels on lysines residues and/or at the N-termini 
and also possible iTRAQ side reactions (y), and no fixed modifications. Peptide 
mass tolerance was set at 100 parts per million (ppm) and MS/MS tolerance 
was set at +/- 0.7 Da. One missed cleavage was also allowed for.  A 95% 
confidence threshold was set (p<0.05) for searching the MS/MS data against 
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SwissProt. A Mascot score threshold of >35 was used for positive protein 
identification. The WARP-LC generated LC-MALDI workflow is illustrated in the 
figure below.  
 
 
Figure 18: LC-MALDI workflow in WARP-LC (WARP-LC user manual, Version 1.1 2006). 
 
IV-1.5.4 Data Analysis 
The 24 OFFGEL separated fractions were analysed individually and resulted in 
24 LC/MALDI runs. Proteinscape software v2.1 (Bruker Daltonics, Bremen, 
Germany) was used to compile all LC/MALDI runs into a single non-redundant 
protein list. The ProteinScape protein list was filtered to include only those 
which had 2 or more iTRAQ labeled peptides contributing to their identification 
and quantification, and all peptides not ranked first were removed. To identify 
the proteins that have significantly changed in expression between the surface 
103 
 
layer (SL) and inner regions (intermediate region – IR, perinecrotic region - PN 
and the necrotic core – NC) of the spheroid, iTRAQ reporter ion ratios were 
determined for each protein - SL/IR = 114/115, SL/PN = 114/116 and SL/NC = 
114/117. The mean ratios were determined for each dataset and then each 
individual ratio divided by the mean to allow normalisation and comparison 
between the datasets.  
 
IV-1.6 6500 Series Accurate-Mass Quadrupole Time-of-Flight (Q-TOF) 
LC/MS  
 
IV-1.6.1 The Agilent 1200 Series HPLC-Chip/MS system  
LC-MS/MS was carried out using an electrospray quadrupole time of flight 
tandem mass spectrometer (Agilent Technologies), equipped with an Agilent 
Chip Cube interface (Agilent Technologies, Waldbronn) and a silicon wafer 
chip-column (Agilent Technologies, Waldbronn). The chip-column combines a 
C18 enrichment column, C18 separation column and a nanospray emitter.  
 
IV-1.6.1.1 HPLC-Chip 
The sample was re-suspended in 10% (v/v) CH3CN and was injected into the 
HPLC-CHIP system via an on-line autosampler (1260 Infinity High Performance 
Micro Autosampler, Agilent). Sample (5μl) was injected and subsequently 
applied to a 160 nL enrichment column and then to a 75 μm x 150 mm 
analytical column packed with ZORBAX 300SB C18 (5 μm; 300 A). The flow rate 
on the analytical pump was set at 300nL/min with the loading pump set at 
4μl/min. Mobile phase A comprised of 0.1% formic acid in water and mobile 
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phase B comprised of 90% acetonitrile in water with 0.1% formic acid. Peptides 
were separated using the following gradients, 
 
Time (Mins) Contribution of Solvent B (%) 
0 3 
50 45 
55 90 
60 90 
62 3 
Table 1:. LC mobile phase gradient conditions (LC-ESI) 
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Figure 19: Outline of the nano-LC mobile phase B gradient during peptide separation (LC-ESI). 
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IV-1.6.2 QTOF-MS/MS  
Analysis was done using the instruments reflector positive ion mode. The 
following acquisition parameters were set for analysis; MS mode: 1 Spectrum 
per second with a mass-to-charge range set at 350-1800 Da, MS/MS mode: 3 
spectra per second with a mass-to-charge range of 60-2000. Drying gas was 
set to a flow rate of 5 L/min at 325°C, Collision energy: slope 3, intercept 2 and 
Capillary voltage was set to 1900 V.  
 
IV-1.6.3 Data analysis 
Mass peak list were generated for each of the 24 fractions, using Spectrum Mill 
software. Mass Hunter (Agilent software) was used to create Xml files which 
were then searched against the SwissProt protein database using Mascot 
(version 2.2). Parameters included in the Mascot search, were as for LC MALDI 
database searching (see above). Peptide mass tolerance was set at 100 parts 
per million (ppm) and MS/MS tolerance was set at +/- 0.7 Da. One missed 
cleavage was also allowed for.  A 95% confidence threshold was set (p<0.05) 
for searching the MS/MS data against SwissProt. Mascot results were imported 
into ProteinCentre, where a combined list (24 fractions) of non-redundant 
proteins was generated for data analysis and data interpretation. 
 Statistical Analysis 
Proteins were indicated as being up or down-regulated within both ESI and 
MALDI MS datasets if they deviated a minimum of one standard deviation (SD) 
from their normalized mean. In order to compare protein levels within a dataset 
the largest reporter ion ratio SD (+/- 0.3Da for MALDI MS data and +/-0.89Da 
for ESI MS data) was applied to all the ratios.  
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Using this criteria arbitrary cut off values of <0.77 (1 divided by the SD or 
inverse SD) and >1.3, were used to assign up- and down-regulated proteins, 
respectively, in the MALDI dataset. Due to the larger SD seen with the ESI data, 
arbitrary values of <0.529 and >1.89 were applied to indicate up and down-
regulated proteins, respectively.  
 
IV-1.7 Gene ontology annotation 
In order to translate the proteomics derived data into biologically relevant 
observations, the data was processed using a web-based application (GOrilla) 
(Eden et al, 2009) which identifies enriched GO terms in target datasets when 
compared to a chosen background dataset. Various sub-categories were 
searched using the application, each time the background dataset would 
include the entire dataset minus those genes making up the target set. The 
GOrilla software tool can be use to identify GO terms enriched in up to three 
categories, which are biological processes, molecular functions and cellular 
components.   
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IV-2 Results  
 
IV-2.1 OFFGEL peptides separation 
The combined iTRAQ labeled peptides were successful separated based on 
charge, using OffGel. Separation was confirmed through the generation of 
unique MS spectra following manual analysis of each of the 24 fractions (see 
supplementary data for spectra). The overall intensities (ranging from 103 to 105 
a.u) suggested sufficient peptide concentrations for duplicate automated MS 
analysis on each single fraction. As such equal volumes of each fraction were 
analyzed using either MALDI-TOF-TOF or ESI-Q-TOF.  
 
IV-2.1.1 MALDI-TOF-TOF 
Data generated from the MALDI-MS instrument was used to further investigate 
the efficacy of OffGel peptide separation. In total, the 24 LC/MALDI runs 
identified 3958 redundant proteins and their distribution across the OffGel 
fractions is shown in figure 20 below. 
Number of proteins identified for each OffGel fraction
OffGel fraction
0 5 10 15 20 25
N
um
be
r 
of
 p
ro
te
in
s 
id
en
tif
ie
d
0
100
200
300
400
500
 
Figure 20: Protein identification distribution across the OffGel fractions. 
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Figure 21: Peptide frequency across OffGel fractions 
 
Of 7051 unique peptides which were identified in total, 52.8% and 68.7% were 
observed in only one and two fractions, respectively. Greater than 90% of all 
peptides were observed in six or less OffGel fractions.  
 
 
 
 
 
 
 
 
 
 
109 
 
IV-2.2 LC/MALDI results 
 
  Compounds Measured MS/MS Identified MS/MS Identified proteins % compounds with 
identified MS/MS 
% identified proteins 
from identified 
MS/MS 
Average 6913 2754 937 234  - - 
Total 165,923 66,099 22,488 5,618 13.5% 24.9% 
Table 2: Summary of results generated following the 24 LC-MALDI runs. 
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From a total of 24 LC-MALDI MS/MS runs, more than 165,923 compounds were 
detected, 66,099 MS/MS were performed, resulting in the identification of 
22,488 peptides from 5,618 proteins. As many proteins are identified multiple 
times, a non-redundant list of 1225 proteins was generated using ProteinScape 
software (Bruker). This dataset was manually checked to ensure the quality of 
the data. During this process non-iTRAQ labelled proteins and iTRAQ ratio 
outliers were removed and only proteins with at least 1 peptide above the 
Mascot significance threshold of 35 (p<0.05), were included for further analysis. 
A resulting dataset with a total of 1024 quantified proteins was created 
(Supplementary Table S1). 
  
IV-2.2.1 iTRAQ quantitation results 
For inclusion in quantitation analysis, only proteins with at least two peptides 
and two iTRAQ values were considered, which resulted in further reducing the 
dataset to 882 proteins (Supplementary Table S2). Changes in expression were 
determined using the following ratio‘s SL/IR = 114/115, SL/PN = 114/116 and 
SL/NC = 114/117. As all regions were compared to the SL, resulting expression 
levels were all relative to the SL. 
  SL/IR 114/115 SL/PN 114/116 SL/NC 114/117  
up-regulated  24 63 187 
down-regulated  23 51 101 
Table 3: Number of up and down regulated proteins indicated in each region relative to the SL, 
using data derived from LC-MALDI analysis of the MCTS fractions.  
 
The majority of proteins (>70%) showed little change in iTRAQ reporter ion 
ratios, i.e. values of >0.77 and <1.3 across the different region relative to the 
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surface layer. Across the three regions, a total of 274 (or 209 unique) proteins 
were up-regulated (iTRAQ ratio >1.3) and 175 (or 114 unique) were down-
regulated (iTRAQ ratio <0.77). The number of proteins that were indicated 
changed increased in proportion to the distance from the surface layer (Table 
3), for example, only 24 proteins were increased in the IR, 63 in the PN and 187 
in the NC compared to the SL.  
 
IV-2.2.1.1 Cluster analysis of response profiles 
To explore expression patterns within the dataset as a whole, proteins that were 
increased or decreased in each of the 3 regions were compared to identify 
trends in expression of specific proteins. Proteins were clustered into 15 
response modes (Table 4), 7 corresponding to different up-regulation modes 
(up in all three regions compared to SL, up in IR only, up in PN only, up in NC 
only, up in OR and PN, up in IR and NC and up in PN and NC), 7 corresponding 
to different down-regulation modes and 1 representing the 559 proteins which 
were not changed across the spheroid regions (Figure 22).  
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Response 
 
IR/PN/
NC 
PN/NC IR/NC NC IR/PN PN IR Total 
Up-
regulated 
10 36 5 135 2 15 6 209 
Down-
regulated 
12 27 7 55 3 9 1 114 
No change        559 
Table 4: Number of proteins clustered into 15 different response modes - 7 up-regulated, 7 
down-regulated and 1 group with no changes across the three spheroid regions compared to 
the surface layer. 
 
 
 
 
 
Figure 22: Response profiles for proteins that are indicated as changed across the MCTS 
regions relative to the surface layer (SL); A. up-regulated in IR/PN/NC, B. up-regulated in 
PN/NC, C. up-regulated in IR/NC, D. up-regulated in NC, E. up-regulated in IR/PN, F. up-
regulated in PN, G. up-regulated in IR, H. unchanged, I. down-regulated in IR, J. down-
regulated in NC, K. down-regulated in IR/PN, L. down-regulated in PN, M. down-regulated in 
IR/PN/NC, N. down-regulated in PN/PC, O. down-regulated in IR/NC. 
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Encouragingly, the most common profile was that representing the 559 proteins 
which demonstrated no change across any MCTS region (Figure 22 H). The 
majority of proteins whose expression levels were modified, exhibited a 
progressive increase or decrease and no proteins displayed extreme changes 
from significantly up- to down-regulation or visa versa across the four regions. 
For example, 10 proteins increased across all three regions relative to the SL 
(Figure 22A), 36 proteins increased in the PN and the NC region relative to the 
SL and IR regions (Figure 22B) and 135 proteins increased in the NC relative to 
the SL, IR and PN regions (Figure 22D). The response profiles highlighted 
groups of proteins which are up or down regulated in a single region alone, for 
example those proteins which were up- and down-regulated in the PN in Figure 
22F and L , respectively. 
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IV-2.2.2 Gene ontology annotation 
Each of the 15 identified iTRAQ response profiles were investigated for the 
presence of any GO enriched terms in each of these categories, Table 5 below, 
highlights those response profiles which do give rise to enriched GO terms. 
(See supplementary data for further details of these results).  
Profile 
 
Process Function Compartment 
Up IR/PN/NC N N N 
Up PN/NC Y N N 
Up IR/NC N N N 
Up NC N Y Y 
Up IR/PN N Y N 
Up PN N N N 
Up IR N N N 
Down IR/PN/NC N N N 
Down PN/NC Y N N 
Down IR/NC N N N 
Down NC Y Y N 
Down IR/PN N N N 
Down PN N N N 
Down IR N N N 
No Change N N N 
Table 5: Response profiles and their results for GO enrichment analysis for cellular process, 
function and compartment (N)Enrichment not seen, (Y) enrichment seen for at least 1 GO term 
in that category.  
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Four biological processes were shown to be enriched for those proteins which 
were indicated as being increased in both the PN and NC. These processes 
included; multicellular organismal process, neurological system, systems 
process and homeostasis. Proteins increased in the MCTS NC demonstrated 
enrichment for 2 different molecular functions, which were intramolecular 
oxidoreductase activity, transporting S-S bonds and protein disulphide 
isomerase activity. With the same group of proteins 14 cellular compartments 
were highlighted as being enriched, many of which were membrane related and 
included entire organelles such as the ER and vesicles.  Those proteins 
demonstrating increased levels in both the IR and PN gave rise to 4 enriched 
biological functions, all of which related to transferase activity, specifically to the 
increases in acetyl-CoA acetyltransferase 2 levels.  
 
Within the down-regulated portion of the dataset, those proteins indicated in the 
PN and NC, displayed enrichment in the biological processes of prostaglandin 
and prostanoid biosynthetic processes both being highlighted by the same 
individual proteins. The proteins which were indicated as being decreased in the 
NC alone were associated with the enrichment of 2 biological processes; 
regulation of nucleotide, nucleobase, nucleoside and nucleic acid metabolism 
and regulation of transcription. Transcription binding was also highlighted in the 
enriched molecular functions of this particular group of proteins.    
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IV-2.2.3 Key biological observations 
 IV-2.2.3.1 Increase in glycolysis, TCA and lipid metabolism related 
proteins within the PN and NC 
From both GO indications and manually assessing the data, important 
difference in carbohydrate and lipid metabolism appeared to be occurring in the 
MCTS inner regions (PN and NC). Specifically, higher levels of enzymes 
involved in glycolysis, the TCA cycle and lipid metabolism were seen in these 
regions. Of 12 enzymes engaged in glycolysis, 8 were up-regulated in the 
perinecrotic region or the necrotic core or both (Table 6), and none were down-
regulated. There was also evidence of an increase in TCA cycle activity with up-
regulation of mitochondrial NAD+ and NADP+ isocitrate dehydrogenase, malate 
dehydrogenase, citrate synthase and cytoplasmic NADP+ isocitrate 
dehydrogenase. Mitochondrial lipid metabolism enzymes such as enoyl-CoA-
hydratase (ECHS1), 3-ketoacyl-CoA thiolase and trifunctional enzyme subunits 
alpha and beta and trans-2,3-enoyl-CoA reductase, along with supporting 
enzymes such as NADH-cytochrome b5 reductase and carnitine O-
acetyltransferase (CRAT), were indicated as being increased in the necrotic 
core. Within the down-regulated proteins in the perinecrotic core and the 
necrotic core, there was no evidence of over-represented enzyme clusters that 
would indicate specific metabolic pathways were suppressed. 
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Table 6: Proteomic analysis of enzymes from glycolysis, TCA cycle and lipid metabolism, 
showing iTRAQ ratios comparing levels in the perinecrotic region (PN) and necrotic core (NC) 
relative to the surface layer (SL). up or down regulated enzymes (ratios of <1.30 and > 0.77) are 
highlighted. 
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IV-2.2.3.2 Increases in chaperone and protein folding proteins within the 
NC 
Together with metabolic difference, increases in specific groups of chaperone 
proteins and protein folding proteins were indicated in the MCTS NC, which 
included protein disulphide isomerases and 4 of the 5 identified 14-3-3 proteins. 
The majority of TCP-1 complex subunits and peptidyl-prolyl cis-trans isomerase 
(PPI) isoforms, however, exhibited no change (Table 7). Six of the up-regulated 
proteins, 78 kDa glucose-regulated protein, endoplasmin, Peptidyl-prolyl cis-
trans isomerase B (the only PPI isoform to show a significant change in 
expression), Protein disulfide-isomerase A4, Protein disulfide-isomerase A6 and 
150 kDa oxygen-regulated protein are members of the same large chaperone 
multi-protein complex. 
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Table 7: Proteomic analysis of chaperone and protein folding proteins showing iTRAQ ratios 
comparing levels in the perinecrotic region (PN) and necrotic core (NC) relative to the surface 
layer (SL). Up- or down-regulated enzymes (ratios of <1.30 and > 0.77) are highlighted. 
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IV-2.3 LC/ESI-Q-TOF Results 
OffGel fraction Number of Mascot queries Proteins identified 
1 12396 60 
2 11552 97 
3 12600 126 
4 12944 110 
5 14065 242 
6 15178 171 
7 12515 118 
8 12500 144 
9 13691 136 
10 15108 148 
11 15134 192 
12 13888 165 
13 11158 177 
14 12238 211 
15 12698 137 
16 12798 171 
17 14867 33 
18 14904 38 
19 13383 44 
20 15851 636 
21 12721 332 
22 11643 99 
23 13390 161 
24 9391 11 
Table 8: Outline of Mascot queries and resulting protein identification for each OffGel fraction 
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In total 3759 proteins were identified in the 24 LC-ESI-Q-TOF runs. When 
combined this represented 827 unique proteins (See supplementary Table S3 
for details). In total 316613 measured MS/MS were searched using Mascot 
against the SwissProt human protein database, on average 13192 MS/MS were 
measured per run, given rise to approximately 157 protein identifications or just 
1.2 % identified proteins from measured MS/MS.  
 
 IV-2.3.1 iTRAQ quantitation results 
Up and down-regulated proteins were indicated if they deviated a minimum of 1 
SD from the normalized mean of 1 (as with the MALDI data analysis, the largest 
SD was used), resulting in <0.529 and >1.89 representing cut off values for up- 
and down-regulated proteins, respectively. ESI-Q-TOF analysis of iTRAQ 
reporter ions resulted in much greater SD values for the different MCTS 
regions, compared to LC/MALDI.  
 
Of the 827 proteins identified with the LC-ESI-Q-TOF analysis only ~72% (593) 
gave accompanying quantification information. As with the LC-MALDI results 
the NC appeared to represent the greatest degree of change when compared to 
the SL, with the IR again showing minimum change.  Despite the more extreme 
cut off points, the degree of change observed across the MCTS regions 
remained similar to that first demonstrated by the LC-MALDI analysis, with 69% 
of proteins demonstrating no change.  
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SL/IR 114/115 SL/PN 114/116 SL/NC 114/117 
Up-regulated 17 62 84 
Down-regulated 21 34 42 
Table 9: Number of up- and down-regulated proteins indicated in each region relative to the SL, 
using data derived from LC-ESI-Q-TOF analysis of the MCTS fractions.  
 
IV-2.3.2 Gene ontology annotation 
Sub-categories of the entire dataset were analysed using GOrilla to annotate 
any enriched GO terms which the may represent. Table 10 below outlines the 
results of these analyses; 
Protein category Process Function Compartment 
Up IR N N N 
Down IR Y N N 
Up PN N N N 
Down PN Y N N 
Up NC N N N 
Down NC Y Y N 
Table 10: GO enrichment analysis for cellular process, function and compartment (N) 
Enrichment not seen, (Y) enrichment seen for at least 1 GO term in that category.  
 
None of the up-regulated categories gave rise to any enriched GO terms when 
analysed using GOrilla. The down-regulated proteins in each region included 
enriched GO terms associated with different biological processes, with 
regulations of secretion, intermediate filament organisation and potassium ion 
transport being highlighted for the IR, PN and NC, respectively. Proteins 
indicated as being down-regulated in the NC demonstrating enrichment of GO 
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terms relating to a biological process and molecular functions, with 5 functions 
all reflecting the biological process and being transport related, specifically ion 
transport (See supplementary data for details). 
 
IV-2.3.3 Key biological observations 
IV-2.3.3.1 Glycolysis, TCA and lipid metabolism related proteins 
Unlike the LC-MALDI generated data, the LC-ESI-Q-TOF data did not indicate 
the pronounced changes in carbohydrate and lipid metabolism. This may be 
due to the total quantified protein number being much lower than with the 
MALDI MS data. Proteins were identified which are associated with 
carbohydrate metabolism such as glycolytic phosphoglycerate mutase, 
succinyl-CoA ligase involved in the TCA cycle and cytochrome c oxidase 
subunit 5A which is part of the terminal enzyme of the mitochondrial respiratory 
chain. These enzymes were all indicated as being increased in the IR with 
cytochrome c oxidase subunit 5A increased also in the PN.  Acetyl-CoA 
acetyltransferase and estradiol 17-beta dehydrogenase both involved in lipid 
metabolism were seen increased in the IR alone and PN and NC, respectively.  
  
 IV-2.3.3.2 Increases in chaperone and protein folding proteins within the 
PN and NC 
In support of the LC-MALDI generated data the ESI-Q-TOF data indicated an 
increase in chaperone and protein folding related proteins, specifically in the PN 
and NC regions.  
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Table 11: Chaperone and protein folding related proteins and their normalized iTRAQ reported 
ion ratio‘s analysed using LC-ESI-Q-TOF. Green used to indicate increased levels (ratios 
expressed as SL/PN and SL/NC resulting in <0.529 being sig increased. 
 
 
IV-2.4 Comparison of MALDI-TOF-TOF  and ESI-Q-TOF data 
 
 
 
 
 
 
 
 
 
 
Figure 23: Ven diagram highlighting the number of proteins identified using both instruments. 
 
 
Protein 
Number of 
peptides 
Peptides 
contributing to 
quantitation PN NC 
Hsp70-interacting protein 6 3 0.4 0.32 
Heat shock 70kDa protein 4 15 3 0.65 0.48 
Heat shock protein 75 kDa, 
mitochondrial 9 2 0.24 0.21 
Heat shock 90kDa protein 
1, alpha-like 3 15 3 0.31 1.36 
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Using the Ultraflex II instrument, MALDI-TOF/TOF analysis resulted in more 
proteins being indentified for the same MCTS samples, when compared to ESI-
Q-TOF analysis using Agilent‘s 6530 series accurate mass ESI-Q-TOF 
instrument. Both instruments gave the same average mascot score of 56, 
suggesting similar confidence levels in those proteins which were identified. A 
total of 211 proteins were indentified using both instruments, meaning MALDI 
contributed to the identification of 792 unique proteins and ESI-Q-TOF 616 
proteins. Using a combination of the two methods increased proteome coverage 
was achieved. Unfortunately as mentioned earlier the labeling efficiency, 
possibly due to inefficient fragmentation of the parent ion, seen using ESI-Q-
TOF was disappointing at just 72%.  As such many of the unique proteins which 
it did identify could not be used to help characterise the MCTS regions. This 
was not true in all cases, for example the ESI MS data did provide addition 
information regarding key biological observations previously indicated by the 
MALDI data. For example, the identification of additional chaperone proteins 
and also with the identification of fumarate dehydratase, which participates in 
the TCA cycle which was not seen in the MALDI data.  
 
Encouragingly, for those proteins which did provide quantitative data the degree 
of change across the regions was consistent using the two instruments. What is 
more, the pattern of change which was indicated was the same using the two 
instruments types, with the highest degree of change seen when comparing the 
NC and SL. Standard deviation values for the iTRAQ reported ions ratio‘s were 
much greater for the ESI-Q-TOF generated data than that generated using 
MALDI. 
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Of the 211 proteins common to both datasets only 41 proteins shared MALDI 
and ESI quantitation information.  Of the 41 proteins, 2 gave contradictory and 3 
gave confirmatory indications of protein expression changes, the remaining 
proteins demonstrated no change for both MS approaches.  
 
IV-2.4.1 Individual protein comparisons using MALDI-TOF-TOF and 
ESI-Q-TOF 
 IV-2.4.1.1 Contradictory results 
A 
  
Leucine-rich PPR motif-containing protein, 
mitochondrial (P42704) 
  MALDI-TOF-TOF ESI-Q-TOF 
Number of fraction identified 
in 3 4 
Median Mascot score 49 84 
Number of peptide identified 13 16 
Median 115 ratio 0.85 0.65 
Median 116 ratio 1.2 0.13 
Median 117 ratio 2.1 0.73 
Median SD for 115 ratio's 1.16 2.28 
Median SD for 116 ratio's 1.24 2.04 
Median SD for 117 ratio's 1.82 1.32 
Normalised 115 median ratio 1.23 0.56 
Normalised 116 median ratio 1.21 0.11 
Normalised 117 median ratio 0.71 0.49 
Normalised 116 median ratio 1.21 0.11 
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B 
Histone H2A.Z (P0C0S5)   
 MALDI-TOF-TOF ESI-Q-TOF 
Number of fraction identified in 1 4 
Median Mascot score 142 283 
Number of peptide identified 4 9 
Median 115 ratio 0.93 0.91 
Median 116 ratio 0.99 0.74 
Median 117 ratio 1.05 0.69 
Median SD for 115 ratio's 1.07 1.15 
Median SD for 116 ratio's 1.02 1.06 
Median SD for 117 ratio's 1.26 1.05 
Normalised 115 median ratio 1.34 0.79 
Normalised 116 median ratio 0.99 0.66 
Normalised 117 median ratio 2.49 0.46 
 Table 12: Quantitation information for the proteins demonstrating contradictory results using 
the two instruments, Leucine-rich PPR motif-containing protein and Histone H2A.Z, for A and B, 
respectively.  
 
Identification of each of the contradictory proteins by ESI-Q-TOF analysis was 
achieved in equal to or more OffGel fractions compare to MALDI-TOF/TOF 
analysis. This resulted in the increase number of peptides assigned to each and 
would have contributed to the higher median Mascot score achieve for each of 
the contradictory proteins, using ESI-Q-TOF analysis. The quantitation 
information resulted in similar standard deviation values using the instruments. 
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IV-2.4.1.2 Confirmatory results  
A 
  Histone H2A type1D 
  MALDI-TOF-TOF ESI-Q-TOF 
Number of fraction identified in 1 2 
Median Mascot score 54 188.5 
Number of peptide identified 2 6 
Median 115 ratio 0.71 0.76 
Median 116 ratio 0.17 0.53 
Median 117 ratio 0.22 0.65 
Median SD for 115 ratio's 1.32 2.47 
Median SD for 116 ratio's 3.72 1.77 
Median SD for 117 ratio's 2.73 1.64 
Normalised 115 median ratio 1.03 0.66 
Normalised 116 median ratio 1.67 0.47 
Normalised 117 median ratio 0.52 0.44 
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B 
 Phosphate carrier protein, mitochondrial 
(Q00325-2) 
  MALDI-TOF-TOF ESI-Q-TOF 
Number of fraction identified in 2 3 
Median Mascot score 73.5 47 
Number of peptide identified 3 8 
Median 115 ratio 0.79 1.25 
Median 116 ratio 0.93 0.75 
Median 117 ratio 1.75 3.58 
Median SD for 115 ratio's 1.27 1.07 
Median SD for 116 ratio's 1.16 1.12 
Median SD for 117 ratio's 1.12 1.15 
Normalised 115 median ratio 1.14 1.07 
Normalised 116 median ratio 0.94 0.66 
Normalised 117 median ratio 4.16 2.42 
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C 
  ADP/ATP translocase 3 (P12236) 
  MALDI-TOF-TOF ESI-Q-TOF 
Number of fraction identified in 3 4 
Median Mascot score 95 39.5 
Number of peptide identified 9 9 
Median 115 ratio 0.92 1.43 
Median 116 ratio 0.99 1.13 
Median 117 ratio 2.24 2.99 
Median SD for 115 ratio's 1.08 1.36 
Median SD for 116 ratio's 1.15 1.38 
Median SD for 117 ratio's 1.09 1.45 
Normalised 115 median ratio 1.32 1.24 
Normalised 116 median ratio 0.99 0.99 
Normalised 117 median ratio 5.3 2.02 
Table 12: Quantitation information for the proteins demonstrating confirmatory results using the 
two instruments, Histone H2A type1D, Phosphate carrier protein, mitochondrial and ADP/ATP 
translocase 3. for A, B and C, respectively. 
   
When comparing the results for the confirmatory proteins the situation was quite 
complex. No one method gave better Mascot scores. ESI-Q-TOF again 
identified each protein in a greater number of fractions and had a greater 
number of peptides assigned to each protein, but this generated higher Mascot 
scores. The standard deviation for the iTRAQ reporter ions was again similar.  
 
 
 
 
131 
 
IV-3 Discussion 
Using the outlined experimental approach approximately 7% of the human 
proteome (1434 /20258 uniprotKB/swissprot annotations) was quantitatively 
analysed. This high level of proteome coverage far exceeds previous efforts in 
proteomics investigations of MCTS (Poland et al, 2002. Gaedtke et al, 2007. 
Kumar et al, 2008). What is more, this study represents the first quantitative 
analysis of the MCTS proteome and by performing quantitation of sub-regions 
of the MCTS, important changes in protein expression were indeed suggested.  
As mentioned previously the majority of protein levels remained unchanged 
across the different MCTS regions. Many of these unaltered proteins included 
products of so-called ‗housekeeping genes‘ (Eisenberg and Levanon, 2003), 
such as beta actin, cytochrome C oxidase subunits, including COX5A and 
COX5B and a number of histones, including histone H2A F/Z.  Of those proteins 
which did appear to demonstrate differential levels across the MCTS regions 
many were members of important cellular and metabolic processes.   
 
Encouragingly a number of proteins encoded by known HIF-1 target genes 
(Benita et al, 2009) were shown at higher levels in the MCTS peri-necrotic 
and/or necrotic core regions, these included enolase 1, phosphoglycerate 
kinase 1 (Semenza et al, 1996), GAPDH (Graven et al, 1999), Glucose-6-
phosphate isomerise, Pyruvate kinase M2 (Semenza, 2003), CD73 
(Synnestvedt et al, 2002), and GLUT-1 (Chapman, Franko and Sharplin, 1981). 
In total 16 of the 88 known HIF-1 target genes were identified using MS/MS 
analysis, with 8 identified using both MS approaches with an additional 2 and 3 
uniquely identified using MALDI and ESI, respectively. These results together 
with the increased levels of the established hypoxic marker Glut-1 and the 
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positive CAIX staining (Hoskin et al, 2003) of the isolated PN region (Section 
III), indicates the hypoxic status of the cells within these regions and also helps 
to validate the separation approach utilized in this study.  
 
Gene ontology annotation of both datasets indicated a number of enriched 
biological processes, molecular function and cellular compartments, within 
different sub-categories of up- and down-regulated proteins. MALDI and ESI 
datasets seemed to have little agreement between gene ontology annotation 
results. This is unsurprising considering the low level of redundancy in proteins 
identified with corresponding quantitation information using both instrument 
types.  
 
MALDI analysis resulted in significantly more proteins identified with 
corresponding quantitation information and as such provided greater insight into 
the biochemical adaptations of those cells residing in different MCTS regions. 
Within the MALDI dataset amongst the up-regulated proteins, enzymes and 
regulators of metabolic pathways were prevalent. In particular, components of 
glycolysis, TCA cycle and lipid metabolism increased progressively in the PN 
region and NC. In general these results were not indicated by ESI analysis, with 
glycolytic enzymes such as phosphoglycerate mutase and the TCA related 
succinyl-CoA ligase demonstrating increased levels in the MCTS IR region. 
Acetyl-CoA acetyltransferase involved in lipid metabolism was also seen at 
increased levels in the IR. Estradiol 17-beta dehydrogenase also involved in 
lipid metabolism was indicated by ESI as being increased in the PN and NC 
regions, increased levels of this enzyme in the PN and NC was not noted in the 
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MALDI dataset but would support the results of the many other enzymes 
involved in lipid metabolism which were.  
 
IV-3.1 Increase in glycolysis, TCA and lipid metabolism related proteins within 
the PN and NC 
 
IV-3.1.1 Glycolysis 
MALDI analysis provided quantitation for an abundance of glycolytic enzymes.  
12 enzymes engaged in glycolysis were seen in total, with 8 indicated as being 
increased in the PN, NC or both, importantly, none were indicated as being 
down-regulated. These results would together suggest an increased in 
glycolysis within the MCTS inner regions (PN and NC). The NC appeared to 
demonstrate the most extreme changes in glycolysis enzyme levels. 
cytochrome oxidase 2 (COX2) which has a major role in switching on glycolysis 
and the TCA cycle was also up-regulated in the NC of HT29 MCTS. 
The preferential reliance on anaerobic glycolysis of cancer cells is an 
established phenomena (Ferreira, 2010) with several oncogenes being 
implicated in the Warburg effect. The MYC oncogene, which is activated in the 
HT29 cell line, is thought to stimulate aerobic glycolysis through activating 
numerous glycolyic enzymes and binding various glycolytic genes (Kim and 
Dang, 2005). The consequences of MYC‘s up-regulation of glycolysis, appears 
to be cell line specific, as MYC activation in a human B cell model resulted in an 
increase in respiration rate which was associated with escalated mitochondrial 
biogenesis (Li et al, 2005), which would be suggestive of increased aerobic 
respiration. Those genes which are known to be transcriptional targets of MYC, 
include those encoding, hexokinase 2, enolase and L-lactate dehydrogenase A 
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chain (Kim and Dang, 2005). Within the MALDI dataset, the results for 
hexokinase 2 and L-lactate dehydrogenase A chain, demonstrated no changes 
in enzyme levels across the different MCTS regions (hexokinase 2 was only 
identified with 1 peptide containing quantitative information, therefore was left 
out of the final protein list). Within the ESI dataset hexokinase 2 was not seen 
and in support of the results from MALDI analysis L-lactate dehydrogenase A 
chain was again shown to remain unchanged. Enolase appeared to be at 
increasing levels in the PN and NC when compared to the SL, within the MALDI 
dataset, however this was not reflected in the ESI dataset with its levels 
demonstrating no change across MCTS regions.  
 
P53 is thought to stimulate mitochondrial respiration through transactivation of 
SCO2 and in turn the synthesis of cytochrome c oxidase 2 (Matoba et al, 2006). 
The Warburg effect is, therefore, thought to be promoted through the 
inactivation of P53. P53 is mutated in HT29 cells, the effect of this on the cells 
preferential method of glucose metabolism is unclear. Within the MALDI dataset 
SCO2 appears at an increased level in the IR and PN. Interestingly, as 
mentioned previously, cytochrome c oxidase 2 was indicated to be at a higher 
level in the NC. Neither SCO2 nor cytochrome c oxidase 2 were identified in the 
ESI dataset.  
 
One might expect that in response to hypoxia the rate of glycolysis is increased, 
facilitate by an increase in pyruvate dehydrogenase kinase (PDK) and thus an 
inhibition of the PDH complex, resulting in the conversion of pyruvate into 
lactate rather then allowing it to be converted into acetyl-CoA and subsequently 
entering the TCA cycle. This is the expected outcome under these conditions, 
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however in the MALDI dataset the opposite effect appears to be occurring, with 
the PDH complex indicated at an increased level in the MCTS NC, quantified 
with both it‘s E1 and E2 subunits, lactate dehydrogenase levels appear to be 
constant across the MCTS regions. In order to relate the enzyme levels of PDH 
complex to it‘s activity levels, it‘s phosphorylation status would have to be 
determine. Validation of the protein level would also have to be done The two 
could be determined using western blotting with the former requiring a phospho-
specific antibody.  
 
IV-3.1.2 TCA cycle 
The tricarboxylic acid cycle or Krebs cycle (Kreb, 1940) was shown to be over 
represented in the MALDI dataset (13 proteins shown to be involved in the 
pathway). Increased levels of a number of the enzymes involved in the TCA 
cycle were seen in the MCTS NC (5 components) and PN (2 components) 
regions, including, isocitrate dehydrogenase isoforms and malate 
dehydrogenase. These results would suggest an increase in the TCA cycle 
activity in the MCTS NC and to a smaller extend in the PN.  
As the oxidation of NADH to NAD+ is required for the conversion of pyruvate to 
acetyl-CoA (the precursor molecule for the TCA cycle) by PDH complex, 
hypoxia would be expected to inhibit the TCA cycle. Previously, inhibition of 
Hypoxia-inducible factor (HIF) hydroxylases by TCA cycle intermediates has 
been shown (Koivunen et al, 2007); therefore an increase in TCA cycle activity 
would be expected to increase the stabilization of HIF-α which is characteristic 
of hypoxia.  
To investigate the functioning of the TCA cycle one would have to quantify TCA 
related metabolite levels. Previously, TCA cycle related intermediates, 
136 
 
succinate, fumarate and malate have been shown at increased levels in colon 
tumour verses normal tissue (Hirayama et al, 2009). Mutated succinate and 
fumarate dehyrogenases have been implicated in tumour formation by 
mechanisms which are thought to include TCA cycle disfunction (Briere et al 
2006). Succinate dehydrogenase levels we seen to be constant across the 
MCTS regions and fumarate dehydrogenase was not identified in either dataset.  
Numerous metabolic pathways require the TCA cycle-catalyzed breakdown of 
acetyl coenzyme A, what is more, atmospheric oxygen is required only by 
cytochrome oxidase, which is the terminal oxidase of the respiratory chain. The 
TCA cycle or components could provide a crucial role even under hypoxic 
conditions. It has been suggested that the TCA cycle may comprise of two 
independent segments, which would allow for independent fluxes, extending 
from α-ketoglutarate to oxaloacete and from oxaloacete to α-ketoglutarate, 
respectively (Briere et al, 2006). Metabolic studies carried out on quiescent 
fibroblast have supported the existence of these distinct fluxes within the TCA 
cycle, importantly, in this study quiescent cells were associated with an increase 
in both canonical TCA cycle activity past citrate and an increase in anaplerotic 
TCA cycle flux from pyruvate to oxaloacetate (Lemons et al, 2010). The present 
results suggest an increase in anaplerotic TCA cycle flux from malate or 
oxaloacete to α-ketoglutarate and vice versa in the NC of MCTS which is where 
you would expect quiescent cells to reside.  
 
IV-3.1.3 Lipid metabolism 
The TCA cycle can also utilize products of fatty acid metabolic processes, such 
as β-oxidation. Altered fatty acid metabolism in the NC and PN was suggested 
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by the apparent increases in its related enzymes in these regions. Higher rates 
of de novo fatty acid biosynthesis have been associated with tumourigenesis 
(Medes, Thomas and Weinhouse, 1953) and could facilitate the survival of the 
cells as their environmental conditions become more unfavourable. Commonly, 
tumour specific alterations in de novo fatty acid synthesis are brought about by 
the over expression of fatty acid synthase (FAS) and/or acetyl-CoA carboxylase 
(Kuhajda et al, 1994 and Menendez et al, 2007). Within both datasets (MALDI 
and ESI) over expression of these enzymes was not noted in any region, when 
compared to the SL.  
Within the MCTS NC enzymes involved in mitochondrial fatty acid chain 
elongation (FAEM), such as enoyl-CoA-hydratase, 3-ketoacyl-CoA thiolase and 
trifunctional enzyme subunits alpha and beta appeared to be increased. 
Typically, increased de novo fatty acid synthesis provides highly proliferative 
cancer cells with lipids for membrane production. The synthesised fatty acids 
can, however, be utilized by the cell to provide energy which would be more 
appropriate for the NC cells, in their nutrient deprived conditions. β-oxidation 
would be the means by which energy can be liberated from synthesised fatty 
acids, and this process was indeed indicated as being up-regulated in the 
MCTS necrotic core, with 75% of enzymes involved in this process being shown 
at higher levels in this region. The activation of fatty acid oxidation has 
previously been indicated as an important mechanism for the survival of cancer 
cells when deprived of glucose (Buzzai et al, 2005). 
FAEM is the reversed process of beta oxidation, which results in many of the 
enzymes involved in each process being the same. Long-chain-3-hydroxyacyl-
CoA dehydrogenase, which is involved exclusively in FAEM, was highlighted as 
being increased in the NC. Other enzymes exclusive to FAEM did not 
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demonstrate the same results. Acyl-CoA dehydrogenase which is involved in β-
oxidation but not FAEM was not seen in either dataset. Other enzymes common 
to the two processes (enoyl-CoA-dehydrogenase and β-ketothiolase) were 
indicated at higher levels in the NC. Clearly, one can not assign with confidence 
any of the enzymes to any of the two processes. What‘s more, comments on 
such processes can only be speculative at this point due to the absence of 
enzyme activity studies, which provide further/ongoing work.  
IV-3.2 Necrosis in the NC? 
The most striking results seen in this investigation are the protein expression 
changes indicated in the NC. The cells of this region have previously always 
been thought to be necrotic or in the process of necrosis. Indeed unsurprisingly 
proteins associated with cell death were highlighted as being in increased in this 
region. What is surprising, particularly with the MALDI dataset is the  number of 
proteins involved in a multitude of cellular and molecular processes which are 
indicated as being increased. This is even more remarkable if you take into 
consideration that this increased protein expression is being contributed to by 
only a portion of the total cell population in this region (i.e the none necrotic 
cells).  
 
IV-3.3 Increases in chaperone and protein folding proteins within the NC 
Proteomic analysis of the NC revealed a notable over expression of various 
chaperones (HSP90, 14-3-3 proteins, protein disulphide isomerases, 150kDa 
oxygen-regulate protein, 78 kDa glucose-regulated protein). This was true for 
the analysis using both instrument types, with ESI analysis indicating the 
increase of additional chaperones (HSP70, HSP70-interacting protein, HSP75M 
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and HSP901A3). The biological relevance of these finding remain to be 
determined and before one can begin to make conclusions the protein 
expression levels must be validated. 
 
IV-3.4 MALDI-TOF-TOF verses ESI-Q-TOF 
Unfortunately, due to the low level of crossover between proteins identified 
using each MS approach; the results did not help to validate each other, as had 
previously been hoped. ESI-Q-TOF analysis generated results, with a low 
number of proteins providing quantitation information. Results following ESI-Q-
TOF analysis demonstrated a large number of unidentified MS/MS when 
searched against Swissprot using Mascot. A possible source of error could be 
due to inefficient fragmentation of the peptides and iTRAQ reporter ion during 
MS/MS analysis. This would help to explain why such a large compound and 
resulting query list would give rise to such a low percent of protein 
identifications. This has previously been shown to be a problem with nLC-ESI 
MS/MS using a QStar XL tandem mass spectrometer (Applied biosystems) 
(Sirran and Botting, 2010. Wiese et al, 2007). With the latter going on to show 
that increasing the collision energy and changing the collision gas from nitrogen 
to argon, reporter ion abundances were improved. 
 
Further work would involve re-analysing these samples using higher collision 
energy. Should this result in an increase in protein identification then this would 
indicate that inefficient fragmentation was indeed a problem. MALDI and ESI 
analyses were carried out using the same sample with MALDI suggesting a 
higher iTRAQ labeling efficiency than ESI (fragmentation efficiency not labeling 
efficiency). As peptides are ionized at a different efficiency using different 
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ionization methods (Bodnar et al, 2003), ESI MS/MS in this experiment may 
have ionized or fragmented non-labeled peptide more effectively than labeled 
peptides compared to MALDI MS/MS, resulting in a low (<75%) iTRAQ labeling 
efficiency seen in the overall results. 
 
Despite the low level of crossover between proteins identified with 
corresponding iTRAQ quantitation information, 3 proteins were seen to 
demonstrate contradictory protein expression levels, in the results for each type 
of analysis. This draws attention to the limitations of iTRAQ (Ow et al, 2009. 
Karp et al, 2010). A number of issues have been reported which impact the 
accuracy of iTRAQ quantitation in general. These include underestimating the 
degree of protein expression changes (Desouza et al, 2008) and poor precursor 
ion selection efficiency leading to the selection of mixed precursors and thus 
mixed MS/MS (Ow et al, 2009).  
 
ESI MS/MS in particular has been associated with inaccuracies in reporter ion 
ratios with ions demonstrating weaker intensities from the chromatographic tail 
contributing to overall quantitation leading to less accurate ratio‘s, when 
compared to MALDI MS/MS (Shirran and Botting, 2010). In the same 
experiment, underestimation of the degree of protein changes was seen with 
both MALDI MS/MS and ESI MS/MS, however this was more apparent in the 
latter.  
 
Despite these issues with iTRAQ quantitation this method does provide a good 
tool to carryout quantitative proteomics and many studies have achieved 
accurate results confirming this (Scheri et al, 2008. Wise et al, 2007). In the 
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current study, the poor ESI MS/MS iTRAQ data make it difficult to comment on 
the accuracy of iTRAQ quantitation using the two methods. The large proteome 
coverage achieve using the combined methods illustrate the power of this 
approach to provide insight into the dynamic proteome of complex biological 
systems. As the current study is concerned with characterising the entire 
MCTS, emphasis is not on the accuracy of determining individual protein 
amounts but on the ability to gain insight into the effects microenvironment 
conditions have on multiple molecular, cellular and biological functions and 
processes. In this respect the results generated here provide a foundation for 
further investigation.  
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V: Validation of the proteomics analysis results 
V-1 Introduction 
Protein quantification using the iTRAQ labelling approach outlined in section IV, 
has a number of limitations, many of which were described in the previous 
discussion in section IV. iTRAQ does not provide absolute quantitation of 
individual protein levels, nor was the current study striving to achieve this. Due 
to the nature of the data generated using this approach, statistically significant 
up or down regulated proteins within any region cannot be confirmed but only 
indicated. Combined results for specific protein response profiles indicated very 
interesting molecular difference between the different MCTS regions; this was 
especially true for those involving different metabolic pathways.  
To help validate these observations further investigation were done using 
complementary analytical techniques at the cell, biochemical and enzymological 
level. Verification of the proteomics findings was performed using 11 specific 
proteins. Proteins were chosen on the basis that they could provide additional 
information regarding a molecular pathway including key enzymes in glycolysis, 
TCA cycle and fatty acid metabolism and were as follows;  
V-1.1 Integrin – α1  
Integrins play a role in a number of cellular processes which impact upon 
tumourigenesis (Rathinam and Alahari, 2010). Expression of specific integrins 
influences the biology of various tumour types, particularly, Integrins play are 
role in biological processes such as cell migration and angiogenesis. 
Proteomics analysis indicated an increase in expression of integrin α1 in the 
MCTS necrotic core. Integrin alpha 1 dimerizes with integrin α1 and together 
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they provide the cell surface receptor for laminin and collagen (Clyman, Turner 
and Kramer, 1990). VEGF has been shown to induce a 5-7 fold increase in 
integrins alpha1/beta1 and alpha2/beta 1, with the induction being brought 
about by an increase in mRNA‘s encoding the alpha 1 and 2 subunits (Senger 
et al, 1997). Collaboration of these two integrin dimers (alpha 1/beta 1 and 
alpha 2/beta 1) provides support for VEGF signal transduction, endothelial cell 
migration and tumour angiogenesis (Senger et al, 2002). The critical role of 
integrin alpha 1 in tumour vascularization was demonstrated with integrin alpha 
1 knockout mice, which exhibited tumours with markedly decreased 
vascularization (Pozzi et al, 2000). The impact this could have in the clinic was 
highlighted with an increase in integrin alpha 1 expression correlating with a 
decrease in survival with patients with advanced melanoma (Vuoristo et al, 
2007). Interestingly, increased expression of alpha 1/beta 1 integrin complex 
has been shown to be critical for cytotrophoblast invasion, which is essential to 
the development of the placenta, during pregnancy (Damsky et al, 1994), this 
could suggest a role for this complex in tumour cell invasion. The properties of 
integrin alpha 1 provide it with the means to promote tumourigenesis and its 
increased expression in the cells of the MCTS NC would implicate is as a 
worthy target for further investigation.  
V-1.2 Pyruvate kinase M2  
Pyruvate kinase participates in the final step of glycolysis, where it catalyzes the 
transphosphorylation from phosphoenolpyruvate (PEP) to ADP, which 
generates ATP (Kayne and Price, 1973. Valentini et al, 2000). The enzyme is 
expressed as different isozymes; L, R, M1 and M2, with expression levels of 
each dependent upon the metabolic requirements of the cell.  
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The present study will focus on the M2 isozymic form (PKM2). PKM2 is 
expressed by all tissues during embryogenesis, after which it is gradually 
replaced by its alterative isoforms. PKM2 is over-expressed in a number of 
tumour types (Gupta and Bamezai, 2010) and is widely accepted as a marker of 
the metabolic state of tumours. Its role in tumour metabolism has lead to it 
being incorporated as a marker when screening for colorectal cancer (Hardt et 
al, 2004). Expression of PKM2 has been shown to be necessary for the shift in 
metabolism towards aerobic glycolysis which is a defining characteristic of the 
Warburg effect (Christofk et al, 2008). This PKM2-dependant metabolic 
phenotype was shown to provide a selective growth advantage for tumour cells 
in vivo (Christofk et al, 2008).  
MALDI analysis of the MCTS suggested an increased expression of PKM2 
within the NC. ESI analysis resulted in no significant differences in reporter ion 
ratios across the different MCTS regions. As an accepted marker of the 
metabolic status of tumours, validation of the levels of this enzyme would help 
to assess the levels of the Warburg effect across the different regions of the 
MCTS and would help to determine if the NC is demonstrating the highest 
levels of glycolysis as was suggested by the proteomics data. 
V-1.3 α-enolase 
Enolase is an essential glycolytic enzyme which was first identified in 1934 
(Lohman and Meyerhof, 1934). It is also known as phosphopyruvate 
dehydratase and is a metalloenzyme that catalyzes the dehydration of 2-
phosphoglycerate (2-PG) to phosphoenolpyruvate (PEP) in the penultimate step 
of glycolysis. Enolase requires certain divalent metal ions for its activity, with 
preference for magnesium which is its natural cofactor.  
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Enolase is an abundant cytosolic protein which can also locate on the cell 
surface (Miles et al, 1991). The enzyme occurs as 3 isomers α, β and γ with 
each made up of two identical subunits and having a molecular weight in the 
range of 82,000–100,000 Da (Malstrom, 1961 and Wold, 1971).  
Enolase expression has been shown to be up-regulated in endothelial cells in 
response to hypoxia and it has been proposed that α-enolase may provide 
protection to cells by increasing anaerobic metabolism, under these conditions 
(Aaronson et al, 1995). α-enolase located on the cell surface is capable of 
binding plasminogen (Miles et al, 1991) and within its role as a plasminogen 
receptor α-enolase could promote tumourigenesis through, for example, 
plasminogen-mediated increased cell migration (Plow et al, 1995). Enolase has 
previously been identified as a tumour marker (Royds et al, 1982).  
Within the MCTS dataset (MALDI) α-enolase was observed to be increased in 
all regions in comparison to the SL. The degree of change suggests a 
progressive increase into the centre of the spheroid relative to the SL region. 
Verification of the quantitation result for this protein will provide insight into how 
accurately the iTRAQ ratios represent the degree of change in protein 
expression. Being a key enzyme involved in glycolysis, its validation will help to 
provide confirmation of the apparent up-regulation of glycolysis within the NC.  
V-1.4 Pyruvate dehydrogenase complex 
The pyruvate dehydrogenase complex (PDHC) is responsible for the 
transformation of pyruvate into acetyl-CoA, via pyruvate decarboxylation. The 
complex represents a link between glycolysis and the TCA cycle with pyruvate, 
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the end product of glycolysis, being transformed to acetyl-CoA which can then 
to enter the TCA cycle.  
The complex is made up of numerous subunits of three enzymes; pyruvate 
dehydrogenase/decarboxylase (E1), acetyltransferase(E2) and 
dihydrolipoamide dehydrogenase(E3) (Perham,1991). Utilizing each of the three 
enzymes the transformation of pyruvate to acetyl-CoA by PDHC requires five 
cofactors; thiamine pyrophosphate (TPP), lipoamide, coenzyme A, FAD and 
NAD+. Pyruvate dehydrogenase/decarboxylase (E1) requiring TPP as a 
cofactor is responsible for the decarboxylation of pyruvate. Following the 
decarboxylation of pyruvate dihydrolipoyl transacetylase (E2) catalyzes the 
transacylation of acetyl from lipoyl to the thiol of coenzyme A, resulting in the 
production of acetyl-CoA. Dihydrolipoyl dehydrogenase (E3) liberates NADH 
from the remaining dihydrolipoate, via flavin-mediated oxidation. This process 
occurs under aerobic conditions (Harris et al, 2002).  
 
The activity of PDH is regulated by pyruvate dehydrogenase kinases (PDK‘s) 1 
to 4, which deactivate the complex through phosphorylation of the E1 subunit. 
The activity of PDKs are regulated by the concentration of metabolic products of 
pyruvate, with increased levels of pyruvate inhibiting their action (Sugden and 
Holness, 2003). The suppression of PDHC by PDK can facilitate anaerobic 
glycolysis, and such a situation has been identified in tumour cells (Koukourakis 
et al, 2005).  
 
Due to its role in linking glycolysis to the TCA cycle, further investigation of the 
PDH complex is required. These investigations may help to determine if the 
apparent up-regulation of the TCA cycle in the PN and NC regions of the 
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MCTS, is as a means to provide additional ATP from pyruvate, following 
glycolysis or alternatively as a mean to utilize products of catabolic processes 
such as lipid and protein catabolism, which may be occurring in response to the 
harsh conditions in which the PN and NC regions are facing.   
 
Within the MALDI dataset pyruvate dehydrogenase/decarboxylase (E1) and 
acetyltransferase(E2) were observed to be increased in the NC, whereas 
dihydrolipoamide dehydrogenase(E3) levels appeared to remain constant 
across the different MCTS regions. The E1-catalyzed process is the rate-limiting 
step of the whole pyruvate dehydrogenase complex, E1 together with E2 will be 
included in the current validation studies.  
 
V-1.5 Citrate synthase 
 
Citrate synthase resides in the mitochondrial matrix and is a ‗pace-making‘ 
enzyme which catalyses the condensation reaction between acetyl-CoA and 
oxaloacetate to form citrate in the first step of the TCA cycle (Wiegand and 
Remington, 1986). Citrate synthase is an important mitochondrial marker and 
has been used routinely to assess mitochondrial volume density and oxidative 
and respiratory capacity (Hoppeler, 1986. Holloszy et al, 1970).  
 
Citrate synthase activity can be used to indicate the integrity of mitochondria; 
this would prove useful in the current study, particularly within the cells of the 
NC. By measuring the activity of citrate synthase across the different MCTS 
regions validation of the proteomics data may be achieved and the results will 
determine whether or not differences in protein levels translate into differential 
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activity. Importantly, determining specific enzyme activity levels will establish if 
proteins within the NC are functionally active 
 
The MCTS MALDI dataset indicated that citrate synthase protein levels 
remained unchanged in the IR and PN regions, but then increased in the NC, 
compared to the SL. ESI analysis, however, suggested no change in protein 
levels.  
 
V-1.6 Isocitrate dehydrogenase (IDH)  
 
An increase in TCA cycle related enzymes and the TCA cycle activity indicated 
within the inner MCTS regions, could facilitate the synthesis of new cell 
components, which would aid the survival of the cells under the stressful 
conditions which they face. Different steps within the TCA cycle can provide 
precursor molecules needed to synthesize many important biological molecules, 
such as; amino acids, nucleotides and lipids.  
  
Isocitrate dehydrogenase (IDH) catalyzes the third step of the TCA cycle, which 
involves the oxidative decarboxylation of isocitrate to produce alpha-
ketoglutarate. Mutations in the active site of this enzyme represent an important 
genetic alteration in glioblastoma multiforme (GBM) the most common and 
lethal type of brain cancer (Parson et al, 2008). Mutations in IDH lead to the 
build-up of high levels of 2-hydroxyglutarate. Many subsequent studies have 
reinforced and supported these finding with IDH becoming an accepted marker 
for secondary GBM (Toedt et al, 2011). Interest in the occurrence of IDH 
mutations in other cancers has led to IDH1 and IDH2 mutations being identified 
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as recurrent in cytogenetically normal acute myeloid leukemia (CN-AML) and 
has been shown to have an unfavorable impact on outcome (Marcucci et al, 
2010). IDH has a role to play in tumourigenesis, the extent of which is currently 
still under investigation. Interestingly, IDH2 knockdown has been shown to 
result in the suppression of hypoxia-induced stimulation of HIF-1 α, establishing 
a positive link between IDH2 and HIF-1α (Kim and Park, 2010). 
 
Proteomics data (MALDI) indicated up-regulation of 3 different IDH isozymes; 
IDH1, IDH2 and IDH3A, in the NC alone, IR, PN and NC, and the PN and NC, 
respectively. The validation of these results could provide further evidence of its 
up-regulation in certain regions of the MCTS, together with additional insights 
into the TCA cycle activity and could support the relationship between IDH2 and 
hypoxia-induced stimulation of HIF-1α.  
 
V-1.7 Malate dehydrogenase 
 
Malate dehydrogenase is another participant of the TCA cycle, where it 
catalyzes the reversible conversion of malate into oxaloacetate (using NAD+). 
Malate dehydrogeanse exists as two main isoforms in eukaryotic cells (Minarik 
et al, 2002). One isoform is found in the mitochondrial matrix and is involved in 
the TCA cycle and the other is found in the cytoplasm and is responsible for 
shuttling malate-aspartate across the mitochondrial membrane (Musrati et al, 
1998). Validation studies will focus on the former isoform and will include 
enzyme activity measurements. As it represents a penultimate step in the 
plenary TCA cycle, the results should indicate TCA activity levels. Proteomics 
analysis (MALDI) identified both isoforms, with the cytoplasmic form showing no 
150 
 
difference across the MTCS regions and the mitochondrial form indicating an 
increase in the NC.  
 
V-1.8 Enoyl CoA hydratase 
 
β-oxidation involves the degradation of fatty acids by the actions of four 
enzymes; acyl-CoA dehydrogenase, enoyl-CoA hydratase, 3-hydroxyacyl-CoA 
dehydrogenase and β- ketothiolase (Kunau, Dommes and Schulz, 1995), 
together these enzymes reduce acyl-CoA liberating a two carbon unit-acetyl 
CoA. This reaction occurs in the mitochondria and is used to generate ATP.   
Each of the four enzymes involved in β-oxidation were seen within the 
proteomics dataset, with enoyl-CoA hydratase and 3-hydroxyacyl-CoA 
dehydrogenase up-regulated in the NC and β- ketothiolase up-regulated in the 
PN region. These results lead to the speculation that β-oxidation was an 
increased metabolic pathway within inner MCTS regions.  
 
Enoyl-CoA hydratase is perhaps the most intensely studies enzymes in β-
oxidation (Agnihotri and Liu, 2003). It hydrates the double bond between the 
second and third carbons on acyl-CoA, the second step of β-oxidation. To gain 
further insights into the increase in β-oxidation suggested by the MS-derived 
data, western blot and IHC analysis will be carried out focusing on this enzyme.  
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V-1.9 7-dehydrocholesterol reductase 
7-dehydrocholesterol reductase (DHCR7) catalyzing the production of 
cholesterol from 7-dehydrocholesterol using NADPH, which represents the 
penultimate step in mammalian sterol biosynthesis (Moebius et al, 1998).  
 
Cholesterol accumulation has been shown to occur in solid tumours (Clayman 
et al, 1983. Dessi et al, 1992), which has been shown to result of increased 
cholesterol synthesis (Clayman et al, 1983). Membrane localised cholesterol 
accumulation has been shown to be particularly important in the progression of 
prostate cancer (Freeman and Soloman, 2004), with a cholesterol-regulated Akt 
pathway being shown to promote cell survival (Zhuang et al, 2005). Within the 
proteomics datasets (Both MALDI and ESI) DHCR7 was increased in the PN 
and NC regions.  DHCR7 was analysed by IHC and western blotting to confirm 
the MS results. 
 
V-1.10 Carnitine o-acetyltransferase 
Carnitine acyltransferases are a group of enzymes which play important roles in 
energy homeostasis and lipid metabolism (Colucci and Gandour, 1988). They 
modulate their effects through regulating levels of acetyl-CoA and long chain 
acyl-CoA within a number of different cellular compartments. Carnitine o-
acetyltransferase (CRAT) is localised in mitochondrial and peroxisomal cellular 
compartments and is responsible for the transesterification of short-chain acyl 
chains.  
 
Mitochondrial CRAT plays a pivotal role in determining the equilibrium between 
acetyl-CoA (+carnitine) and acetylcarnitine (+free CoA) therefore modulating the 
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acetyl-CoA/CoA ratio. This creates an important buffer effect under conditions 
where increased acetyl-CoA is present due to, for example, increased 
production through lipid metabolism or glycolyic derived pyruvate oxidation 
(Elgersma et al, 1995. Van Roermund et al, 1999). Increased CRAT levels in 
the NC of MCTS were indicated in the MALDI dataset, this enzyme was not 
identified using ESI MS/MS. As both glycolysis and lipid metabolism appear to 
be increased also in this particular region, increases in CRAT would seem 
plausible, validation of the levels by western blotting would confirm this.  
 
V-1.11 HCSL-associating protein -1 
 
HCSL-associating protein -1 (HAX-1) was originally identified as a mitochondrial 
Src kinase substrate and was suggested to play a role in B cell signal 
transduction (Suzuki et al, 1997). HAX-1 is a ubiquitously expressed protein 
which interacts with a number of cellular and viral proteins. As such it has been 
implicated in multiple cellular processes and signaling pathways (Lees, Hart and 
Marshall, 2008. Carlsson et al, 2008). Negative regulatory roles in apoptosis 
have been suggested as one of its many roles.  
 
HAX-1 has been shown to be over-expressed in various types of human 
malignancies (Mirmohammadsadegh et al, 2003. Ramsey et al, 2007) and is 
associated with increased proliferation (Mirmohammadsadegh et al, 2003). The 
over-expression of HAX-1 suggested in the SL of MCTS (MALDI data) would be 
consistent with these findings as the SL represents the highly proliferative 
portion of the MCTS.  
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Validation of the results seen for this protein would help to confirm the ability to 
highlight changes in protein expression across each MCTS region. What‘s 
more, this protein was identified using only one unique peptide (and as such 
was excluded from the 882 final protein list), successful validation of its levels 
will therefore provide confidence in the value of considering so called ‗one hit 
wonders‘.   
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V-2 Aims and Objectives 
Having generated quantitative information for a large number of proteins, which 
together suggest interesting and potentially very important molecular 
differences between the different MCTS regions, validation studies were 
required to support these results.   
 
Validation was achieved through the use of multiple complementary analytical 
techniques, including; IHC, WB and enzyme assays. Validation studies were 
focused on those proteins outlined in the introduction to this chapter and the 
technique chosen for validation were dependant on both the protein under 
investigation and the quality of antibody available against it.   
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V-3 Methods 
Spheroid culture, separation, paraffin embedding and subsequent sectioning 
were as described previously (Section II). Spheroid sections were taken through 
to IHC analysis and separated spheroid sub-region pellets were used for 
western blot and enzyme activity analysis.  
V-3.1 Immunohistochemistry 
Spheroid sections were de-waxed and rehydrated prior to immunodetection. 
This was achieved through successive incubations in 100% xylene for 10 
minutes, 50% xylene/ethanol for 5 minutes, 100% ethanol for 10 minutes, 90% 
ethanol for 5 minutes and 70% ethanol for 5 minutes. All incubations were 
carried out at RT.  
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Antibody Raised in Dilution Incubation 
time (mins) 
Blocking 
serum 
Secondary 
antibody 
Integrin alpha 
1 * 
rabbit 1:200 90 goat  Anti-rabbit 
ECHS1** rabbit 5:1000 90 goat Anti-rabbit 
PDHE1-α* mouse 1.5:1000 90 horse Anti-mouse 
PDHE2-α * rabbit 2.5:1000 Overnight 
(5°C) 
goat Anti-rabbit 
MDH2 ** rabbit 1:500 – 
1:2000 
90 – 
overnight 
(5°C) 
goat Anti-rabbit 
DHCR7** rabbit 1:500 – 
1:5000 
90 – 
overnight 
(5°C) 
goat Anti-rabbit 
HAX-1 ** goat 1:500 90 rabbit Anti-goat  
Table 13: Primary antibody specifications, including dilutions, incubation times, blocking serum 
and secondary antibody requirements, for those antibodies used in IHC analysis; Integrin α-1 
(cat#Ab78479), Enoyl coenzyme A hydratase, short chain 1 (ECHS1, cat# AV45699), Pyruvate 
Dehydrogenase E1-alpha subunit (PDHE1-α, cat# Ab67592),  Pyruvate Dehydrogenase E2-
alpha subunit (PDHE2-α, cat# Ab678479), Malate dehydrogenase 2(NAD+) (MDH2, cat# 
SAB1100059), 7-Dehydrocholesterol reductase (DHCR7, cat# D7570) and HCLS1 associated 
protein X-1 (HAX-1, cat# SAB2500504). * Abcam  **Sigma. 
 
De-waxed and rehydrated sections were incubated with an appropriate primary 
antibody (made up using 0.01M PBS), following microwave mediated antigen 
retrieval (Cattoretti et al, 1993) in the presence of citrate buffer (100mM, pH 
6.0). Sections were washed by incubating for 10 minutes in 0.01M PBS, which 
was repeated twice. Biotinylated secondary antibodies (Vector) were used at a 
1:200 dilution in PBS. Sections were washed by incubating for 10 minutes in 
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0.01M PBS, this was repeated twice. Positive staining was visualized using 
DAB reagent (Vector) counterstained with Scotts tap water. Images were 
captured using a QiCam attached to a Leica DM RB light microscope using 
Qcapture software (Spectra Services, Ontario, Canada). IHC negative controls 
were prepared by omitting the primary antibody. 
V-3.2 Western blotting  
For Western blot with each antibody, 50μg protein of each sample (SL, PN and 
NC) was used.  
V-3.2.1 Cell lysis 
Spheroid sub-region pellets were lysed by sonication in the presence of RIPA 
buffer (Tris-HCL 50mM, NaCl 150mM, KF 5mM, EDTA 1mM, NP-40 1% and 
protein inhibitor cocktail). 
Protein concentrations were determined using the Bradford assay as previously 
described (IV- 1.1.2).  
 
V-3.2.2 SDS-PAGE 
SDS-PAGE gels were used to separate protein samples according to their 
electrophoretic mobility, using the Mini Protean II system from Biorad. The 
percentage of the resolving gel was selected in accordance with the molecular 
weight (MW) of the protein to be immuno-detected and this is presented in the 
following table; 
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Protein  Molecular weight (kDa) % of resolving gel  
Integrin α-1 200 6 
ENO1 43 12 
PDHE1  63 12 
PDHE2 35 15 
MDH2  29 15 
ECHS1 47 12 
DHCR7  45 12 
CRAT 54 12 
HAX-1  36 15 
β-actin  48 12 
Table 14: Proteins and their required percentage of resolving gel, including; ; Integrin α-1, 
Enolase-1 (ENO1),   Pyruvate Dehydrogenase E1-alpha subunit (PDHE1-α), Pyruvate 
Dehydrogenase E2-alpha subunit (PDHE2-α),  Malate dehydrogenase 2(NAD+) (MDH2), Enoyl 
coenzyme A hydratase, short chain 1 (ECHS1), 7-Dehydrocholesterol reductase (DHCR7), 
Carnitine o-acetyltransferase (CRAT), HCLS1 associated protein X-1 (HAX-1) and β-actin.  
The composition of the resolving gels used was as follows: 375 mM Trisma-
Base pH 8.8, 0.1% sodium dodecyl sulfate, 0.05% Ammonium persulfate and 
0.05% N,N,N‘,N‘-Tetramethylethylenediamine (Temed), with 6%, 12%, or 15%  
v/v acrylamide/bis-acrylamide 29:1 solution as indicated in the table above. The 
resolving gel was completed with a stacking gel, which consisted of the 
following; 375 mM Trisma-Base pH 6.8, 3.9% v/v acrylamide/bis-acrylamide 
29:1 solution, 0.1% sodium dodecyl sulfate, 0.05% Ammonium persulfate and 
0.1% Temed in distilled water. 
V-3.2.2.1 Protein separation and membrane transfer 
Prior to SDS-PAGE separation 50µg of total protein for each samples was 
mixed with 25% sample loading buffer (225mM Tris-HCl pH 6.8, 50% glycerol, 
159 
 
5% SDS, 0.05% bromophenol blue, 0.25 M DTT). Samples were heated at 70˚C 
for 10 min, in order to denature the tertiary structure of the proteins before being 
loaded onto the gel. The samples were left to migrate for 90 min at 100 volts in 
electrophoresis buffer (95mM Tris, 960mM glycine and 1% SDS).  
 
V-3.2.2.2 Visualisation of the protein separation 
Coomassie blue (0.25g) was dissolved in a solution (90ml) containing a 1:1 ratio 
of methanol :distilled H2O, 11% glacial acetic acid and then filtered. The SDS-
PAGE gel was immersed in at least 5 volumes of the above mentioned solution 
for a minimum of 4 hours on a shaking platform. To de-stain the gel, a solution 
containing a 1:1 ratio of methanol :distilled H2O , 11% glacial acetic acid was 
used The gel was treated with this solution for 24 hours at RT on a rocker, with 
changes after 30 minutes, 2 hours and 6 hours. 
 
V-3.2.3 Immunodetection 
Following SDS-PAGE, the separated proteins were then transferred to a 
polyvinylidene difluoride (PVDF) membrane (Amersham Biosciences). This was 
done in the presence of transfer buffer (10% transfer buffer 10X (190mM Tris, 
1.92M glycine and 1% SDS), 20% ethanol and 70% distilled H2O). The transfer 
was performed at 300mA for 90 min, using a Mini Protean II system from 
Biorad.  
The PVDF membrane was initially incubated overnight at 4oC with 0.01M PBS, 
pH 7.4, 0.05% nonidet P-40 (NP40) and 5% w/v milk or BSA, under gentle 
rocking. The membranes were then exposed to primary antibodies in 0.01M 
PBS (0.05% NP40, 1% w/v BSA) for 90 min under gentle rocking, the 
concentration and antibody details are specified in table 15.   
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Antibody Raised in Dilution Blocking Secondary antibody 
Integrin α-1* rabbit 1:500 BSA Goat – anti – rabbit 
ENO1 ** Mouse 1.5:1000 Milk Rabbit – anti - mouse 
PDHE1 * mouse 1.5:1000 BSA Rabbit – anti - mouse 
PDHE2 * rabbit 5:1000 BSA Goat – anti – rabbit 
MDH2 **  rabbit 1:1000 Milk Goat – anti – rabbit 
ECHSI ** rabbit 2.5:1000 Milk Goat – anti - rabbit 
DHCR7 **  rabbit 1:500 Milk Goat – anti – rabbit 
CRAT ** rabbit 1:1000 Milk Goat – anti - rabbit 
 
HAX-1 **  Goat 1:1000 Milk Rabbit – anti – goat 
β-actin ** goat 1:500 Milk Rabbit – anti – goat  
Table 15:. Primary antibody specifications, including dilutions, incubation times, blocking serum 
and secondary antibody requirements, for those antibodies used in western blot analysis; 
Integrin α-1 (cat# Ab78479), Enolase-1 (ENO1, cat# WH0002023M1),   Pyruvate 
Dehydrogenase E1-alpha subunit (PDHE1-α, cat# Ab67592), Pyruvate Dehydrogenase E2-
alpha subunit (PDHE2-α, cat# Ab78479),  Malate dehydrogenase 2(NAD+) (MDH2, cat# 
SAB1100059), Enoyl coenzyme A hydratase, short chain 1 (ECHS1, cat# AV45699), 7-
Dehydrocholesterol reductase (DHCR7, cat# D7570), Carnitine o-acetyltransferase (CRAT, cat# 
AV53559), HCLS1 associated protein X-1 (HAX-1, SAB2500504) and β-actin (cat# 
SAB2500022). *Abcam  **Sigma. 
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The membranes were then washed three times with 0.01M PBS (0.05% NP40) 
for 15 min at RT, on the rocker. Following washes, the membrane was 
incubated with an immunoglobulin/HRP conjugated secondary antibody against 
the species in which the primary antibody was raised. The secondary antibody 
was used at a 1/2,000 dilution in 0.01M PBS (0.05% NP40, 1% w/v milk) and 
was incubated for 60 min at RT, under gentle rocking. Subsequently, the 
membranes were washed three times again. Protein detection was performed 
by exposing the membrane to ECL plus chemiluminescence reagent (GE 
Healthcare, Buckinghamshire), according to the manufacturers instructions, with 
the image developed on Scientific imaging film (Kodak, Hemel Hempstead, UK). 
The film was developed using an Optimax x-ray film processor (Protec 
Medizintechnik Gmbh). 
V-3.3 Analysis of functional enzyme activity 
Analysis of pyruvate kinase, citrate synthase and malate dehydrogenase  
enzyme activity were carried out across the SL, PN and NC regions of  MCTS.   
V-3.3.1 Cell lysis 
Separated spheroid sub-region pellets were homogenized using both chemical 
(lysis buffer) and physical methods (sonication). The method of choice was 
dependant on the enzyme activity under investigation. Cell pellets were lysed in 
buffer (25mM Tris HCl [pH7.6], 1mM EDTA, 1mM PMSF and 5mM DTT) and 
sonicated (6 cycles of 5 seconds at 50% intensity, on ice, using a SH70A 
sonicator) in preparation for pyruvate kinase and malate dehydorgenase 
enzyme activity analysis. Once lysed, samples could be stored at -80°C, in the 
presence of glycerol (10% v/v) without deterioration in enzyme activity (data not 
shown).  
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For analysis of citrate synthase activity, cells isolated from different regions of 
spheroids were lysed using sonication on ice (15 seconds at 50% intensity, 
using a SH70A sonicator), in the presence of in 0.01M PBS. The resulting cell 
lysates were used immediately for analysis.   
V-3.3.2 pyruvate kinase 
Pyruvate kinase activity was measured by a continuous assay coupled to 
lactate dehydrogenase (LDH) and the oxidation of NADH was measured at 
340nm.  
V-3.3.2.1 Reaction mixture 
Each reaction contained 100mM KCl, 5mM MgCl2, 0.6mM ADP, 0.5mM PEP, 
180 μM NADH, 10 μM FBP, 8 Units of LDH, 10μl cell lysate in a final reaction 
volume of 1ml Tris HCl (50mM, pH7.5).  
V-3.3.2.2 Determining pyruvate kinase activity  
The reaction was started by the addition of PEP and oxidation of NADH was 
monitored at 340nm for 2 min. Specific enzyme activity was calculated using a 
molar extinction coefficient for NADH of 6220 M-1cm-1. Specific activity was 
determined using the following equation:  
 
∆A340/min 
Ʃ X P 
∆A340/min 
6.22 X mg       
Protein               
reaction mixture 
ml 
Specific activity =  
= 
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Where Ʃ = molar extinction coefficient for NADH (6220 M-1cm-1) and P = protein 
concentration in the reaction mixture (mg/ml). 
 
V-3.3.3 Malate dehydrogenase  
Malate dehydrogenase activity was determined by measuring the decrease in 
absorbance at 340 nm resulting from the oxidation of NADH.  
 
V-3.3.3.1 Reaction mixture 
Each reaction contained 0.6 mM oxaloacetate, 0.04mM NADH and a 20μl 
sample volume in a final reaction volume of 1ml phosphate buffer (100mM, pH 
7.5).  
 
V-3.3.3.2 Determining malate dehydrogenase activity 
The oxidation of NADH was measured at 340nm using a Multiskan Spectrum 
spectrophotometer (ThermoScientific, Hemel Hempstead, UK) and the reaction 
time was 2 min. Specific enzyme assays were calculated using a molar 
extinction coefficient for NADH of 6220 M-1cm-1. The rate of change in 
absorbance (∆A/min) was recorded. Specific activity was determined using the 
following equation:  
 
 
Where Ʃ is the molar coefficient for NADH (6220 M-1cm-1) and P is the amount 
of protein in the cuvettte. Protein concentrations were determined using the 
Bradford assay.  
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V-3.3.4 Citrate synthase 
The activity of citrate synthase was determined by measuring the conversion of 
acetyl-CoA and oxaloacetate to citrate and CoA-SH coupled to the irreversible 
reaction, where CoA-SH converts dithionitrobenzoic acid (DTNB) to 
thionitrobenzoic acid (TNB). 
V-3.3.4.1 Reaction mixture 
Each reaction contained 0.5mM oxaloacetate, 0.3mM acetyl CoA, 0.1mM 
DNTB, 25μl Triton-X-100, 100 μl cell lysates in a final reaction volume of 1ml 
Tris HCl buffer (0.1M, pH 8.0). 
V-3.3.4.2 Determining citrate synthase activity 
The production of TNB was measured at 412nm over 2 min using a Multiskan 
Spectrum spectrophotometer (ThermoScientific). Specific enzyme activity was 
determined using a molar extinction coefficient of 13.6 mM-1cm-1 for TNB. The 
rate of change of absorbance rA = (∆A/MIN) was recorded. Specific activity was 
determined using the following equation: 
 
V  is the specific activity of the enzyme and is expressed μmol/min/mg, 
depending on ƿ. Where ƿ is the amount of protein in the cuvette and Ɛ is the 
molar extinction coefficient of TNB at 412nm and pH 8.1 (13.6 mM-1cm-1). 
Protein concentration were determined using the Bradford assay.  
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Ɩ  corresponds to the optical path length (=1cm) 
VB is the stoichiometric number of TNB in the reaction (= 1)  
V cuvette represents the volume of solution in the cuvette (=1000μl) 
V sample  represents the volume of sample added to the cuvette.  
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V-3 Results 
V-3.1In situ validation of proteins using IHC 
IHC studies exhibited good agreement with proteomics analysis. Positive 
staining for integrin α-1, a cell surface receptor, was observed, increasing in 
intensity from the MCTS surface to the PN and surrounding the surface of those 
cells located in the necrotic core (Figure 24A a, b). Enzymes enoyl coenzyme A 
hydratase (ECHS1) and pyruvate dehydrogenase E2 (PDH E2) are 
mitochondrial proteins important in β-oxidation and glycolysis/TCA cycle 
metabolic pathways respectively. ECHS1 demonstrated positive staining 
primarily in the NC and in pockets of cells in the PN (Figure 24A d, e), whereas 
PDH E2 was observed almost exclusively in the NC region only (Figure 24A g, 
h). HCLS1-associated protein X-1 (HAX-1) was selected as an example of a 
protein that was down-regulated in proteomics analysis and IHC indicated that 
only the MCTS peripheral layer (SL) exhibited significant staining (Figure 24A j, 
k) 
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Figure 24: A. Immunohistochemistry images of spheroid sections, using antibodies against 
integrin α-1 (a-c), enoyl coenzyme A hydratase 1 (anti-ECHS1) (d-f), pyruvate dehydrogenase 
E2 (anti-PDH E2) (g-i) and HCLS1-associated protein X-1 (anti-HAX-1) (j-l). Images c, f, i and l 
are negative controls for each antibody. B. Schematic representation of the equivalent iTRAQ 
response (— no change, ↑ up-regulated, ↓ down-regulated) in perinecrotic region (PN) and 
necrotic core (NC) relative to the surface layer (SL). 
V-3.2 Western blot analysis of protein levels across the MCTS regions 
Four proteins in which changes in levels were indicated within different MCTS 
regions using iTRAQ quantification were analysed by western blotting. Three 
up-regulated enzymes involved in metabolic pathways (NAD+-dependent 
malate dehydrogenase, MDH2, TCA cycle ; carnitine o-acetyltransferase, 
CRAT, lipid metabolism; enolase 1, ENO-1, glycolysis), integrin alpha-1 and 
one down-regulated protein (HAX-1) were used (Figure 25). MDH2 (36kDa,  
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theoretical mol. wt. 35.5kDa) and ENO-1 (47kDa, theoretical 47.1kDa) were 
both increase in the perinecrotic core (PN) and necrotic core (NC) compared to 
the surface layer, with the former most abundant in the NC and the latter most 
abundant in the PN region. CRAT (71kDa, theoretical 70.9kDa) was only 
increased in the NC region and HAX-1 (32kDa, theoretical 31.6kDa) was 
present only in the surface layer indicating that it was down-regulated in the 
inner regions of MCTS. Truncated forms of the cell surface protein, integrin 
alpha-1 (99kDa and 72-95kDa, theoretical 130.8kDa), increased in the PN and 
NC. The lower than expected molecular weight in conjunction with multiple 
bands suggest that partial trypsin digestion of the extracellular regions of the 
protein may have occurred during spheroid segregation. 
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Figure 25: A. Western blot analysis of NAD+-dependent malate dehydrogenase (anti-MDH2), 
carnitine o-acetyltransferase (anti-CRAT), enolase 1 (ENO1), integrin alpha-1, HCLS1-
associated protein X-1 (anti-HAX-1) and β-actin. B, 50μg of total protein was used for each 
sample. Schematic representation of the equivalent iTRAQ response (— no change, ↑ up-
regulated, ↓ down-regulated) in PN and NC relative to the SL. 
 
V-3.3 Analysis of Malate dehydrogenase, citrate synthase and pyruvate kinase 
activity within different regions of the MCTS 
The activity of three enzymes that play a major role in glycolysis and TCA cycle 
pathways were assayed. All three were observed to increase from the surface 
layer to the necrotic core. NAD+-dependent malate dehydrogenase displaying a 
5.7-fold increase in PN relative to SL and 17.7-fold in NC relative to SL. Citrate 
synthase showed a 1.7-fold increase in PN relative to SL and 2.7-fold in NC 
  
A  B  
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relative to SL. Pyruvate kinase exhibited a 1.3-fold increase in PN relative to SL and 10.0-fold in NC relative to SL 
 
 
Figure 26: Specific activities of NAD
+
-malate dehydrogenase (A), citrate synthase (B) and pyruvate kinase (C) in the oxic surface layer (SL), perinecrotic region 
(PN), necrotic core (NC) of HT-29 MCTS. Each value represents the mean ± standard deviation for three independent experiments. 
 
Overall the complementary techniques resulted in the verification of the majority of proteins analysed. Integrin alpha-1, Pyruvate 
Dehydrogenase E2, Enoyl-CoA Hydratase, Carnitine O-Acetyltransferase and HCSL-associating protein -1 demonstrated complete 
agreement between the different techniques used for their analysis. Agreement was seen between up to three (Integrin alpha-1) and with 
at the least two different techniques.  
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Western blot anaysis of both α- enolase and malate dehydrogenase 
demonstrated a good level of agreement with the MS/MS data, with only small 
differences in the level of up-regulation seen for the PN and NC. Importantly, 
malate dehydrogenase protein levels were shown to correlate with its activity. 
Pyruvate kinase M2 activity levels were seen to be increased in the PN and to 
an even greater extent in the NC.  MS/MS analysis of this enzyme indicated 
increases in its levels in the NC alone. Citrate synthase demonstrated a similar 
result with increased enzyme activity (indicated using the enzyme assay) in the 
absence of increased enzyme amounts (indicated by the MS/MS data). 
Analysis of both pyruvate dehydrogenase E1-alpha subunit (PDHE2) and 7-
dehydrocholesterol reductase (DHCR7) failed to provide satisfactory results. 
The antibody used to determine PDHE2 protein levels consistently generated 
an incorrect molecular weight band when run on SDS-PAGE gel, as part of WB 
analysis (data not shown). IHC and WB analysis results both indicated 
contradictory results compared to those indicated by MS/MS analysis. As the 
assurance that the antibody was not specifically recognising the correct protein, 
the results were omitted from this thesis.  The antibody used to investigate 
DHCR7 levels both by IHC and WB demonstrated very low specificity. This 
unspecific binding resulted in the results for this protein also being omitted. 
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Integrin alpha-1    Malate Dehydrogenase    
 SL PN NC  SL PN NC 
MS/MS data - ++ +++ MS/MS data - +++ +++ 
IHC - ++ +++ WB - +++ +++ 
WB - ++ +++ Enzyme assay - ++ +++ 
Pyruvate Kinase M2    Enoyl-CoA Hydratase    
 SL PN NC  SL PN NC 
MS/MS data - - +++ MS/MS data - + +++ 
Enzyme assay - + ++ IHC - + +++ 
Alpha Enolase    
Carnitine O-
Acetyltransferase 
   
 SL PN NC  SL PN NC 
MS/MS data - +++ ++ MS/MS data - - +++ 
WB - +++ +++ WB - - +++ 
Pyruvate 
Dehydrogenase E2 
   
HCSL-associating 
protein -1 
   
 SL PN NC  SL PN NC 
MS/MS data - - +++ MS/MS data +++ - - 
IHC - - +++ IHC +++ - - 
Citrate Synthase    
 SL PN NC 
MS/MS data - - +++ 
Enzyme assay - ++ +++ 
 
Table 16: Comparison of protein levels determined using MS, IHC, WB and enzyme assays for the proteins targeted for validation. Red and green shaded cells 
indicate inconsistent and consistent results, respectively.  
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V-4 Discussion  
The aim of this chapter was to provide validation of a number of protein 
quantitation levels indicated by proteomics investigations. This was achieved 
using immunohistochemistry (IHC), western blotting and enzyme assays. 
Technical issues relating to antibody specificity were encountered for some 
proteins during their analysis using IHC and western blotting. However the 
majority of proteins chosen for validations studies were successfully analysed 
and importantly their expression levels on the whole supported those indicated 
by the proteomics investigations.  
 
The high level of agreement in determined protein levels using the different 
experimental analysis, provided confidence in the iTRAQ quantitation results 
presented in chapter 2. By choosing key proteins in glycolysis, the TCA cycle 
and lipid metabolism these validation studies provide further evidence to 
support the occurrence of important metabolic changes which appear to be 
taking place within the inner regions of the MCTS. 
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V-5 Biological relevance of the validation studies 
 
As outlined in the introduction, each protein was choose to be included in the 
validation studies based on their ability to provide additional information, for 
example regarding changes in metabolic pathways which we indicated by the 
MS data. The findings for the validation studies and their impact on glycolysis, 
the TCA cycle and lipid metabolism are outlined below; 
 
V-5.1 Glycolysis 
The present results further highlight the up-regulation of glycolysis within the PN 
and NC regions of MCTS. Increases in PKM2 activity seen in the PN and to a 
greater extent NC of MCTS would indicate that the increase in glycolysis related 
enzymes indicated by the MS/MS data, in these regions would be a 
consequence of the increased rate of glycolysis. PKM2, being an established 
marker of the metabolic status of tumours, is required for the specific metabolic 
phenotype which provides a selective growth advantage for tumour cells. 
Enolase 1 (alpha-enolase) levels were also seen to increase in both the PN and 
NC, being the enzyme involved in the step before pyruvate kinase exerts in 
effect, higher enolase 1 levels would be required to provide the increased 
amount of phosphoenolpyruvate being utilized by increased PKM2 activity. The 
agreement of PKM2 and enolase activity and levels, with MS/MS derived data, 
respectively and the increases seen with both enzymes provides strong 
evidence that glycolysis is indeed increased within the PN and NC of MCTS.  
Increases in PDHE2 levels would suggest that aerobic glycolysis is utilized by 
the cells of the MCTS NC. To confirm these findings additional work is required 
particularly to determine PDHE1 protein and activity levels as this is the 
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regulatory subunit of the PDH complex in particular its phosphorylation status. 
This information would be useful before conclusions can be drawn on the 
relationship between glycolysis and the TCA cycle within the PN and NC of 
MCTS.  
 
V-5.2 TCA cycle 
Malate dehydrogenase enzyme activity levels were confirmed to be increased in 
the PN and further increased in NC of MCTS. Together with increases in citrate 
synthase, the pacemaker for the TCA cycle, these results would suggest an 
increase in TCA cycle activity within the PN and NC of MCTS. As the TCA cycle 
is a mitochondrial process, its up-regulation would support the presence of 
intact functionally active mitochondrion within the necrotic core of MCTS, the 
presence of which is significant in its self. Citrate synthase being a marker of 
mitochondrial function would further support this finding. 
 
V-5.3 Lipid metabolism 
The confirmation of increased levels of enoyl-CoA hydratase in the PN and NC, 
through IHC would support the hypothesis that the process of β-oxidation is 
increased in the PN and NC of MCTS. Activity levels would provide a more 
accurate indication, and as such would need to be pursued in future work. The 
increase in carnitine O-acetyltransferase also confirmed in the NC would further 
support the presence of increased β-oxidation occurring in this region. As 
carnitine O-acetyltransferase is required to buffer high acetyl-CoA levels, its up-
regulation in the NC would be expected in response to both increases in 
glycolysis and β-oxidation, processes which each contribute to high acetyl-CoA 
levels.   
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V-5.4 Metabolic adaptations occurring in the PN and NC of MCTS 
The most prominent characteristic of glycolysis in oncology is the Warburg 
effect. Glycolysis-associated enzymes are likely to be already increased in the 
surface layer cells of HT29 MCTS to produce energy at a high rate (up to 200 
times greater than normal cells), which will ultimately leading to lactic acid 
formation (Ferreira, 2010). Proteomic analysis indicated that glycolytic enzymes 
are increased further in hypoxic (PN) and NC cells. Enzymes characteristic of 
the Warburg effect, pyruvate dehydrogenase E1 and E2 subunits (PDH is 
increased by pyruvate dehydrogenase kinase 1 activation rather than up-
regulation of gene expression) and lactate dehydrogenase (required to convert 
pyruvate to lactate for anaerobic glycolysis) appeared unchanged in the PN 
region by proteomic analysis. Conversely, the levels of both PDH subunits were 
increased (but LDH levels remained constant) in the NC (PHDE2 increase 
indicated by both MS/MS and IHC data), which together with an elevation in 
other glycolytic and TCA cycle enzymes would suggest auxiliary modulation of 
central glucose-associated metabolic pathways. Under the harsh conditions in 
which cells in the PN and NC need to adapt, a number of mechanisms for ATP 
production may be required to meet energy demands including increased 
anaerobic glycolysis, re-instatement of the TCA cycle and metabolism of lipids. 
 
V-5.5 Integrin alpha -1 over-expression in the NC of MCTS 
Proteomics analysis indicated an increased in expression of integrin alpha 1 in 
the MCTS NC, confirmation of this was provided by Western blot and IHC 
analysis. The activities of integrin alpha 1 provide it with the means to promote 
tumourgenesis through, for instance, promotion of tumour vascularisation (Pozzi 
et al, 2000) and increased cell invasion and migration (Damsky et al, 1994). 
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Identification of its increased expression in the cells of the MCTS NC, together 
with the variously altered metabolic processes would suggest that this 
population of cells could present a very significant contribution to solid tumour 
progression.  
 
V-5.6 Autophagy as a survival mechanism for the cells of the MCTS NC 
Strong evidence is provided for increased protein expression, including enzyme 
activity in biological processes such as carbohydrate and lipid metabolism, 
within the necrotic core of MCTS. Evidence of full length functionally active 
enzymes (Western blots and enzyme assays) indicates the presence of viable 
cells, within this region. Autophagy is a cellular catabolic response to nutrient 
starvation (Klionsky and Emr, 2000) and as part of a survival mechanism of 
hypoxic cells under metabolic stress (Mazure and Puyssergur, 2010). could 
provide a rationale for the observed changes.  
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VI- Autophagy analysis of MCTS and monolayer cells 
 
VI-1 Introduction 
Autophagy is a catabolic process which involves the degradation of a cells own 
organelles and protein aggregates, through the lysosomal machinery. It is a 
conserved process which was first identified in yeast. In mammals, it was first 
described as an unusual presence of cytoplasmic organelles in the lumen of 
degradative vacuoles in developing kidney cells (Clark, 1957). Autophagy plays 
a pivotal role in the maintenance of cellular homeostasis, where it is seen as a 
response to cellular stress, such as nutrient deprivation, growth factor removal, 
endoplasmic reticulum (ER) stress and mitochondrial damage (He and Klionsky, 
2009). In the absence of stress, a basal level of autophagy is present which 
serves as a housekeeping function, particularly important in quiescent and 
terminally differentiated cells (Klionsky and Emr, 2000).  
 
Autophagy can facilitate cell survival under nutrient deprived conditions 
(Klionsky and Emr, 2000) and has been associated with a number of metabolic 
pathways (Rabinowitz and White, 2010).Having demonstrated that the necrotic 
core of MCTS contain viable cells, expressing distinct protein profiles, with full 
length, functionally active proteins which are suggestive of a shift in metabolic 
response to their environment. This chapter will investigate autophagy within 
the MCTS NC and explore the proteome of monolayer cells in which autophagy 
has been induced.  
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VI-1.1 Autophagic pathways in mammals 
All autophagic pathways ultimately lead to the delivery of cytosolic components 
to lysosomes where they are consequently degraded. Different mechanisms do 
however contribute to the transport of these cytosolic components (reviewed, 
Mizushima et al, 2008 and He and Klionsky, 2009). Three main types of 
autophagy have been highlighted in mammals (Rodriguez-Navarro and Cuervo, 
2010), these include macroautophagy, microautophagy and chaperone-
mediated autophagy (CMA). These pathways are illustrated in the figure below 
(Figure 27); 
  
Figure 27. Outline of the major autophagic pathways in mammalian cells. A. Macroautophagy 
involving bulk degradation, B. Microautophagy involving direct invagination and C. Chaperone 
mediated autophagy (CMA) involving the degradation of individual proteins. (Taken from 
Rodriguez-Navarro and Cuervo, 2010)   
 
VI-1.1.1 Macroautophagy  
The macroautophagic pathway involves the formation of double-membrane-
bound structure, known as an autophagosome, which encloses the cytoplasmic 
constituents targeted for degradation. The autophagosome then goes on to fuse 
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with the lysosome at which point, single-membrane-bound autophagic bodies 
are released into the lysosome for degradation (Mizushima et al, 2002). 
 
VI-1.1.2 Microautophagy 
Microautophagy involves the transfer of cytosolic components into the 
lysosomal compartment by direct invagination of the lysosomal membrane, 
which is in the absence of prior sequestration into an autophagosome. The 
engulfing membranes fuse, resulting in the lysosomal delivery of the cytosolic 
components wrapped in a single membrane derived from the invaginated 
lysosomal membrane (Mortimore et al, 1988). 
 
VI-1.1.3 Chaperone-mediated autophagy 
Chaperone-mediated autophagy (CMA) is a lysosomal pathway of proteolysis 
and involves the delivery of individual soluble proteins from the cytosol into the 
lysosomal lumen (Dice, 2007).  During CMA proteins displaying a consensus 
peptide sequence are recognized by a hsc70-containing chaperone/co-
chaperone complex, with which it binds and is subsequently delivered to the 
lysosome where it is degraded.  
VI-1.2 Monitoring and detecting Autophagy 
At present a direct quantitative method to detect autophagy remains to be 
established. Electron microscopy is the most sensitive method and is currently 
the gold standard for detection of autophagy. Using this method, 
autophagosomes containing intact cytoplasmic materials and organelles, and 
autolysosomes containing partially degraded materials, are identified and used 
to monitor the process of autophagy, within a particular cell type (Yla-Anttila et 
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al, 2009). Unfortunately, this method is labour-intensive, expensive and is not 
applicable to clinical samples.  
An alternative approach to detecting autophagy uses the microtubule 
associated protein light chain 3 (MAP LC3, commonly referred to as LC3) 
(Kuznetsov and Gelfand, 1987). LC3 has several mammalian homologs 
including LC3B, which is routinely used to monitor autophagy. Induction of 
autophagy, results in the cleavage and lipidation of cytoplasmic LC3 (LC3I) to 
form LC3II (conjugated with phosphatidylethanolamine [PE]), which is then 
recruited to the membranes of autophagosomes. As the amount LC3II is 
proportional to the amount of autophagosomes present, LC3II can be used as 
an indication of macroautophagy. (Kabeya et al, 2000). Routine assays for 
monitoring the other autophagic pathways remain to be developed.  
 
VI-1.3 Autophagy and Tumourigenesis 
The role of autophagy in tumourigenesis is complex .Originally a role for 
autophagy as a tumour suppressor was highlighted, with the deletion of the 
gene encoding the autophagy promoting protein beclin-1 giving rise to tumours 
in nude mice (Liang et al, 1999). Additional roles have been indicated through 
the activation of autophagy by a number of established tumour suppressors 
such as p53 (Crighton et al, 2006. Budanov and Karin, 2008), PTEN (Arico et 
al, 2001) and ARF (Reef et al, 2006). In contrast, inhibition of autophagy via 
oncogenes such as Akt (Degtyarev et al, 2008), Ras and ERK (Furuta et al, 
2004) has also been demonstrated.  
 
This apparent paradox is thought to be brought about through the distinct roles 
that autophagy can play in tumour progression, which are ultimately tumour-
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type and stage-specific. Current evidence would collectively suggest roles for 
autophagy as a tumour suppressor during tumour initiation and then as a 
survival strategy in established tumours. This stage-specific influence of 
autophagy in tumour progression has been schematically depicted by Roy and 
Debnath (2010) and is outlined below (Figure 28); 
 
 
 Figure 28: The stage dependant role of autophagy in tumour progression. (Adapted by Roy 
and Debnath 2010). 
 
VI-1.3.1 Tumour suppressive roles of autophagy 
Autophagy provides a tumour suppressive role by eliminating damaged 
organelles and protein aggregates, for example, mitochondria and ER 
chaperones. This, together with its role in preventing the accumulation of 
oxidative stress helps to protect against genome instability and thus provides a 
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barrier against tumour progression. Up-regulation of p62 which is commonly 
seen in human tumours contributes to oxidative stress. Autophagy limits p62 
up-regulation thus providing an additional mechanism by which autophagy 
provides a tumour suppressive function (Mathew et al, 2009). 
 
Autophagy has been shown to be an essential oncogene-induced senescence 
effector (OIS) (Young et al, 2009). By contributing to the induction of 
senescence, autophagy restricts growth and proliferation during oncogenic 
stress, thus providing a further barrier to tumourigenesis. Necrosis can provide 
an alternative route to cell death in apoptosis-defective cells. Necrotic cell death 
is, however, associated with inflammation and accelerated tumour growth 
(Degenhardt et al, 2006). By providing a buffer to metabolic stress, autophagy 
can prevent necrosis in these cells, therefore, possibly providing some 
protection against further tumour progression.   
 
VI-1.3.2 Pro-tumourigenic roles for autophagy 
It is becoming widely accepted that autophagy provides a selective advantage 
to cope with various stresses faced by tumours in vivo. Autophagy has been 
shown to be induced in hypoxic regions of tumours, where it‘s thought to 
promote survival (Degenhardt et al, 2006). What‘s more, HIF1 has been shown 
to positively regulate autophagy. HIF-1α can activate autophagy by increasing 
the levels of one of its downstream targets, Bcl-2/adenovirus E1B 19 kDa-
interaction protein (BNIP3), in turn inducing mitophagy, which acts as a ROS 
control mechanism under hypoxic conditions (Zhang et al, 2008). BNIP3 
contributes to the disruption of the beclin1-Bcl-2 complex, resulting in the 
liberation of beclin1, which can then induce autophagy, under hypoxic 
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conditions (Bellot et al, 2009). HIF-1-independent mechanisms have been 
implicated in inducing autophagy in response to hypoxia including the AMPK 
and UPR pathways, details of which are described elsewhere (Papandreou et 
al, 2008. Rouschop et al, 2010). 
 
Detachment induced cell death or anoikis results when the cell loses contact 
with its basement membrane. The induction of autophagy was seen in non-
transformed cells following matrix detachment (Fung et al, 2008). In this 
instance autophagy provided a survival mechanism for cells facing detachment 
induced cell death.  This apparent autophagic mediated anoikis resistance may 
be important in promoting tumour dissemination and metastasis, where 
attachment independence is required by the cell. However, as the current 
investigations have to date only been done using in vitro models, this 
hypothesis must be tested in vivo.  
 
VI-1.4 Autophagy and metabolism 
Bulk degradation of cytoplasm and organelles via autophagy provides the 
essential material required to support metabolism during nutrient deprived 
conditions. Cells possess internal nutrient stores, which they must utilize in 
order to survive, under these conditions. Autophagy provides the cell with 
access to these nutrient stores. Through degradation of carbohydrates, 
proteins, lipids and nucleic acids autophagy can liberate sugars, amino acids, 
fatty acids and nucleosides stores which can be reutilized by the cell (Figure 
29). 
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Figure 29: (Adapted from Rabinowitz and White, 2010) Autophagy as a mechanism for 
liberating cellular nutrient stores.  
 
Following liberation, sugars such as glucose are catabolised via glycolysis 
and/or the pentose phosphate pathway (PPP) and pyruvate generated by 
glycolysis can be further metabolised via the TCA cycle. Amino acids liberated 
from degraded proteins can be used either for new protein synthesis or to 
generate ATP through central carbon metabolism. Free fatty acids, which are 
released following autophagic degradation of lipid stores can go on to 
participate in the TCA cycle (following their conversion to acetyl CoA), resulting 
in ATP or citrate production. Citrate produced in this manner can then be used 
by the cell for new lipid synthesis. Nucleosides generated through the 
degradation of nucleic acids can be utilized for new nucleic acid synthesis or 
alternatively can be catabolised by the combined action of the PPP and 
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glycolysis, to generate ATP, required by the nutrient deprived cell. Catabolism 
of some amino acids (glutamine) results in the generation of ammonia, which 
can in turn stimulate autophagy further (Eng and Abraham, 2010). In summary, 
the products derived from autophagy can be used by the nutrient deprived cell 
as substrates for both biosynthesis and energy production.  
 
VI-1.5 Autophagy within the necrotic core of multicell spheroids; A mechanism 
for surviving extreme physiological conditions?  
Many of the stimuli which induce autophagy are ones which would be 
commonly seen within the necrotic core of MCTS. These include hypoxia and 
nutrient depravation. Multiple observations in our laboratory have led us to 
question the viability of cells located in the necrotic core of MCTS. Should there 
be a viable proportion of cells within the necrotic core then it would be 
reasonable to propose that these cells could be undergoing autophagy as a 
potential survival mechanism. The results seen for the protein profile of this 
particular population of cells (Section IV) would certainly support this. What‘s 
more, unlike the other cells of the MCTS, cells located in the necrotic core are 
non-adherent, could autophagy be facilitating this contact independence?  
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VI-2 Aims and Objectives 
 
Through the liberation of internal cellular nutrient stores required for 
biosynthesis and energy production, autophagy can facilitate cell survival within 
the NC of MCTS.  
 
To investigate this hypothesis, initially, the presence of autophagic cells within 
the MCTS will be determined. Specifically, using LC3II as an autophagic 
marker, immunofluorecence studies will be performed to compare the level of 
macroautophagy between cells located on the surface of the MCTS (SL) and 
those residing in the necrotic core (NC).  
 
Proteins have been shown to accumulate in autophagy-defective mammalian 
cells (Mathew et al, 2009). This would indicate that autophagy has a significant 
impact on the cellular proteome. For this reason a second strategy will use a 
quantitative proteomics (as outlined in Section IV) approach to compare 
autophagic (serum-starvation induced) versus non-autophagic (normal) tumour 
cells in an in vitro monolayer system. This may provide an insight into the 
molecular changes required for autophagy induction. The resulting protein 
profiles of normal and autophagic cells will be compared to each other and to 
those from equivalent cells in the necrotic core of MCTS. In combination these 
studies may provide important insights into the molecular basis of tumour-
specific autophagy, which at present largely remain to be determined. 
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VI-3 Methods 
 
Autophagy was investigated in DLD1 and HT29 cells cultured as monolayer‘s 
and both monolayer and MCTS, respectively. Cell line and MCTS culture 
conditions were as described previously (Section III).  
VI-3.1 Autophagy induction in DLD1 and HT29 monolayers 
Autophagic response to starvation was first investigated using DLD1 
monolayers. Using six well plates, cells were grown on glass coverslips (3cm x 
3cm) and were subjected to starvation conditions, which involved incubation for 
24hrs with incomplete RPMI (lacking both serum and amino acids), in the 
presence of the protease inhibitors, E64d and pepstatin A, both at a 
concentration of 10μg/ml. Prior to incubation cells were washed twice using 
HBSS in order to remove any residual supplemented foetal bovine serum.  
 
Following starvation, the cells were fixed by treatment with 1ml of ice cold 
methanol for 20mins at -20˚C. Slides were then allowed to air dry for a further 
30mins, followed by 2 washes with 2mls of PBS (0.01M, pH 7.4, at 25 °C)  
None specific binding was avoided through blocking with 200μl of 10% normal 
rabbit serum (made up in 0.01M PBS) for 30 minutes at RT.   
 
VI-3.2 Immunofluorescence detection of Autophagy in DLD1 and HT29 
monolayers 
Following blocking, coverslips were then incubated with 50μl of anti-LC3 
(Abgent, UK), primary antibody, at a concentration of 50μg/ml (1:20) in 1% of 
blocking buffer for 60mins at room temperature. The coverslips were washed 
twice with PBS and incubated with 50μl of a fluorescein or DsRed conjugated 
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anti-rabbit secondary antibody, for DLD1 and HT29, respectively, both at a final 
concentration of 20μg/mL (1:50), for 60mins in the dark at room temperature. 
The coverslips were then washed twice in PBS and stained with Hoescht 33342 
in PBS (1:100) for 2-3mins. Finally the coverslips were washed twice in PBS, 
mounted on APES coated slides using a drop of vectashield and analysed using 
a Zeiss Axiovert 200M confocal microscope (Welwyn Garden City, UK). 
 
In this experiment a negative control using non starved cells was performed. 
 
VI-3.3 Immunofluorescent analysis of Autophagy in HT29 MCTS 
The aliquots containing cells in suspension derived from the necrotic core and 
the surface layer of MCTS (~700μm in diameter) were pelleted onto a slide by 
cytospin centrifugation at 800g for 5mins. The slides were fixed in methanol at -
20˚C for 30mins and then air dried at room temperature for a further 30min 
before being processed for immunofluorescence. Slides were blocked for 30 
minutes using rabbit serum (10%) made up in PBS. The cover slips were then 
incubated for 60mins at room temperature with 50μl of the primary antibody, 
rabbit anti-human LC3 (Abgent, Cambridge, UK), at a final concentration of 
50μg/ml (1:20 dilution) in 1% of blocking buffer (normal rabbit serum). The cover 
slips were washed twice with PBS and incubated with 50μl of a fluorescein-
conjugated anti-rabbit antibody, at a final concentration of 20μg/ml (1:50 
dilution), for 60mins in the dark at room temperature. The cover slips were then 
washed twice in PBS and stained with Hoescht 33342 in PBS (1:100 dilution) 
for 2-3mins. Finally the cover slips were washed twice in PBS, mounted on 
APES coated slides using a drop of vectashield and analysed using a Zeiss 
Axiovert 200M confocal microscope (Welwyn Garden City, UK).  
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VI-3.4 Autophagy induction in HT29 monolayers 
HT29 monolayers growing in T75 flasks were subjected to starvation inducing 
conditions as described previously. This was done on a much larger scale, 
requiring 10x confluent T75 flasks for treatment and a further 10 for controls, in 
order to provide sufficient amounts of protein for proteomics analysis. HT29 
monolayers were grown in parallel under standard conditions and these cells 
served as a control for comparison.  
 
Protein from cells grown under both starvation inducing and normal conditions, 
were isolated and prepared for proteomics investigations as described 
previously (Section VI). Total protein was iTRAQ labeled at the peptide level 
with duplicate comparisons generated and was as follows; 
Starved 
(iTRAQ 
reported) 
Normal 
(iTRAQ 
reporter) 
115 114 
117 116 
 
Following labeling peptide samples were combined, OffGel separated and 
analysed using RP-nano HPLC followed by MALDI-TOF TOF MS as outlined 
previously (IV-1.5). Data analysis and interpretation was again as described 
previously (IV-1.6.3.IV-1.7).  
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VI-4 Results  
 
VI-4.1 Autophagic response to nutrient deprivation in DLD1 monolayers 
LC3-positive staining was observed as green florescence in the cytoplasm of 
DLD1 cells cultured in serum deprived conditions. Incubation in complete 
medium in the absence of lysosomal inhibitors, resulted in significantly less 
fluorescence in the cytoplasm of control cells when compared to the starved 
cells. Hoechst staining showed equal cell numbers for both starved and control 
cells in the 24hrs of culture. These results would suggest that autophagy was 
induced in DLD1 cells subjected to starvation conditions. 
 
Figure 30: Starvation induces accumulation of LC3- positive puncta in DLD1 cells. Cells were 
stained with FITC (green), conjugated an anti rabbit antibody, to detect LC3 and Hoechst (blue) 
to stain the nuclei. 
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VI-4.2 Autophagic response to nutrient deprivation in HT29 monolayers 
 
 
Figure 31: Starvation induces accumulation of LC3- positive puncta in HT29 cells. Cells were 
stained with DsRed (red), conjugated to an anti rabbit antibody, to detect LC3 and Hoechst 
(blue) to stain the nuclei. 
 
As with DLD1 cells, there was an increase in LC-3 positive red fluorescent 
staining in HT-29 cells following serum removal. Incubation with complete 
media (control) resulted in no such affect. Hoechst staining (blue) was used to 
highlight the cell nuclei. Together these results would suggest that autophagy 
can be induced in both DLD1 and HT29 cells following 24 hours of serum 
removal.  
 
VI-4.3 Proteomic response to nutrient deprivation in HT29 monolayers 
 
A total of 24 LC/MALDI runs were carried out. ProteinScape was used to 
manually process the data as described previously (IV-1.5.4). A resulting 
dataset was generated which contained 1415 unique proteins (see 
supplementary table S4).  
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VI-4.3.1 iTRAQ quantitation results 
 
 
 
 
Figure 32:.Reporter ions used for each HT29 monolayer sample  
 
To take advantage of iTRAQ's 4-plex ability all four of the reporter ions were 
incorporated to produced duplicate ratio information and thus represent a 
technical replicate. Labeling was as outlined in figure 32 and the following 
ratio‘s were used; control/starved = 114/117 and starved/control = 115/116.  
The mean +/- standard deviation was used to indicate up- and down-regulated 
proteins within the dataset, with >1.36 and <0.73, in 115/116 and 114/117 
indicating up-regulation in starved/autophagic cells, and <0.77 and >1.3 in 
115/116 and 114/117indicating down-regulation in the control. 
 
A total of 1333 proteins were identified with quantitation information for 115/116 
ratio, with ratios ranging from 0.14-4.12. The number of proteins was reduced to 
1194 following the removal of proteins identified by only 1 peptide. A total of 
1367 proteins were identified with quantitation information for 114/117 ratio 
ranging from 0.22-2.73. This number being reduced to 1254 following the 
removal of those proteins identified by 1 peptide alone. This meant that report 
ions 114 and 117 demonstrated a higher labeling efficiency then did 115 and 
116, and thus more proteins could be quantitatively analysed using this ratio 
(114/117).   
 
 
 
116 
117  
Control 
Starved  
114 
115 
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Control/starved 
114/117 
Starved/control 
115/116 
Up-regulated  180 192 
Down-regulated 101 259 
Table 17: Significantly up or down regulated protein levels, giving a ratio of <0.77 and > 1.3 for 
114/117 and 115/116 and <0.73 and > 1.36 for 115/116 and 114/117, respectively. 
 
Out of a total of 1194 proteins, 451 gave rise to 115/116 ratio values which 
would indicate change in protein expression and 281 proteins gave rise to 
114/117 ratio‘s which would indicated change in expression. The latter 
represents 22% of the dataset, significantly lower than the 37% change seen 
with the 115/116 ratios. Between the two ratios 55 and 40 proteins were in 
agreement for up- and down-regulated respectively. For those proteins 
demonstrating no change 709 were in agreement between the two ratios, giving 
a total number of proteins in agreement of 804 or 67.3%.  
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VI-4.5 Detection of autophagic cells in the MCTS necrotic core region  
 
 
 
 
Figure 33: LC3 immunofluorescence (FITC, green) and Hoechst imaging (blue) of HT29 
spheroids. Surface layer (SL) and necrotic core (NC) cells prepared in (A, D) the absence of 1˚ 
and the 2˚ antibodies; (B, E) the absence of the 1˚ antibody only; (C, F) the presence of both 
antibodies.  
 
The presence of autophagic cells was explored using anti-LC3 
immunofluorescence analysis of cells isolated from the necrotic core region and 
the surface layer of HT29 MCTS. LC3-positve staining observed in the 
cytoplasm in necrotic core cells (Figure 33F) was significantly greater than that 
observed in the viable rim (Figure 33C). Moreover, the fluorescence observed in 
the viable rim (Figure 33C) was not significantly different from that observed in 
the negative control in which the primary antibody was omitted (Figure ?B), 
Visualization of the nuclei of the two cell populations was achieved using 
Hoechst 33342 stain and confirmed that similar concentrations of cells were 
present for both MCTS regions. These results would suggest that the process of 
autophagy is up-regulated in the NC cells of MCTS.  
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VI-4.6 Comparison of protein expression between nutrient deprived HT29 
monolayers and NC cells in HT29 spheroids 
As immunofluorescent studies suggested the up- regulation of autophagy in 
both nutrient deprived HT29 monolayer and HT29 MCTS NC cells, protein 
changes common to both cell populations were compared. Table 18 
summarizes these results. 
   
  
 
MCTS 
NC 
Nutrient 
starved 
115/16 
Nutrient 
starved 
114/117 
Common 
to all  
NC and 
Nutrient 
starved 
115/116 
NC and 
Nutrient 
starved 
114/117 
Total 
Up-
regulated 
187 180 192 16 28 36 49 
Down-
regulated 
101 259 101 2 18 6 21 
Table 18: Outline of the number of proteins common to HT29 MCTS NC and nutrient deprived 
monolayer cells (for both 115/116 and 114/117 ratio‘s, unique to each ratio and in total)  
 
Of those proteins identified as up-regulated in MCTS NC 26% were also 
highlighted as being up-regulated in nutrient deprived monolayer cells, using the 
same cell line. Of those proteins identified as down-regulated in MCTS NC 21% 
also appeared to be down-regulated in their nutrient deprived monolayer 
counterparts. To assess the margin for false-positive matches between the two 
datasets, those proteins which were identified as down-regulated in MCTS NC 
cells were compared to those identified as up-regulated in nutrient deprived 
monolayer‘s for both ratios. This comparison resulted in 13 proteins (~13%) 
shown to be in agreement. 
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VI-4.7 Gene ontology annotation 
 
Investigations using GOrilla resulted in no enriched gene ontology terms for 
biological processes, molecular functions or cellular compartments, when 
searching the proteins which were indicated by the 115/116 ratio as being 
increased or decreased (>1.36 OR <0.73. respectively) in nutrient deprived 
verses control.  
 
Those proteins indicated by the 114/117 ratio as being decreased (>1.3) also 
failed to provide any gene ontology annotation. The only sub-dataset to result in 
any identified GO enrichment term was the proteins identified by 114/117 ratio 
(<0.77) as being increased in nutrient deprived versus control (full details are 
outlined in the supplementary data and summarized in table below);
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Biological processes Molecular functions Cellular components 
oxidation-reduction process 
electron transport chain 
respiratory electron transport chain 
generation of precursor metabolites  
and energy 
organic acid catabolic process 
carboxylic acid catabolic process 
cellular catabolic process 
organic acid metabolic process 
oxoacid metabolic process 
carboxylic acid metabolic process 
cellular ketone metabolic process 
small molecule catabolic process 
catabolic process 
cellular lipid catabolic process 
small molecule metabolic process 
lipid oxidation 
fatty acid beta-oxidation 
fatty acid oxidation 
monocarboxylic acid catabolic  
process 
fatty acid catabolic process 
ion transport 
acetyl-CoA metabolic process 
dicarboxylic acid metabolic process 
lipid modification 
hydrogen ion transmembrane  
transporter activity 
oxidoreductase activity 
monovalent inorganic cation  
transmembrane transporter activity 
inorganic cation transmembrane  
transporter activity 
cation transmembrane transporter  
activity 
catalytic activity 
substrate-specific transmembrane  
transporter activity 
transmembrane transporter activity 
oxidoreductase activity, acting on the  
CH-CH group of donors 
ion transmembrane transporter  
activity 
substrate-specific transporter activity 
cofactor binding 
cell surface binding 
mitochondrial part 
mitochondrion 
membrane-enclosed lumen 
organelle lumen 
intracellular organelle lumen 
mitochondrial matrix 
mitochondrial membrane 
organelle membrane 
mitochondrial inner membrane 
organelle inner membrane 
cytoplasmic part 
intracellular membrane-bounded  
organelle 
membrane 
membrane-bounded organelle 
mitochondrial membrane part 
membrane part 
proton-transporting two-sector  
ATPase complex 
organelle part 
intracellular organelle part 
endoplasmic reticulum part 
proton-transporting ATP synthase  
complex 
mitochondrial part 
mitochondrion 
membrane-enclosed lumen 
Table 19: Gene ontology terms enriched for biological processes, molecular functions and cellular component highlighted as being enriched for those proteins 
indicated as up-regulated in the NC by the 114/117 ratio
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Gene ontology annotations highlighted proteins in multiple metabolic and 
catabolic biological processes as being enriched in response to nutrient 
deprived conditions. Reflecting this increase in metabolic related processes the 
mitochondrion and multiplex mitochondrial sub-compartments were particularly 
prevalent. Molecular functions enriched by this group of proteins mainly 
involved transport activities.  
  
VI-4.8 Key biological observations 
VI-4.8.1 Glycolysis, TCA and the electron transport chain 
Unlike within the necrotic core of MCTS the nutrient deprived cells appear not to 
require the need for further increases in glycolysis. This is suggested by all but 
one of the identified glycolytic enzymes being indicated as remaining 
unchanged, when compared to control conditions. With a high 115/116 ratio 
ADP-dependant glucokinase was indicated as being increased under nutrient 
deprived conditions, within the MCTS regions this protein remained unchanged. 
A total of 17 TCA cycle related enzymes were identified within the dataset. 7 Of 
these (114/117 ratios) were at increased levels and 6 (115/116 ratios) were at 
decreased levels (see Table 20). The 115/116 ratio did indicate 2 TCA cycle 
enzymes with increased levels the same as from 114/117 ratios. Importantly, no 
contradictory results were observed between the two ratios, with proteins either 
in agreement of demonstrating change with only one ratio. 
Citrate synthase and isocitrate dehydrogenase [NAD] subunit alpha were both 
shown to be increased under the nutrient deprived conditions of the current 
investigation, as they were in the necrotic core of MCTS.  
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Of the 46 proteins associated with the electron transport chain which were 
identified only 10 proteins appeared to remain unchanged between nutrient 
deprived and control conditions.  A total of 8 proteins were indicated as being 
present at decreased levels under nutrient deprived conditions, these we mainly 
indicated by the 115/116 ratio (7) with 114/117 exhibiting high ratios suggestive 
of decreased levels in just 2 proteins, one of which was in agreement with that 
indicated by 115/116 (Cytochrome c) and one additional protein (NADH 
dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9). In total 31 proteins 
associated with the electron transport chain were shown to be increased under 
nutrient deprived conditions. Of the 31 proteins 23 were highlighted by 114/117 
ratios, 5 of which were further supported by 115/116 ratios (>1.3). Just 3 
proteins demonstrated contradictory iTRAQ quantitation information (Succinate 
dehydrogenase [ubiquinone] flavoprotein subunit, cytochrome c oxidase subunit 
5A and NADPH:adrenodoxin oxidoreductase) with 115/116 ratios suggesting 
decreased levels whilst 114/117 ratios demonstrating the opposite.  
 
A total of 23 lipid metabolism related proteins were identified within the dataset. 
Of these 23 proteins 10 exhibited no change in either iTRAQ ratio, this include 3 
proteins were also highlighted as showing no change in the necrotic core 
regions of MCTS. In total 9 Proteins appeared to be increased in response to 
nutrient deprived conditions (6 and 4 indicated by 115/116 and 114/117 ratios, 
respectively). Carnitine O-palmitoyltransferase 2 was shown to be increased by 
both ratios, interestingly this protein was indicated as being down-regulated in 
the necrotic core of MCTS. A total of 4 proteins were highlighted as being 
decreased in 115/116 ratio. 
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Accession Protein 
MW 
kDa pI Scores Peptides SC 
115/116 
ratio 
# 
115/11
6 
CV% 
115/116 
114/117 
ratio 
# 
114/117 
CV%11
4/117 
GLYCOLYSIS            
ADPGK ADP-dependent glucokinase  54.1 5.8 111.0 2 5.8 1.33 2 22.74 1.02 3 24.14 
G6PI Glucose-6-phosphate isomerase  63.1 9.1 508.7 11 16.7 0.8 10 26.24 1.07 15 29.75 
K6PL 6-phosphofructokinase 85.0 7.9 106.0 2 3.1 0.93 2 11.7 1.15 2 16.75 
K6PP 6-phosphofructokinase type C 85.5 8.5 196.6 5 6.6 0.86 3 23.21 1.18 5 10.2 
ALDOA Fructose-bisphosphate aldolase A  39.4 9.2 1526.5 20 45.9 0.76 45 46.16 1.2 45 29.79 
G3P 
Glyceraldehyde-3-phosphate 
dehydrogenase  36.0 9.3 942.4 14 33.1 0.77 34 69.97 1.09 36 37.79 
PGK1 Phosphoglycerate kinase 1  44.6 9.2 1342.2 19 42.4 0.97 34 42.26 1.02 37 37.55 
PGAM1 Phosphoglycerate mutase 1  28.8 6.8 493.7 7 37.8 0.82 8 22.43 1.37 11 20.04 
ENOA Alpha-enolase  47.1 7.7 1737.4 23 51.2 0.75 44 44.73 1.2 44 36.24 
KPYM Pyruvate kinase isozymes M1/M2  57.9 9.0 1480.3 22 40.5 0.86 36 67.02 1.04 37 26.62 
ODPA 
Pyruvate dehydrogenase E1 
component subunit alpha 43.3 9.3 120.3 4 8.5 1.24 4 20.34 0.99 4 15.24 
ODP2 
Dihydrolipoyllysine-residue 
acetyltransferase  69.0 8.9 298.0 4 6.2 1.17 6 21.32 0.69 5 12.01 
PYC 
Pyruvate carboxylase, 
mitochondrial  
129.
6 6.4 219.7 4 4.1 1.04 6 18.8 0.66 5 15.89 
TCA            
ACLY ATP-citrate synthase  
120.
8 7.1 233.5 5 6.0 0.73 6 52.82 1.19 9 31.86 
CISY Citrate synthase, mitochondrial  51.7 9.1 390.1 7 15.0 1.53 8 35.32 0.75 9 11.27 
ACON Aconitate hydratase, mitochondrial 85.4 7.9 265.7 3 4.9 0.73 3 5.26 1.02 3 2.03 
IDH3A 
Isocitrate dehydrogenase [NAD] 
subunit alpha, mitochondrial  39.6 6.5 142.7 4 14.8 1.21 3 6.73 0.71 3 3.07 
IDH3B 
Isocitrate dehydrogenase [NAD] 
subunit beta 42.2 9.3 106.0 2 5.5 0.7 3 27.71 1.01 4 8.99 
IDHC 
Isocitrate dehydrogenase [NADP] 
cytoplasmic  46.6 6.6 358.4 6 12.8 0.75 14 34.95 0.96 15 25.28 
IDHP 
Isocitrate dehydrogenase [NADP], 
mitochondrial  50.9 9.6 492.5 9 18.8 1.22 19 36.73 0.79 25 28.91 
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ODO1 
2-oxoglutarate dehydrogenase, 
mitochondrial  
115.
9 6.4 442.3 14 14.8 1.34 15 24.09 0.67 18 40.64 
ODO2 
Dihydrolipoyllysine-residue 
succinyltransferase  48.7 9.9 251.0 6 14.6 1.23 5 18.92 0.73 8 19.32 
DLDH Dihydrolipoyl dehydrogenase 54.1 8.9 276.1 5 10.2 0.98 10 29.15 0.79 12 21.45 
SUCB1 
Succinyl-CoA ligase [ADP-forming] 
subunit beta 50.3 7.7 55.1 2 3.5 1.28 2 1.64 0.76 2 19.27 
SUCA 
Succinyl-CoA ligase [GDP-forming] 
subunit alpha 36.2 9.9 358.1 6 21.4 1.13 8 24.27 0.94 9 13.44 
SUCB2 
Succinyl-CoA ligase [GDP-forming] 
subunit beta 46.5 6.1 236.3 3 6.5 1.3 2 22.16 0.69 4 15.64 
DHSA 
Succinate dehydrogenase 
[ubiquinone] flavoprotein subunit 72.6 7.3 451.3 8 16.1 0.68 12 60.42 0.77 12 29.57 
DHSB 
Succinate dehydrogenase 
[ubiquinone] iron-sulfur subunit 31.6 9.9 199.1 3 11.4 0.84 4 78.06 0.67 5 28.82 
MDHC 
Malate dehydrogenase, 
cytoplasmic  36.4 7.7 129.1 2 6.6 0.75 4 29.01 1.01 4 20.3 
MDHM 
Malate dehydrogenase, 
mitochondrial  35.5 9.8 1072.5 11 36.4 1.06 33 54.8 0.77 34 33.07 
ELECTRON TRANPORT CHAIN            
NDUAC 
NADH dehydrogenase [ubiquinone] 
1 alpha subcomplex subunit 12  17.1 10.0 67.1 2 13.8 0.92 3 36.86 0.79 3 11.87 
NDUA2 
NADH dehydrogenase [ubiquinone] 
1 alpha subcomplex subunit 2  10.9 10.4 102.7 2 32.3 1.91 2 25.98 0.85 3 11.57 
NDUA4 
NADH dehydrogenase [ubiquinone] 
1 alpha subcomplex subunit 4  9.4 9.9 51.2 1 27.2 2.32 1  1.10 1  
NDUA6 
NADH dehydrogenase [ubiquinone] 
1 alpha subcomplex subunit 6  17.9 10.8 124.4 2 10.4 0.62 2 7.37 1.04 2 25.08 
NDUA7 
NADH dehydrogenase [ubiquinone] 
1 alpha subcomplex subunit 7  12.5 10.7 106.9 2 21.2 1.39 2 8.82 0.93 3 18.35 
NDUA9 
NADH dehydrogenase [ubiquinone] 
1 alpha subcomplex subunit 9 42.5 10.3 108.6 3 7.7 0.87 5 20.34 0.71 4 13.06 
NDUBA 
NADH dehydrogenase [ubiquinone] 
1 beta subcomplex subunit 10  20.8 9.4 64.2 2 14.5 1.17 1  0.99 2 15.49 
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NDUB4 
NADH dehydrogenase [ubiquinone] 
1 beta subcomplex subunit 4  15.2 10.2 61.0 2 17.8 0.97 1  0.72 3 56.66 
NDUB7 
NADH dehydrogenase [ubiquinone] 
1 beta subcomplex subunit 7  16.4 9.9 80.5 2 13.1 0.90 3 77.62 0.73 3 18.36 
NDUB8 
NADH dehydrogenase [ubiquinone] 
1 beta subcomplex subunit 8 21.8 6.3 70.5 2 11.3 1.26 3 24.83 0.85 4 21.78 
NDUB9 
NADH dehydrogenase [ubiquinone] 
1 beta subcomplex subunit 9  21.8 9.3 127.3 2 15.6 0.93 3 87.98 1.54 4 88.67 
NDUC2 
NADH dehydrogenase [ubiquinone] 
1 subunit C2  14.2 9.5 114.6 4 16.0 1.48 4 62.77 1.14 4 23.73 
NDUV1 
NADH dehydrogenase [ubiquinone] 
flavoprotein 1 50.8 9.5 142.5 5 10.3 0.83 4 9.33 0.70 5 10.39 
NDUV2 
NADH dehydrogenase [ubiquinone] 
flavoprotein 2 27.4 9.2 92.4 3 14.1 0.53 3 24.57 1.14 4 22.09 
NDUS3 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 3 30.2 7.8 198.0 4 19.7 0.86 4 17.39 0.71 4 17.57 
NDUS5 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 5  12.5 10.1 110.8 3 33.0 1.33 2 34.83 0.81 2 9.66 
NDUS6 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 6 13.7 9.8 68.5 1 11.3 0.78 2 3.77 0.98 2 33.49 
NDUS8 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 8 23.7 6.0 75.9 1 8.6 1.93 1  0.52 1  
DHSA 
Succinate dehydrogenase 
[ubiquinone] flavoprotein subunit 72.6 7.3 451.3 8 16.1 0.69 12 60.42 0.77 12 29.57 
DHSB 
Succinate dehydrogenase 
[ubiquinone] iron-sulfur subunit 31.6 9.9 199.1 3 11.4 0.84 4 78.06 0.67 5 23.82 
CYB5 Cytochrome b5  15.3 4.7 237.4 2 20.1 0.97 2 69.19 0.47 2 47.88 
CYB5B Cytochrome b5 type B  16.3 4.7 70.9 2 14.4 0.69 3 46.03 1.15 3 64.15 
QCR1 
Cytochrome b-c1 complex subunit 
1 52.6 5.9 401.0 9 25.4 0.85 9 72.33 0.65 8 21.94 
QCR2 
Cytochrome b-c1 complex subunit 
2 48.4 9.3 163.1 4 11.9 1.04 4 17.73 0.96 3 10.19 
QCR6 
Cytochrome b-c1 complex subunit 
6 10.7 4.2 160.5 2 28.6 1.23 2 36.38 0.64 2 6.91 
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QCR7 
Cytochrome b-c1 complex subunit 
7 13.5 9.2 151.1 2 18.9 0.97 5 32.04 0.74 3 8.15 
QCR8 
Cytochrome b-c1 complex subunit 
8  9.9 10.4 112.1 3 34.1 1.12 3 4.97 0.86 3 13.08 
CYC Cytochrome c  11.7 10.1 93.9 2 24.8 0.69 3 28.10 1.44 3 44.91 
COX2 Cytochrome c oxidase subunit 2  25.5 4.5 82.6 2 7.5 1.43 6 27.79 0.76 7 20.83 
COX41 
Cytochrome c oxidase subunit 4 
isoform 1 19.6 10.0 179.2 4 24.9 1.35 4 22.42 0.81 4 23.31 
COX5A Cytochrome c oxidase subunit 5A 16.8 6.4 185.3 4 26.7 0.76 6 44.66 0.64 5 22.33 
COX5B Cytochrome c oxidase subunit 5B 13.7 10.2 256.9 3 24.8 1.34 1  0.75 3 20.63 
CX6A1 Cytochrome c oxidase subunit 6A1 12.1 9.7 86.1 2 43.1 0.80 1  1.10 2 10.34 
CX6B1 Cytochrome c oxidase subunit 6B1  10.2 7.5 311.1 6 75.6 1.62 11 23.22 0.85 12 16.72 
COX6C Cytochrome c oxidase subunit 6C  8.8 10.8 280.1 5 34.7 1.17 7 12.11 0.71 8 10.81 
CY1 Cytochrome c1, heme protein 35.4 9.8 191.5 4 14.2 1.40 6 22.72 0.90 7 45.46 
ATPA ATP synthase subunit alpha 59.7 9.6 988.7 12 23.7 1.03 32 36.78 0.77 33 22.54 
ATPB ATP synthase subunit beta 56.5 5.1 1551.7 17 34.2 1.17 42 58.82 0.74 42 29.19 
ATP5H ATP synthase subunit d 18.5 5.1 208.6 5 23.6 1.24 6 22.38 0.65 7 21.80 
ATPD ATP synthase subunit delta 17.5 5.2 102.4 1 8.3 0.87 2 18.20 0.80 3 13.96 
ATP5L ATP synthase subunit g 11.4 10.0 192.5 2 27.2 0.90 2 44.54 0.79 2 18.43 
ATPG ATP synthase subunit gamma 33.0 9.7 53.4 1 7.4 1.79 1  0.95 1  
ATPO ATP synthase subunit O 23.3 10.5 291.5 4 21.6 1.06 6 36.12 0.74 5 13.48 
ATP5J ATP synthase-coupling factor 6 12.6 10.0 125.0 1 17.6 3.29 1  0.22 2 53.95 
ACPM Acyl carrier protein 17.4 4.6 135.8 2 11.5 1.66 3 12.26 0.45 2 4.87 
ETFA 
Electron transfer flavoprotein 
subunit alpha 35.1 9.5 565.1 8 26.1 0.90 13 30.02 0.69 13 26.33 
ETFB 
Electron transfer flavoprotein 
subunit beta  27.8 9.2 651.5 14 47.5 1.07 20 36.94 0.78 25 17.46 
ADRO 
NADPH:adrenodoxin 
oxidoreductase 53.8 9.6 162.9 3 9.6 0.67 2 48.19 0.71 3 20.66 
             
LIPID METABOLISM            
FAS Fatty acid synthase  
273.
3 6.0 1227.3 19 8.6 0.92 44 48.64 1.07 45 30.15 
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FACR1 Fatty acyl-CoA reductase 1  59.3 9.8 79.1 2 9.3 2.05 1  0.88 2 9.39 
AL3A2 Fatty aldehyde dehydrogenase  54.8 8.9 183.9 2 9.5 0.51 2 23.33 0.81 3 9.66 
ACSL3 Long-chain-fatty-acid--CoA ligase 3  80.4 9.4 144.8 4 6.7 1.44 1.64 5 1.10 4 13.49 
ACSL4 Long-chain-fatty-acid--CoA ligase 4  79.1 9.4 119.4 1 1.8 1.69 1.92 1 0.97 1  
ACSL5 Long-chain-fatty-acid--CoA ligase 5  75.9 6.5 247.9 4 7.0 0.97 1.1 4 1.19 4 10.30 
ACADV 
Very long-chain specific acyl-CoA 
dehydrogenase 70.3 9.6 259.4 6 10.4  4 22.93 1.07 6 21.91 
HCD2 
3-hydroxyacyl-CoA dehydrogenase 
type-2 26.9 9.1 369.9 7 31.8 0.88 11 52.97 1.00 16 44.44 
THIM 
3-ketoacyl-CoA thiolase, 
mitochondrial  41.9 9.3 210.1 6 14.9 1.15 4 10.03 0.78 5 8.61 
THIK 
3-ketoacyl-CoA thiolase, 
peroxisomal  44.3 9.8 141 3 12.5 1.17 2 9.19 0.53 3 15.88 
ACAD9 
Acyl-CoA dehydrogenase family 
member 9 68.7 9.0 115.6 2 2.9 0.84 3 97.36 0.71 3 14.74 
ACOD Acyl-CoA desaturase  41.5 9.5 75.4 1 7.0 0.32 2 47.08 0.94 2 33.65 
ACSF2 
Acyl-CoA synthetase family 
member 2 68.1 8.5 136.6 2 8.3 1.87 1  0.77 2 5.44 
ACBP Acyl-CoA-binding protein  10.0 6.2 354.1 5 40.2 1.16 7 23.24 1.18 8 23.13 
ECHA Trifunctional enzyme subunit alpha 82.9 9.8 390 6 9.3 1.06 8 26.63 0.88 10 35.56 
ECHB Trifunctional enzyme subunit beta 51.3 10.0 412.1 9 16.0 1.36 14 41.34 0.77 11 22.30 
PUR2 
Trifunctional purine biosynthetic 
protein adenosine-3  
107.
7 6.3 224 7 7.2 1.08 7 40.01 0.94 7 16.21 
ECHM 
Enoyl-CoA hydratase, 
mitochondrial  31.4 9.4 857.5 11 34.5 1.04 18 46.91 0.65 20 37.83 
THIC 
Acetyl-CoA acetyltransferase, 
cytosolic  41.3 6.5 113.8 2 6.0 0.90 2 4.92 0.77 2 13.35 
THIL 
Acetyl-CoA acetyltransferase, 
mitochondrial  45.2 9.6 267.2 5 11.0 0.96 8 44.81 0.96 8 37.66 
ACACA Acetyl-CoA carboxylase 1  
265.
4 5.9 189.2 3 1.9 0.74 5 52.16 0.93 5 18.70 
CPT1A 
Carnitine O-palmitoyltransferase 1, 
liver isoform  88.3 9.5 163.6 4 5.7 0.73 3 22.41 0.84 4 10.88 
CPT2 
Carnitine O-palmitoyltransferase 2, 
mitochondrial  73.7 9.1 93.1 3 6.2 1.36 2 1.11 0.62 4 45.48 
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Table 20: Proteomics analysis of enzymes associated with lipid metabolism, showing iTRAQ ratios comparing levels in nutrient deprived and control conditions. 
Increased or decreased proteins were indicated by >1.3 and <0.77 in 115/116 and 114/116 and <0.77 and >1.3 in 115/116 and 114/117, respectively.  
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VI-5 Discussion  
Autophagy was seen in response to nutrient deprivation in DLD1 and HT29 
monolayer‘s following 24 hours serum removal. The successful induction of 
autophagy allowed comparisons between autophagic versus normal HT29 cells, 
to be carried out. An iTRAQ based proteomics approached allowed the levels of 
1415 individual proteins to be investigated, this represents almost 7% of the 
human proteome. Similar levels of proteome coverage were seen using the 
same approach to characterise the proteome of HT29 MCTS (section IV).  
 
The 4plex functionality of iTRAQ allowed inverse duplication of iTRAQ ratios 
done in the hope of providing more robust quantitation results. The change in 
protein levels for the two ratios 115/116 and 114/117 was 37 and 22%, 
respectively. As seen with the MCTS investigations the majority of protein levels 
remained unchanged, as would be expected. Between the two ratios 30 and 
40% agreement was seen proteins indicated as up- or down-regulated, 
respectively. In total 67.3% agreement was demonstrated between the two 
ratios. For the remaining 32.7 % those proteins not showing agreement 
represented proteins demonstrating borderline values in the alternative ratio, 
proteins not identified with both ratio values and proteins demonstrating very 
different indicated protein levels.  
 
As mentioned previously there are a number of issues which can influence the 
accuracy of iTRAQ. These issues can include inaccurate assignment of 
peptides to proteins and contamination from multiple parent ions contributing to 
reporter ion peaks intensities in the MS/MS mode (Karp et al, 2010). The 
precision of iTRAQ data can be affected by variance heterogeneity, with low 
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signal data demonstrating increase variability (Karp et al, 2010), this is 
particular important considering that low abundance peptides will dominate a 
typical dataset. Despite iTRAQ limitations, it did provide an appropriate tool for 
the current investigations. The current study was concerned with gaining insight 
into the biochemical changes associated with autophagy. As such, initial focus 
was placed on establishing the response of specific groups of proteins defined 
by the MCTS results. Such results were indicated when comparing autophagy 
versus normal cells, with many changes in important metabolic pathways 
observed in response to nutrient deprivation, as was the case with the inner 
MCTS regions. 
 
IV-5.1 Comparison of nutrient deprived HT29 monolayers and NC cells in HT29 
spheroids  
Comparison of the monolayer data with that for the NC of MCTS, revealed 357 
proteins in agreement for each of the ratios used in the monolayer investigation 
and those seen for the NC. Taking both monolayer ratios, 26% and 21% 
agreement was seen between those proteins indicated as up and down 
regulated in nutrient deprived HT29 monolayer and HT29 MCTS necrotic core 
cells, respectively (Supplementary Table S5 details all proteins showing 
agreement between the two independent experiments). Considering that 30-
40% agreement was seen between the two ratios in the monolayer 
investigation, 30% would represent a high level of agreement between the two 
very different cellular systems. 
 
An important consideration of the two autophagic processes was the difference 
in induction mechanism and dynamics. In the MCTS, autophagy is likely to be 
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induced progressively as multiple cellular nutrients become increasingly scarcer 
over a period of days. These nutrients will not only include organic nutrients 
such as carbohydrates, lipids and proteins but also others such as oxygen. In 
contrast induction of autophagy in monolayers will be more discrete, with the 
sudden removal of organic nutrients (but retaining a normoxic environment) 
prompting the cells to respond in a matter of hours. These differences may elicit 
different autophagic responses, possibly incorporating unique mechanisms. 
Autophagy can be induced by hypoxia and in such cases is HIF-dependant 
(Mazure and Puyssergur, 2010). Through increased levels of BNIP3 and 
BNIP3, autophagy induction provides hypoxic cells with a means of survival 
(Bellot et al, 2009). Hypoxia alone can induce autophagy, which was shown in 
the presence of media containing high levels of both glucose and amino acids 
(Mazure and Puyssergur, 2010).  
HIF-1 activates the expression of multiple glycolytic enzymes promoting an 
increase in glycolysis (Semenza, 2009). HIF-1 mediated expression of pyruvate 
dehydrogenase kinase drives an increase in the conversion of glucose to 
pyruvate and subsequently to lactate, suppressing metabolism through the TCA 
cycle (Kim et al, 2006). HIF-1 has previously been shown to promote anabolic 
processes such as lipid (Krishnan et al, 2009) and glycogen synthesis 
(Pescador et al, 2010). Recently autophagy has been shown to facilitate 
glycolysis (Lock et al, 2011) and has been implicated in the regulation of lipid 
metabolism (Singh et al, 2009). The relationship between hypoxia and 
autophagy together with the similar alterations in metabolism which they both 
bring about make it difficult to assign hypoxia independent roles to autophagy.  
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Interestingly, alterations in carbohydrate and lipid catabolism and metabolism 
were indicated in autophagic cells in both the presence and absence of hypoxia 
(MCTS necrotic core and autophagic monolayer cells). As with the MCTS data, 
alterations in carbohydrate and lipid catabolism and metabolism represented 
the key biological observations which were noteworthy when comparing 
autophagic versus normal monolayer cells.  
IV-5.2 Alterations in carbohydrate and lipid metabolism  
IV-5.2.1 Glycolysis 
Compared to the 7 glycolytic enzymes which were indicated as being increased 
in the NC of MCTS, only a single glycolytic enzyme was indicated as being up-
regulated in autophagic versus normal monolayer cells. ADP-dependant 
glucokinase was increased in response to the induction of autophagy. Due to 
HIF-1 being responsible for the increased expression of multiple glycolytic 
related enzyme, it is possible that autophagy in the absence of hypoxia resulted 
in less glycolytic enzymes being up-regulated.  
IV-5.2.2 TCA cycle 
TCA related enzyme levels for both autophagic monolayer and MCTS necrotic 
core cells indicated alterations under nutrient deprived conditions. The outcome 
appeared complex and did not seem to involve a simple up-regulation of the 
entire cycle activity.  
Briere and collegues have suggested that the TCA cycle may comprise of two 
independent segments, which would allow for independent fluxes, extending 
from α-ketoglutarate to oxaloacete and from oxaloacete to α-ketoglutarate 
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(Briere et al, 2006). Metabolic studies carried out on quiescent fibroblast have 
supported the existence of these distinct fluxes within the TCA cycle, in which 
an increase in both canonical TCA cycle activity and an increase in anaplerotic 
TCA cycle flux (from pyruvate to oxaloacetate) were observed (Lemons et al, 
2010). 
 
Figure 34: The TCA cycle with the independent fluxes highlighted. Red indicated the flux 
between α-ketoglutarate to oxaloacete and blue is used to indicate the second flux from 
oxaloacete to α-ketoglutarate). 
 
 
Three of the four enzymes that control the flux between malate and α-
ketoglutarate are increased in the perinecrotic region and necrotic core of 
MCTS, whereas four of the five enzymes that control the flux from α-
ketoglutarate to malate show no change across the MCTS relative to the 
surface layer. This suggests an increase in anaplerotic TCA cycle flux from 
malate or oxaloacete to α-ketoglutarate, not only in the quiescent hypoxic cells 
of the perinecrotic region, but also autophagic cells within the necrotic core. 
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With the autophagic monolayer cells, difference responses were observed in 
the TCA cycle enzymes. Only citrate synthase was increased out of the four 
enzymes that control the flux between malate and α-ketoglutarate, whereas five 
enzymes which control the canonical flux from α-ketoglutarate to malate were 
indicated as increased. This would suggest that opposite fluxes are increased 
between autophagic monolayer and necrotic core cells. These opposing effects 
could well reflect the difference in oxygen status of the two autophagic cell 
types. In the absence of sufficient oxygen the autophagic cells of the MCTS 
necrotic core were unable to generate ATP through the electron transport chain 
(ETC), as TCA cycle generated NADH and intermediates (succinate) may be 
redirected away from the ETC through increasing the flux between malate and 
α-ketoglutarate. Autophagic monolayer cells, on the other hand, in the presence 
of sufficient levels of oxygen, are able to utilize the ETC for ATP production. 
Therefore, increases in the flux from α-ketoglutarate to malate would produce 
increased succinate and NADP levels available for oxidation via the ETC. 
Indeed increases in ETC associated proteins levels were indicated in the 
autophagic monolayer cells (see below).  
The TCA cycle provides autophagic cells with the means to utilize its internal 
nutrient stores, liberated through autophagy during carbohydrate, protein and 
lipid degradation. Free sugars liberated from the degradation of carbohydrates 
can drive and increase in glycolysis. Pyruvate generated through increases in 
glycolysis (as indicated in the MCTS NC cells) can be fed into the TCA cycle 
where it can be directed into various processes which involve the metabolism of 
different amino acids. Liberated free amino acids (from the degradation of 
proteins) can provide intermediates for the TCA cycle; these include α-
ketoglutarate from glutamine and oxaloacete from aspartate. Lipophagy 
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(autophagy of lipids) can provide free fatty acids for energy production through 
β-oxidation, which will result in the generation of acetyl-CoA in the mitochondria. 
Acetyl-CoA can be use to support the TCA cycle.  
IV-5.2.3 Electron transport chain 
In total 67% of ETC associated proteins that were identified were up-regulated 
in autophagic monolayer cells compared to the control. No such increase in 
ETC activity was indicated for the NC cells of the MCTS. As indicated 
previously ETC is oxygen dependant and HIF-1 activates the expression of a 
number of glycolytic genes, driving glycolysis and suppressing pyruvate 
oxidation via both the TCA cycle and oxidative phosphorylation through the ETC 
(Semenza, 2009). HIF-1 can modulate mitochondrial respiration by activating 
the transcription of the LON gene, which encodes a mitochondrial protease 
responsible for the degradation of COX4-1 subunit (Zhong et al, 2010), a key 
subunit in the terminal oxidase in mitochondrial ETC (elevated levels of COX4-1 
were indicated in the autophagic monolayer cells). HIF-1 modulates 
mitochondrial oxidative metabolism in response to hypoxia as an adaptive 
mechanism to reduced reactive oxygen species (ROS) levels (Chen, Thomas 
and Kapahi, 2009).  
IV-5.2.4 Lipid metabolism 
Like with the autophagic necrotic core cells, autophagic monolayer cells would 
appear to exhibit altered lipid catabolic and anabolic processes. Proteins 
associated with β-oxidation and mitochondrial fatty acid chain 
elongation(FAEM) were indicated as being increased in the autophagic 
monolayer and necrotic core cells. With the necrotic core cells, indicated 
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increases in lipid related metabolic pathways were slightly more convincing with 
7 proteins highlighted as being up-regulated and only a single protein shown to 
be down-regulated, which compared to the 10 and 4 proteins indicated as being 
up- and down-regulated for the equivalent autophagic monolayer cells results, 
respectively.   
The autophagic degradation of lipids can provide free fatty acids for 
participation in β-oxidation oxidation. HIF-induced anabolic pathways have 
previously been described with HIF promoting glycogen synthesis in the 
presence of glucose (Pescador et al, 2010). As β-oxidation and FAEM involve 
the activities of the same enzymes it is difficult determine if either or both of the 
process are being increased under autophagic conditions. However, long-chain-
3-hydroxyacyl-CoA dehydrogenase, which is involved exclusively in FAEM, was 
highlighted as being increased in the both the autophagic monolayer and 
necrotic core cells. Both β-oxidation oxidation and FAEM would provide the 
autophagic cells with adaptive mechanism to support their survival under the 
conditions which they face. β-oxidation would help contribute cellular energy in 
the form of NAD+ - NADH. FAEM would allow the autophagic cells to store 
energy (in the form on long chain fatty acids) for use should the environmental 
conditions deteriorate further.  
IV-5.2.5 Chaperone proteins 
Proteomics analysis of autophagic necrotic core cells suggested a notable 
increase in various chaperone proteins. Similar results were not seen with 
autophagic monolayer cells. Hypoxic related oxidative stress placed on the 
necrotic core cells may bring about increases in chaperone protein levels in 
order to modulate the harmful effects to the cell, however, increases in 
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chaperone proteins were not evident in the hypoxic cells of the MCTS peri-
necrotic core. Chaperone-mediated autophagy represents possibly the least 
studied autophagic mechanism. The organised nature of this mechanism, 
involving the selective degradation of specific proteins, suggests it could be 
induced in a progressive manner. Chaperone-mediated autophagy in the 
necrotic core cells, may be result of a progressive mechanism over a period of 
days rather than hours. Autophagic monolayer cells may lack the ability to 
orchestrate this process in the limited time in which they needed to respond to 
the sudden removal of serum. 
By combining data generating during the analysis of the two different 
autophagic cell types multiple important metabolic responses to autophagy 
began to emerge.  Many of these metabolic responses were common to each 
and differences could be due to differences in hypoxic status of the two cell 
types and in the methods of autophagy induction. The majority of metabolic 
alteration indicated as being utilized by the autophagic cells in this investigation 
have previously been shown or at least proposed to be involved in autophagy. 
This would help to validate the results. As the current investigation represents a 
global investigation of autophagy and a relatively large proportion of the 
proteome was quantitatively analysed, previously unknown protein responses 
maybe represented in the dataset. As such this represents future work and may 
provide helpful insight into the exact mechanisms involved in autophagy which 
at present are still largely being determined. 
Positive cytoplasmic LC3-II staining of cells isolated from the necrotic core of 
MCTS (HT29) would suggest that this population of cells are not only viable but 
are undergoing elevated levels of autophagy. The emergence of autophagic 
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cells, with a unique repertoire of metabolic activities and cellular processes 
(Section IV), in the necrotic core of MCTS has potential implications in the 
understanding of tumour biology. In particular, it identifies a population of cells 
driven towards cell survival by severe nutrient deficiency and anaerobic 
conditions and possibly representing those cells most resistant to tradition 
therapies. Autophagic cells in the necrotic core of tumours, which is mostly 
overlooked, could have major implications on the treatment of cancer.  
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VII: Influence of the physiological microenvironment on the transcriptome 
of HT-29 cells 
 
VII-1 Introduction 
The transcriptome comprises of all RNA molecules which are produced by a cell 
or population of cells, they include mRNA, rRNA, tRNA and other none coding 
RNA. The transcriptome is defined as the genes that are actively being 
expressed at any given time and its study is termed transcriptomics. 
Gene expression is required to produce functional RNA and protein molecules 
in the cell through two main stages; transcription and translation. Firstly, during 
transcription specific regions of DNA are copied (by RNA polymerase) to 
produce complimentary RNA molecules, known as a primary transcripts. Most 
human genes contain both exons and introns, with only exons carrying 
information required for protein synthesis or translation. For this reason most 
primary transcripts are processed through splicing to remove these non-coding 
intronic sequences, which results in the generation of messenger RNA (mRNA) 
containing exons alone. In some instances the primary transcript itself is the 
functionally important molecule, this is true for tRNA and rRNA. For a 
comprehensive overview of transcription see Hager et al, 2009. 
mRNA generated through transcription is used as a template for protein 
synthesis during translation. Translation occurs once the mRNA molecules 
associate with ribosomes. Each triplicate nucleotide code on the mRNA 
molecule is used to specify a single amino acid. Activation is the process by 
which tRNA molecules combine with amino acids (a process requiring ATP). 
Each type of tRNA molecule binds specifically to a single amino acid. tRNA 
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molecules are responsible for delivering amino acids to the mRNA-ribosomal 
structure (polysome). Complimentary tRNA-amino acid complexes are attracted 
to specific codons on mRNA molecules. Multiple tRNA- amino acid complexes 
bind to the mRNA, acting as a framework the ribosome holds each in place until 
peptide bonds between the different amino acids are formed.  This process is 
repeated with the ribosome moving along to the next in a series of codons, 
gradually adding a single amino acid at a time. Ultimately this process 
assembles long polypeptide chains. Once formed the polypeptide chains must 
be processed to generate mature proteins. Firstly, this can involve folding of the 
polypeptide to produce secondary and tertiary structures and in combination 
with other polypeptides and/or prosthetic groups to generate a quaternary 
structure. Excellent reviews of translation have been provided elsewhere 
(Marintchev and Wagner , 2004. Kapp and Lorsch , 2004).  
VII-1.1 The relationship between protein and mRNA levels 
The proteome dictates the cellular state and behaviour of a cell and as such 
genome-wide analysis at the protein level provides the most direct reflection of 
gene expression. Despite this, previous efforts in gene expression analysis 
have focused on profiling of mRNA levels and whilst this does provide important 
insights many factors can influence the relationship between mRNA and protein 
levels. 
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Figure 35: taken from Abreu et al, 2009. Outline of factors which can impact upon translation 
and protein degradation.  
 
The ratio between protein and mRNA molecules is influenced by both 
translation and protein degradation.  Cellular mRNA concentrations are affected 
by both transcription and mRNA degradation. The process of eukaryotic 
translation requires the actions of a number of specialized factors and can be 
divided into three main events; initiation, elongation and termination (Reviewed 
by, Marintchev and Wagner, 2004), each of which can be affected by multiple 
factors.  
Translational initiation can be impacted upon by the ribosomal binding location, 
specifically, ribosomes may bind to upstream open reading frames (uORFs) 
thus changing the translation efficiency of the main open reading frame (Calvo, 
Pagliarini and Mootha, 2009). Secondary structures present on the mRNA 
molecule can also modulate translation by hindering ribosomal passage 
(Pelletier and Sonenberg, 1987). Translation initiation requires the recruitment 
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of ribosomes to the start codons located at translational initiation sites, which 
are characterised by the presence of a Kozak sequence (Kozak, 1989, 1999). 
Sub-optimal Kozak sequences can have a negative impact upon translation 
initiation.  
Translational elongation represents the sequential addition of amino acids from 
acyl-tRNA to the polypeptide chain and its rate can be affected by translation 
initiation rates, the activation status of elongation factors, the choice of codons 
and the abundance of different tRNAs (Browne and Proud, 2002).  
Translation efficiency can be mRNA specific, with the poly(A) tail length 
affecting transcript stability and showing correlation with translational efficiency 
(Preiss and Hentze, 1998). Modifications to the core components of the 
translation machinery such as RNA binding proteins (RBP‘s) and microRNA‘s 
may influence translation (Abaza and Gebauer, 2008).  
Protein degradation can be broadly divided into two main systems; ubiquitin 
mediated proteolysis and lysosomal degradation. Ubiquitin mediated proteolysis 
involves the ubiquitination of targeted proteins, which flags that particular 
protein for degradation by the proteasome (Glickman and Ciechanover, 2002). 
In eukaryotes, degradation through ubiquitin mediated proteolysis usually 
requires the poly-ubiquitinylation of the target protein. Also degradation signals 
are encoded within the proteins sequence, such as; N-degrons, which are 
present at the proteins N-termini and relate to the half-life of the protein 
(Bachmair, Finley and Varshavsky, 1986) and sequences enriched in proline, 
glutamic acid, serine and threonine (PEST) (Rogers, Wells and Rechsteiner, 
1986) which have been shown to correlate with rapid protein turnover 
(Rechsteiner and Rogers, 1996). The locations of these sequences are 
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important for the stability of a protein, with signals located in unstructured 
regions of the protein favouring protein degradation (Dyson and Wright, 2005. 
Gsponer et al, 2008).  A number of different processes contribute to lysosomal 
degradation and include; autophagy, phagocytosis, receptor-mediated 
endocytosis and pinocytosis.  
VII-1.2 Studying gene expression  
There are many different techniques for studying gene expression, such as RT 
PCR and Northern blotting, however these mainly allow for the study of 
individual genes or low numbers of gene products at a time. Whole-genome 
wide analysis of gene expression can be achieved through transcriptomics 
and/or proteomics strategies.  
Initial attempts involving transcriptomics incorporated the use of microarrays 
(Schena et al, 1995). Original microarrays required individual clones of each 
gene, in the genome of the sample under investigation, to be spotted on glass 
or silicon slides in a grid arrangement. To study gene expression mRNA 
isolated from cells of interest was reversed transcribed into cDNA incorporating 
fluorescent labeled nucleotides for detection. This labeled cDNA was then 
hybridized to complementary cDNA attached to the slide. Upon excitation by a 
laser, cDNA hybrids omit fluorescence which indicated their expression. The 
level of fluorescence can be used to quantify the level of expression. As this 
method is only possible for organisms with relatively few genes, its use is 
limited. Fortunately, advancements in microarray technology have included 
oligonucleotide chips (Fodor et al, 1993) which employs synthetic 
oligonucleotides synthesized directly on to the surface chips/slides in a set 
pattern to produce specific sequences complementary to specific mRNA or 
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cDNA. As with DNA microarrays. fluorescent dyes are incorporated to identify 
hybridization locations. Oligonucleotide chips can be prepared at a density of 1 
million per cm2 , this together with the automated de novo synthesis approach in 
which the chips are made, allow whole human genome microarrays to be 
prepared easily.   
 
VII-1.3 Transcriptomics as a tool in drug discovery 
 
 
The ability to carry out large-scale profiling of gene expression provides 
attractive opportunities for drug discovery and drug development. Studies using 
microarray profiling to define the patterns of gene expression within the cell 
lines which comprise the National Cancer Institutes (NCI) in vitro drug screen 
(Ross et al, 2000. Scherf et al, 2000) reflect the perceived importance of this 
strategy for drug discovery. These studies have demonstrated that variations in 
the transcript levels of certain genes relate to mechanisms of drug sensitivity 
and resistance (Scherf et al, 2000).  
 
Perhaps the most successful transcriptomics strategies for drug discovery to 
date, have involved those which have looked at differences between subsets of 
a specific disease. This approach was used to reveal two molecularly distinct 
forms of diffuse large B-cell lymphoma (DLBCL), which had gene expression 
patterns indicative of different stages of B-cell differentiation and correlated with 
different patient survival rates (Alizadeh et al, 2000). These findings went on to 
established the NF-kappaB pathway as a new molecular target for drug 
development, for the treatment of DLBCL (Davis et al, 2001).  
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VII-2 Aims and Objectives 
Global mRNA levels will be determined across different regions of HT29 MCTS, 
these levels will be compared to the corresponding protein levels determined by 
proteomics (Section IV). It is hoped that the information provided by these 
studies will contribute to the identification of potential drug targets.  
Global mRNA expression levels will be investigated using Agilents One-Colour 
Microarray- Gene Expression Analysis (Quick Amp Labelling) kit.  
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VII-3 Methods 
Gene expression analysis was carried out using Agilent‘s One-Colour 
Microarray- Gene Expression Analysis (Quick Amp Labelling) kit and all 
experimental methods were in accordance to the manufacturers outlined 
protocol, and is summarised below; 
 
Figure 36: Workflow for Microarray sample preparation and processing. 
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VII-3.1 RNA Isolation 
RNA was isolated from the various MCTS sub-regions (SL, IR, PN and NC) 
stored as frozen cell pellets (III-1.5). This was done using the RNAqueous®-
Micro RNA purification kit (Ambion®,) following the protocol provided by the 
manufacturer. Briefly, to homogenise cell pellets, 100µl of 4 M guanidinium 
thiocyanate lysis solution (which also inactivates endogenous ribonucleases) 
was added to the cell pellets and RNA extracted using the Micro Filter 
Cartridges. The cell lysate solutions were repeatedly passed through the filter, 
in the presence of ethanol (100%). Various wash solutions were used to remove 
all other components of the lysate apart from RNA by centrifugation at 200 g 
through the filters for 30 seconds. Elution of total RNA was done using 
preheated (75 oC) elution solution provided with the kit. 
VII-3.2 DNase Inactivation 
DNase inactivation was carried out using DNase 1, a DNase inactivation agent 
supplied with the RNAqueous®-Micro RNA purification kit. Purified RNA 
samples were treated with 1µl of DNase 1 in the presense of DNase 1 buffer 
(Also supplied with the kit). The RNA samples were incubated with both the 
DNase 1 and DNase buffer, for 30 mins at 37 oC. This was followed by an  
additional 10 mins at 95 oC, needed to inactivate the DNase 1. 
 
VII-3.3 Determining the RNA concentration 
The RNA content of the samples was determined spectrophotometrically using 
a Cary 50 Bio UV- Visible spectrophotometer (Varian Ltd, UK) using quartz 
cuvettes. The absorbance was read at 260nm and 280nm, with the 260nm 
readings used to calculate the RNA content of the sample and the 260:280 ratio 
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used to indicate the presence of any protein contamination (ratios of 1.8 or 
greater was used to indicate good quality RNA extraction).  
 
VII-3.4 Determining the RNA integrity using the Agilent 2100 Bioanalyzer 
As a quality control step RNA integrity of each sample was determined. This 
was achieved using the 2100 Bioanalyzer (Agilent Technologies), which is a 
chip-based nucleic acid separation system which utilizes micro-fluidics, capillary 
electrophoresis, and fluorimetry to determine RNA length, distribution and 
concentration. The RNA Nano 6000 LabChip kit (Agilent Technologies) was 
used together with a standardized RNA ladder (Ambion, Austin, TX, USA) for 
RNA analysis of the four MCTS sub-regions.  
The Bioanalyzer using a software algorithm called RIN (RNA Integrity Number) 
assigns a number from 1 to 10, with 1 being the most degraded and 10 being 
the most intact profile. This represents the quality of the isolated RNA and takes 
into account the entire electrophoretic trace of the RNA sample (Agilent 
application note 5988-7650EN, 2002). As such RNA degradation can be 
identified prior to microarray analysis, should this have occurred within the 
MCTS sub-region samples. 
VII-3.5 Internal calibration 
Internal calibration was achieved through the use of the Agilent One-Colour 
RNA Spike-In Kit. For every 100 ng of total RNA in the labelling reaction, 1 μL of 
One-Colour Spike-Mix was added.  
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VII-3.6 Reverse transcription 
Using the isolated mRNA as a template the moloney murine leukemia virus 
reverse transcriptase (MMLV-RT) was used to create double stranded cDNA. 
This process was initiated using an oligo dT-promoter primer. 
 
VII-3.7 cRNA synthesis and labeling 
Following the separation of the double stranded cDNA, cRNA was synthesised 
using the T7 RNA polymerase. This was done in the presence of Cyanine 3 (Cy 
3, a green dye, 550 nm excitation, 570 nm emission) fluorescently labeled 
nucleotides.  
 
VII-3.8 cRNA purification 
RNeasy mini kits (Qiagen) were used to purify the cRNA. Samples were added 
to the RNeasy spin column and centrifuged for 15 seconds at 8000 g. 
Sequential washes in triplicate were carried out before the RNA was eluted in 
30μl of RNase-free water.  
 
VII-3.9 Hybridization 
Whole human Microarrays (Agilent) with 4x44K oligonucleotide probes were 
used for transcriptomic analysis. Samples were introduced to the arrays and 
hybridization was carried out at 65°C at 10 rpm, in a hybridization oven 
equipped with a rotator rack, for 17 hours. Agilent‘s SureScan high-resolution 
DNA microarray scanner was used to visualize the microarray results. 
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VII-3.10 Controls 
75 features on the 4x44K microarrays, were replicated x10 to allow for intra-
array reproducibility measures.  
 
VII-3.11 Data analysis 
Agilent‘s feature extraction software (version 9.5) was used to analyse the 
microarray data. This software tool finds and places microarray grids, rejects 
outlier pixels, accurately determines feature intensities and ratios, flags outlier 
features and calculates statistical confidences 
 
VII-3.12 Data interpretation  
The expression analysis file created from each sample (array) scanning was 
imported into GeneSpring GX software (version 11.5) for further data 
characterization. GeneSpring extracts the expression data and performs 
standard normalisation and transformations. Default settings were chosen; 
including cut off signal values of threshold = 5, normalised data to the 75 th 
percentile and baseline transformation to the median of all samples performed. 
GeneSpring was used to annotate the quality control information derived from 
the feature extraction software. Differentially expressed genes were defined by 
a 2-fold difference, generating a cut off p-value of 0.05 (derived from an 
ANOVA).  
 
VII-3.13 Gene Ontology 
GeneSpring software associated differentially expressed genes with gene 
ontology terms. This was done if the association reached a p-value cut off of 
0.01 or greater using the gene ontology consortium database.  
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VII-4 Results 
 
VII-4.1 RNA concentration and integrity 
RNA quantities isolated from the various MCTS regions varied significantly, with 
the necrotic core giving rise to the highest RNA concentration, this was followed 
by the perinecrotic region, with the intermediate region providing the lowest 
RNA amounts (Table 21). As a quality control step the integrity of each RNA 
sample was investigated. RNA integrity numbers (RIN) were determined for 
each sample. RIN values are generated based on the entire electrophoretic 
trace of each RNA sample, not the ratio of the 18s and 28s ribosomal bands 
alone. In this way the presence of degradation products can be seen (Figure 
37).  
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Figure 37: Electropherograms indicating RNA integrity for the different HT29 MCTS regions, (A) surface layer, (B) intermediate region, (C) peri-necrotic region and 
(D) necrotic core.
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Sample RNA area RNA concentration 
(ng/µl) 
rRNA ratio 
(28s/18s) 
RNA Integrity 
Number (RIN) 
A (SL) 138.7 95 1.4 8.2 
B (IR) 25.9 18 0.8 7.3 
C (PN) 230.1 157 0.2 - 
D (NC) 526.4 360 0.1 - 
Table 21:. Outline of RNA area, 28S to 18S fragment ration and resulting RNA integrity and 
concentration values for the different HT29 MCTS regions. – indicated those samples which 
could not be assigned an accurate RIN number.  
 
 
 
Both the surface layer and intermediate region RNA samples were assigned 
with good RIN values, 8.2 and 7.3, respectively, suggesting that these samples 
suffered minimal degradation. The electrophoretic trace for both the perinecrotic 
and necrotic core regions demonstrated evidence of high levels of degradation, 
as such neither was assigned a RIN values. None of the samples gave rise to 
particularly encouraging 28s:18s ratios. None of the samples generated a 
28S:18S ratio of 2:1 which would be indicative of intact RNA . RNA degradation 
levels appeared to progressively increase with increasing distance into the 
MCTS central regions.   
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Figure 38: Box-whisker plot displaying the distribution of normalized intensity values for each 
region. Entities with intensity values beyond 1.5 times the inter-quartile range are shown in red. 
The box whisker shows the median intensity values (dark line) and the 25
th
 and 75
th
 quartile. 
The whiskers extend up to 1.5 times the interquartile. 
 
A range of intensity values were seen across the different MCTS region, the SL 
and PN regions gave rise to the greatest range of intensity values with each 
having a high proportion of entities demonstrating intensity values beyond 1.5 
times the inter-quartile range (Figure 38). The NC demonstrated the smallest 
distribution of normalized intensity values with both a small inter-quartile range 
and limited number of entities with intensity values beyond this range (1.5 
times). The IR, whilst not exhibiting the largest range in intensity values did give 
rise to the largest inter-quartile range.  
233 
 
 
Figure 39: Normalized signal intensity values for each gene identified across all HT29 MCTS 
regions (SL, surface layer, IR, intermediate region, PN, peri-necrotic core, NC, necrotic core). 
Color indications based on the SL normalized intensity values with red and blue indicative of a 
=/> 2 fold change above or below the mean, respectively. 
 
A total of 7,875 gene transcripts were detected across each of the MCTS 
regions. Current gene counts predict the presence of 21,823 human genes 
(Ensemble) with 20,930 known protein-encoding genes and 893 novel protein-
encoding genes. The number of human gene transcripts is thought stand at 
168,848 (Ensemble). These figures would suggest that approximately 38% of 
the genome was being expressed by each of the regions of the MCTS.  This 
number may be an overestimate as the total number of detected genes includes 
redundancy from the presence of isoforms. Figure 39 above outlines the 
normalized intensity values for each of the detected genes across the different 
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MCTS, with the colour indicating the expression of the gene across the regions, 
relative to the SL. 
 
VII-4.2 Gene expression across the MCT regions 
Genes were indicated as changed in their expression in the different MCTS 
regions, if they demonstrated a 2-fold difference in intensity values from the SL 
data, with which they were compared. Changes in gene expression were 
greatest between the SL and PN, with 65% of genes exhibiting either an 
increase or decrease in expression, leaving just 35% remaining unchanged. 
The NC gave rise to the smallest change in gene expression, with 61% of 
genes remaining unchanged, when compared to the SL (Table 22 outlines 
these results). The largest number of increased genes across the MCTS 
regions when compared to the SL was seen within the PN, with 3,038 or 38% of 
the detected genes being increased.  The PN also gave rise to the largest 
number of decreased genes at 2,119 or 27% of the total transcripts observed.  
(Summary tables for up- and down-regulated genes for each region compared 
to the SL are outlined in the supplementary data).  
 
 
IR PN NC 
Increased 
expression 
2,621 3,038 1,958 
Decreased 
expression 
1,180 2,119 1,099 
No change 4,047 2,718 4,818 
Table 22: Number genes with expression changes >2.00 across each HT29 MCTS region 
compared with the SL. 
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Many of the detected genes showed differential expression in multiple MCTS 
regions. For example, of the 2,621 genes increased in the IR, 1,189 also had 
increased expression in the PN region. Of the 1,958 genes increases in the NC 
1,152 and 114 also displayed increases in the IR and PN regions, respectively 
and 476 and 524 genes in the NC region decreased in expression in the IR and 
PN, respectively. A total of 283 genes were indicated as being down-regulated 
in the IR and PN.  
 
VII-4.3 Cluster analysis of gene expression response profiles  
Cluster analysis was done to assign each of the 7,875 detected genes to a 
gene expression response profile. A total of 12 cluster profiles were created, 
with a high proportion of genes assigned to those profiles which included genes 
giving intensity values within 2-fold of the mean (A, B, C and D) and therefore 
indicative of no significant change. Together profiles A, B, C, D included 3,021 
genes. Profiles B and D did include a small number of genes with intensity 
values differing greater than 2-fold from the mean, particularly a decrease in NC 
and an increase in SL gene expression levels in profiles B and D, respectively. 
Genes in profile E included those with expression levels increased in IR and 
PN, but not NC, relative to the SL regions. Profile F highlights those genes 
which are increased in the IR, decreased in the PN and unchanged in NC 
compared to SL. Profiles G and J include genes increased and decreased only 
in the IR, respectively. Profiles H and K, include genes which are decreased in 
the SL and remain unchanged in the other MCTS regions, apart from a few with 
increased expression in the IR and PN, respectively. Those protein increased 
and decreased in the PN only, are highlighted in profiles I and L, respectively. 
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There were no genes increased or decreased in the NC only region compared 
to SL. 
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Figure 40: Cluster analysis 
of the 7875 detected genes 
revealing 12 gene 
expression response 
profiles.  
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VII-4.4 Gene ontology analysis of the gene expression response profiles  
 
Gene ontology analysis was done using GeneSpring to reveal the presence of 
any enriched GO terms within each of the 12 cluster profiles (Table 23). 7 
profiles gave rise to enriched GO terms, with the number of genes assigned to a 
particular profile not correlating with the number of enriched terms subsequently 
founds. Profile C which represents the largest group of genes, all of which show 
little variation across the 4 regions, gave rise to no enriched GO terms. Indeed 
all those profiles (A, B, C and D) containing genes which remained unchanged 
across MCTS regions gave low numbers of enriched GO terms. Profile G 
representing those gene increased in the IR alone, included the greatest 
number of enriched GO term, the most significant of which include signaling 
pathways and receptor activity. (GO terms enriched for each profile are outlined 
in Table S6, in the supplementary data). 
 
Profile Number of genes 
assigned to the profile 
GO terms enriched 
A 772 25 
B 218 0 
C 1181 0 
D 850 4 
E 466 0 
F 401 0 
G 752 84 
H 122 0 
I 1064 44 
J 757 1 
K 297 36 
L 1007 24 
 
Table 23: Gene ontology analysis for the genes differentially expressed across the different 
MCTS regions 
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VII-4.5 Gene ontology analysis for the genes differentially expressed across the 
different MCTS regions 
 
Gene ontology analysis of each of the differentially expressed groups of genes 
across the different MCTS regions, revealed enrichment of multiple GO terms 
associated with various biological processes, molecular functions and cellular 
components (Table 23). Most significantly enriched GO terms associated with 
genes under-expressed in the IR, included those relating to biological 
processes such as cellular metabolic pathways, metabolic processes and RNA 
processing. For those genes indicated as being over-expressed in the IR, GO 
terms associated with biological processes such as those relating to cell 
signaling and cellular homeostasis were enriched. Molecular functions such as 
signal receptor and transducer activity were also shown to be enriched, which 
would support the GO analysis results seen for profile G, which contains the 
majority of genes demonstrating an increase in expression in the IR region, and 
within which GO terms relating to signaling pathways and receptor activity were 
seen. For genes which were indicated as being up-regulated in the PN region, 
significantly enriched GO terms included those associated with the regulation of 
metabolic processes and immune response. For genes highlighted as 
decreased in their expression in this region enriched GO terms included the 
electron transport chain, generation of precursor metabolites and energy. 
Molecule function related terms which were also seen to be enriched included 
those relating to NADH dehydrogenase and oxidoreductase activity. Despite 
having the smallest number of both up- and down- regulated genes differentially 
expressed genes, the NC include some enriched GO terms. Increased genes in 
this area included ones associated with lipid, sterol and cholesterol biosynthetic 
and metabolic processes. Genes shown to be down-regulated in the NC 
included enriched terms associated with DNA binding and transcription. (GO 
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terms enriched for each differentially expressed group are detailed in Table S7, 
supplementary data).  
 Biological 
process 
Molecular 
function 
Cellular 
component 
Increased in IR 78 36 22 
Decreased in IR 43 18 17 
Increased in PN 29 18 2 
Decreased in PN 30 16 28 
Increased in NC 51 13 25 
Decreased in NC 6 2 8 
Table 24: GO analysis results for differentially expressed genes across each MCTS region, 
compared to the SL.  
 
 
VII-4.6 Comparison of mRNA and protein levels  
There was very little agreement between mRNA and protein levels. Just two 
proteins demonstrated increased levels in the transcriptomics and proteomics 
data, in the IR compared to the SL. No proteins, previously indicated as being 
decreased (Section IV) in this region gave corresponding mRNA levels. The PN 
demonstrated the greatest agreement between protein and mRNA levels giving 
6% agreement, the NC and IR demonstrated similar levels at 4.5% and 4.2% 
respectively. (mRNA levels reflecting those of the protein level are highlighted in 
yellow in Suppl. Table S8). 
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IR 
 
      
  mRNA  Protein Both 
Up- regulated 2621 24 2 
Down- regulated 1180 23 0 
PN       
  mRNA  Protein Both 
Up- regulated 3058 63 4 
Down- regulated 2119 51 3 
NC       
  mRNA  Protein Both 
Up- regulated 1958 187 8 
Down- regulated 1099 101 5 
Table 25: Comparison of differentially expressed mRNA and protein levels across the HT29 
MCTS regions in comparison to the surface layer. 
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VII-4.7 Key biological observations 
 
VII-4.7.1 Glycolysis 
Transcriptomic analysis revealed limiting expression of glycolysis related genes. 
The majority of genes encoding glycolytic proteins and enzymes were not 
detected which would suggest that these were not being actively transcribed by 
the cells within the MCTS regions. A total of 7 glycolysis related genes were 
expressed across the different MCTS regions, four of which 
(phosphoglucomutase-2, fructose-bisphosphate aldolase A, phosphoglycerate 
kinase 1 and pyruvate kinase M1/M2) were also seen at the protein level and 
three (hexokinase, phosphoglucose isomerase and triosephosphate isomerase 
) were seen at the mRNA level alone. Of those seen at both the mRNA and 
protein level just one (fructose-bisphosphate aldolase A) demonstrated 
expression levels which were in agreement.  
 
VII-4.7.2 TCA cycle 
The number of detected gene transcripts which were associated with the TCA 
cycle was overall very low. Three TCA cycle related genes were detected at the 
mRNA (dihydrolipoamide S-succinyltransferase, succinate dehydrogenase and 
malate dehydrogenase), none of which confirmed results seen with the 
proteomics data. Succinate dehydrogenase was not shown to differ significantly 
at the protein level, however, mRNA levels were increased in the PN and NC. 
The most significantly enriched GO term associated with biological processes 
for genes decreased in the PN relative to the SL, was the electron transport 
chain, which is supported by the TCA cycle.  
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VII-4.7.3 Lipid metabolism 
The most significant enriched GO term (p-value = 2.46E-8) associated with 
biological process for those genes increased in their expression in the MCTS 
NC was shown to be lipid metabolic processes with 120 individual genes being 
associated with this term. This supports results seen for the proteomics data. 
Despite the high number of lipid metabolism associate genes, which were 
shown to be up-regulated in their expression only two (enoyl-CoA hydratase 
and carnitine O-palmitoyltransferase) were also seen at the protein level, with 
carnitine O-palmitoyltransferase demonstrating down-regulation at both the 
mRNA and protein levels within the MCTS NC.  
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VII-5 Discussion 
Transcriptomics studies carried out using MCTS pose unique challenges. 
mRNA samples taken from different regions of the MCTS suffered degradation 
to differing degrees. Degradation levels were seen to increase progressively 
with increasing distance into the central spheroid regions. This is likely to 
inversely correlate with the proportion of viable cells, which gradually decreased 
from the outer to inner regions, possibly due to the inherent dynamic nature of 
MCTS. This should be taken into account when interpreting the results. As 
proteins isolated from different MCTS regions also suffer issues relating to 
turnover, as do their mRNA counterparts, despite un-equivalent RNA integrity 
across the MCTS, limiting comparisons between regions, comparisons between 
proteins and their corresponding mRNA levels between the same MCTS 
regions may still represent some value. mRNA and protein undergo completely 
independent and different processes of turnover, many of which were outlined 
in the introduction to this thesis and these include rates of synthesis and 
degradation, this constitutes the low correlation between their levels.  
 
RNA integrity (defined by its RIN number) did not appear to influence the 
intensity for each sample, as a range of values observed in each region 
independent of the integrity. If RNA integrity negatively influenced hybridization, 
an increase in low intensity signals for the highly degraded mRNA samples (PN 
and NC) would be expected.  
 
Unlike protein levels, mRNA levels did not show a gradual change with 
increasing distance from the SL. The differences in the quality of the samples 
taken from each region make comparisons in gene expression changes across 
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the regions difficult. Sample quality indicated by both the 28s:18s ratio and RIN 
values, would be expected to influence hybridization, and therefore gene 
expression measurement. An increase in under-expressed genes would then be 
present for both the PN and NC (degraded samples), compared to the SL. This 
was not seen within the results and leads to the suggestion that the gene-
expression changes seen across the MCTS regions could reflect the true 
mRNA. However, the absence of gene transcripts which demonstrate increased 
levels in the PN and/or NC may reflect problems in hybridization encountered 
by the degraded mRNA present within these regions.  
 
Gene ontology annotation of the data provided important insights. 
Encouragingly, increases in lipid metabolism indicated previous from the 
proteomics analysis of both the MCTS NC region and autophagic cells, was 
supported by the transcriptomics data, with this biological process being shown 
to be the most significantly enriched GO term for those gene over-expressed in 
the MCTS NC. 
 
Poor correlation was seen between mRNA and protein levels. Poor correlation 
between mRNA and protein levels has been reported previously (Anderson and 
Seilhamer, 1996. Tian et al, 2004). Considering the elaborate regulatory 
mechanisms present at the cellular transcription level it is possible to envisage 
the many different opportunities which could bring about discrepancies between 
transcript and protein abundances. Some of these mechanisms were 
considered in the introduction and possibilities for regulatory interventions 
include; chromatin structure modifications, binding of transcription factors, post-
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transcription related processes such as splicing, nuclear export of mRNA and 
differential ribosomal loading, together with post-translation protein degradation.  
 
The half-lives of mRNA and protein molecules vary dramatically. As both 
transcriptomics and proteomics provide only a snap-shot into the transcriptome 
or proteome at a given time point, comparison between the two are likely to be 
inherently inaccurate. Analysis and subsequent comparisons over time, using 
multiplex batches of MCTS, for both transcriptomics and proteomics analysis, 
could reduce this problem and improve reproducibility. 
 
Technically, aspects relating to the analysis of the two sample types can 
provide sources of error, including factors affecting the variability of sample 
preparation which is very different for transcriptomics and proteomics. 
Proteomics required multi-dimensional separation prior to quantitative analysis 
for instance whereas the current transcriptomics studies involved less sample 
processing steps. However using the one colour microarray system meant that 
mRNA analysis was done independently for each MCTS region, unlike the 
proteomics analysis where samples were combined following iTRAQ labelling, 
and analysed in combination using MS. Genome coverage varies dramatically 
between the two approaches with gene microarrays providing the ability to 
measure all the total human transcriptome whilst proteomics techniques, such 
as mass spectrometry, typically achieving significantly lower genome coverage. 
In summary, differences in all aspects of the two approaches may be  present 
including sampling, sample preparation, abundance measurements, data 
analysis and data interpretation. Influences of such difference on the presented 
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results can not be verified and can only represent options for speculation 
regarding the differences in mRNA and protein levels seen. 
 
Gene expression is not a unidirectional process initiated with the transcriptome 
and followed by the proteome, the two are inseparably connected, with the 
proteome largely regulated by the transcriptome and the transcriptome subject 
to feedback from the proteome. Instances of both discordance and concordance 
between mRNA and protein levels are expected and each would have biological 
importance. Similarities between mRNA and protein levels would help confirm 
biomarkers for instance, whereas, differences between the two could represent 
post-transcriptional regulatory mechanisms which may provide further 
opportunities for therapeutic intervention for instance.  
 
Both transcriptomics and proteomics have important roles to play in the 
understanding of cancer biology. The use of microarrays alone has 
demonstrated important diagnostic potential in the clinic (Ramaswamy et al, 
2001).  The combined use of the two approaches may provide the greatest 
insight to date. For the current dataset, inconsistent RNA quality between the 
samples hindered the interpretation of the results but further investigation of 
specific mRNA-protein pairs may provide a start point for revealing post-
transcriptional regulatory mechanisms, in this sense the transcriptomics dataset 
may prove useful in the future.   
 
In terms of target identification unfortunately the inability to compare transcript 
levels between the different MCTS regions meant that differences and thus 
potential targets could not be identified with any confidence. From the 
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comparisons which were carried out, lipid metabolism was highlighted as being 
increased in the NC, relative to the SL, this had previously been established 
with the proteomics analysis together with validation studies, and therefore 
could be accepted with greater confidence.  
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VIII: Conclusions 
 
The results presented in this thesis demonstrate that the experimental approach 
is technically feasible. MCTS were generated which included 3 distinct regions. 
Using serial trypsin treatments the spheroids could be stripped to isolate cells 
which reside at different depths within them and this in combination with gentle 
homogenization liberated NC cells residing within the centre of the MCTS.  This 
separation method generated 4 experimental samples; the SL, IR, PN and NC. 
The SL, PN and NC samples contained cells which displayed different 
characteristics. These included size and hypoxic status, indicated by FACS and 
immunohistochemistry analysis, respectively. Whilst contamination of any one 
MCTS region with another could not be ruled out, data would indicate that the 
opportunity for this was minimal; this was especially true for the SL and NC 
regions. Contamination of the PN region with cells of the NC, represents the 
largest source of contamination and would appear to be the most difficult to 
control for. Thorough washing of the separated PN fragment was shown to limit 
the problem and ultimately each sample was deemed appropriate for 
proteomics and transcriptomics analysis. A single batch of MCTS was shown to 
provide sufficient amounts of RNA or protein for a single transcriptomic and 
proteomics analysis, respectively, this was true for each of the experimental 
regions.   
 
Proteomics analysis of the MCTS regions combining the use of MALDI-TOF-
TOF and ESI-Q-TOF analysis provided quantitation information for 
approximately 7% of the human proteome. This level of proteome coverage far 
exceeds previous efforts in proteomics investigations of MCTS and represents 
the first proteomics study to compare different MCTS regions. The use of the 
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different MS technologies provided complimentary results with each contributing 
independent protein identification and corresponding quantitation information. 
Issues were however encountered with the use of the ESI-Q-TOF instrument, 
with concerns raised regarding insufficient fragmentation of parent ions, which 
may have contributed to the disappointingly low number of proteins providing 
quantitation information and the large number of unidentified MS/MS, which 
were seen.   
 
By performing quantitation of sub-regions of the MCTS, changes in protein 
expression were indicated. The majority of protein levels remained unchanged 
across the different regions, including many proteins encoded by housekeeping 
genes. As would be expected the largest degree of change was seen between 
the SL and NC, followed by the SL and PN, with the smallest change in protein 
expression levels indicated between the SL and IR. Encouragingly, proteins 
encoded by known HIF-1 target genes were shown at higher levels in the MCTS 
PN and/or NC regions.  
 
Data from the proteomics analysis suggested important molecular differences 
between MCTS regions. These most notably included indicated changes in 
multiple metabolic pathways, such as; glycolysis, the TCA cycle and lipid 
metabolism. Glycolytic and TCA cycle related enzymes were seen at increased 
levels in the PN and to an even greater extent in the NC. The existence of 
distinct fluxes within the TCA cycle has previously been proposed, results 
comparing the SL and the NC of MCTS suggested an increase in anaplerotic 
TCA cycle flux from malate or oxaloacetate to α-ketoglutarate and vice versa, in 
the NC. Altered lipid metabolism was indicated predominantly within the NC, 
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specifically, enzymes involved in fatty acid elongation in the mitochondria and β-
oxidation were seen increased in this region.  
Validation of the iTRAQ derived protein quantitation data was achieved using 
complementary analytical techniques at the cell, biochemical and enzyme 
activity level. In total 11 proteins were chosen for investigation in the validation 
studies, with the majority of these proteins representing important components 
of either glycolysis, the TCA cycle or lipid metabolic processes.  Of these 12 
proteins 7 gave rise to results which supported those seen for the proteomics 
analysis, 2 demonstrated contrary levels and 2 were omitted due to technical 
issues that impacted upon the accuracy of analysis. Validation studies provided 
additional evidence of the up-regulation of glycolysis, the TCA cycle and lipid 
metabolism which was indicated by proteomics studies, to be occurring in the 
PN and NC regions of MCTS. Increased activity of PKM2 in both the PN and 
NC suggests an increase in glycolysis occurring within the cells located in these 
regions. Increased activity of citrate synthase, a pacemaker for the TCA cycle 
and malate dehydrogenase, within both the PN and NC would support the 
results of the proteomics analysis which indicated increased TCA cycle activity 
with the PN and NC regions. Evidence supporting up-regulation of β-oxidation 
within the NC was provided with western blot and immunohistochemistry 
analysis indicating increased levels of carnitine O-acetyltransferase and enoyl-
CoA hydratase, respectively, within the PN and to a great extent NC.   
Having demonstrated that the necrotic core of MCTS contain viable cells, 
expressing distinct protein profiles, with full length, functionally active proteins, it 
was necessary to investigate the means by which these cells were surviving, 
under the harsh conditions which they face. Autophagy, being a response which 
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can help facilitate cell survival under nutrient deprived conditions, was 
investigated within the NC. Positive cytoplasmic LC3-II staining of cells isolated 
from the necrotic core suggested this region was undergoing elevated levels of 
autophagy.  
The ability to induce autophagy in monolayer‘s allowed comparisons in protein 
expression levels between autophagic and none autophagy cells to be carried 
out, using proteomics analysis. The results were subsequently compared to 
those protein responses seen within the NC of MCTS. Proteomics analysis of 
the autophagic versus normal cells revealed difference in protein expression 
levels between the two samples. Using various bioinformatics tools these 
changes were investigate further in the hope that the data would suggest 
biochemical changes associated with autophagy.  
Many proteins that demonstrated increased or decreased levels in autophagic 
versus none autophagic monolayer cells were seen at similar levels within the 
NC of MCTS (with 26% and 21% crossover, respectively). Many of those 
proteins that increased in the autophagic monolayers were associated with 
some of the metabolic pathways highlighted in the proteomics analysis of the 
MCTS regions.  
Unlike NC cells within the MCTS, glycolysis did not appear as up-regulated in 
autophagic monolayer cells; this could be due to the absence of activated HIF-
1, under normoxic conditions, which would reduce the expression of multiple 
glycolytic related enzymes which display a HIF-1 response element. Autophagic 
monolayer cells showed increased levels of TCA cycle related enzymes. NC 
and autophagic monolayer cells appeared to up-regulated different TCA cycle 
fluxes, with autophagic monolayer‘s indicating an increase in canonical flux from 
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α-ketoglutarate to malate. These differences again maybe due to their different 
oxygen status and could reflect the autophagic monolayer cells ability to utilize 
the ETC for ATP production. Indeed the ETC was indicated as up-regulated in 
the autopagic monolayer cells, with 67% of those proteins identified which are 
associated with the ETC indicated at increased levels. Proteins associated with 
β-oxidation and mitochondrial fatty acid chain elongation (FAEM) were also 
indicated as being increased in the autophagic monolayer and NC cells. 
Through degradation of carbohydrates, proteins, lipids and nucleic acids 
autophagy can liberate stored sugars, amino acids, fatty acids and nucleosides 
which can be reutilized by the cell. The TCA cycle provides autophagic cells 
with the means to utilize its liberated internal nutrient stores. Sugars liberated 
from the degradation of carbohydrates can drive an increase in glycolysis. 
Pyruvate generated through increases in glycolysis (as indicated in the MCTS 
NC cells) can be fed into the TCA cycle where it can be directed into various 
processes which involve the metabolism of different amino acids. Liberated free 
amino acids (from the degradation of proteins) can provide intermediates for the 
TCA cycle; these include α-ketoglutarate from glutamine and oxaloacetate from 
aspartate. Lipophagy can provide free fatty acids for energy production through 
β-oxidation, which will result in the generation of acetyl-CoA in the mitochondria. 
Acetyl-CoA can be use to support the TCA cycle.  
Proteomics analysis of autophagic necrotic core cells suggested an increase in 
various chaperone proteins, similar results were not seen with autophagic 
monolayer cells. Hypoxic related oxidative stress may contribute to these 
elevated levels in necrotic core cells, however, increases in chaperone proteins 
were not evident in the hypoxic cells of the peri-necrotic core. This observations 
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lead to the suggestion that different methods of autophagy induction seen 
between MCTS NC cells and autophagic monolayer‘s (progressive and acute, 
respectively) could bring about differences in contribution of each type of 
autophagy, with the NC cells possibly demonstrating increased levels of 
chaperone mediated autophagy.  
Transcriptomics has established its role in drug discovery and it is anticipated 
that it will contribute to the identification of chemotherapeutic agent of the future. 
With this in mind transcriptomic profiling of the MCTS regions were carried out. 
Discrepancies in RNA integrity isolated from the different regions limited the 
value of their comparison. Degradation levels were seen to progressively 
increase with increasing distance into the central spheroid regions, raising the 
possibility of autophagy contributing to the degradation of RNA in the NC. As 
protein degradation would also be expected to be increased with increasing 
distance into the central spheroids regions, some value remained in comparing 
gene and protein expression within each region.    
These comparisons revealed very little correlation between mRNA and protein 
levels. These differences were thought to represent real biological 
discrepancies between transcript and protein abundances and also technical 
discrepancies due to the very different experimental approaches required to 
quantify each. Importantly, despite the poor level of correlation increases in lipid 
metabolism indicated previous from the proteomics analysis of both the MCTS 
NC region and autophagic cells, was supported by the transcriptomics data. 
The initial aim of this thesis was to identify novel targets for therapeutic 
intervention. It was anticipated that a shortlist of proteins increased in the PN 
and/or NC would be generated through proteomics analysis of the MCTS 
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regions. This shortlist would then provide the focus for further work with proteins 
previously not associate with hypoxic, necrosis or cancer being pursued as 
possible leads in target identification. In reality such an outcome was extremely 
oversimplified and to some extend the potential of the model together with the 
experimental approach used to study it was underestimated. Quantitative 
proteomics analysis of the MCTS regions did in fact reveal a short list of 
proteins increased in the PN and NC with no previous association to hypoxic, 
necrosis or cancer (Supplementary table S9), and these may upon further 
investigation prove to hold potential as targets for drug development.  
The main findings of the study were the identification of changes in multiple 
cellular metabolic pathways in response to their microenvironment conditions. 
By demonstrating similar changes in autophagic cells this underpinned their 
importance in aiding cell survival. The majority of metabolic alteration indicated 
as being utilized by the autophagic cells in this investigation have previously 
been shown or at least proposed to be involved in autophagy. This would help 
to validate the results. As the current investigation represents a global 
investigation of autophagy in both 2D and 3D systems with a relatively large 
proportion of the proteome quantitatively analysed the data may prove valuable 
in contributing to the understanding of the molecular basis of autophagy, which 
at present in still being determined. What‘s more the NC of MCTS may 
represent a more accurate reflection of autophagy as it would be occurring in 
vivo, as such transcriptomic and proteomics data detailing gene and protein 
expression within this region may prove an important resource.     
Up-regulation of lipid metabolism was indicated by proteomics analysis of both 
autophagic NC and autophagic monolayer cells. These results were further 
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supported by the transcriptomics analysis which revealed an increased in 
expression of genes associated with lipid metabolism, within the NC. Such 
striking results may pinpoint lipid metabolism as being the most important 
pathway in the search for drug targets, highlighted in the thesis. The 
reprogramming of energy metabolism being proposed as an emerging hallmark 
of cancer certainly would support this.  
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IX: Future work 
 
The main limitations of the work detailed in this thesis include issues relating to 
the regio-specific dissection of the MCTS. Question marks remain concerning 
contamination of any one region with another; this is particularly true for 
contamination of the peri-necrotic fraction with cells of the necrotic core. To 
address this problem alternative spheroid separation strategies must be 
explored.  
 
An attractive approach involves separating the spheroids using flow cytometry 
cell sorting techniques following Hoechst 33342 staining (Durand, 1982). 
Hoechst 33342 staining of MCTS results in unequal distribution of the stain 
throughout the spheroid, the outer most cells being more intensely stained than 
the inner most. Following the disaggregation of the Hoechst 33342 treated 
spheroids the cells can then be separated by fluorescent activated cell sorting 
according to their degree of staining, which will reflect their depth within the 
spheroid (Durand, 1982). This method may reduce contamination and 
importantly it will provide a separation approach not requiring the need for 
trypsin, as cells could be disaggregate using homogenization alone. This is an 
important consideration, as with the current method the study of cell surface 
proteins is hindered due to treatment of the spheroids with trypsin, during which 
their extracellular components maybe lost. Considering that surface proteins 
including growth factor or extracellular matrix receptors are sensors of the 
microenvironment and represent an important class of proteins which are 
targeted for therapeutic intervention, their study is potentially very valuable. Cell 
surface receptor proteins that do not contain trypsin cleavage sites would be 
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included in the analysis using the current method and the use of alternative 
enzymes to disaggregate spheroids could also be considered.  
 
 Following separation of the MCTS using this second approach, proteins from 
different regions should be quantitatively analysed. Repeats of both the original 
transcriptomics and proteomics analysis are also required. Ideally these studies 
would support data already generated and would hopefully provide additional 
insight into the cellular transcriptome and proteome‘s response to their 
physiological microenvironmental conditions. Should the same metabolic 
pathways be highlighted then validation studies should be carryout out to 
determine their role in facilitating cell survival. These could include knock down 
studies targeting key components of each pathway and monitoring the resulting 
cells response to nutrient deprivation for example.   
 
This thesis outlines a drug discovery strategy which is cell phenotype driven as 
opposed to current approaches which are focused on exploiting or targeting 
oncogenic mutations  By providing an alternative angle these studies may 
provide a complimentary approach. The results of this study have identified 
several possible candidate proteins and pathways for further study. Issues 
concerning ‗druggability‘ will inform which proteins are selected for target 
validation studies and particular emphasis will be placed on those proteins that 
have not been extensively studied previously (i.e. not known targets). The 
validation studies will consist of analysis of distribution of the protein in human 
tumour and normal tissue (via immunohistochemistry for example) and siRNA 
knockdown studies to identify the biological effect of suppressing the specific 
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target. Those proteins which emerge from these studies as validated targets 
would then enter drug discovery programs. 
 
The proteomics strategy employed in this thesis demonstrated great potential, 
as reflected by the encouraging proteomics coverage levels achieved. As such 
the same strategy could be applied to the analysis of MCTS for other colon 
cancer cell lines and MCTS of other cancer cell lines to look for commonality in 
protein responses. 
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